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degradation of cyclin B1 
 
 
 
Abstract 
 
 Post-translational modification of proteins with ubiquitin regulates many aspects of cell 
physiology, including protein degradation. A uniform polyubiquitin chain that is linked through 
Lys48 has been widely accepted as central for recognition and destruction by the 26S proteasome. 
Work in more recent years has demonstrated that the repertoire of proteolytic signals may 
encompass chains of other linkage types, including Lys11-linked ubiquitin chains and short 
assemblies of mixed linkage. In this dissertation I examine whether catalysis mediated by the 
Anaphase-Promoting Complex/Cyclosome (APC/C) is dependent on polyubiquitination and 
whether the proteolytic machinery exerts a requirement for specific ubiquitin linkages to 
efficiently degrade cyclin B1.  
 In chapter II, I describe a novel method in which Xenopus cell-cycle extracts are made 
largely dependent on exogenous ubiquitin by inhibiting ubiquitin recycling, allowing us to 
evaluate the relative contribution of distinct ubiquitin linkages in APC/C-mediated ubiquitination 
and degradation. Utilizing this approach, in chapter III, I found that the conjugation of single 
ubiquitin moieties to multiple lysine residues in cyclin promotes efficient degradation of cyclin 
B1 in mitotic Xenopus extracts. Lysine11-ubiquitin chain-formation becomes essential to 
proteasomal targeting only when the number of available lysine residues in cyclin B1 is  
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restricted. Analysis in a reconstituted system revealed that APC/C catalyzes multiple  
monoubiquitination with rapid kinetics and species bearing four or more monoubiquitins on 
distinct lysines are recognized by ubiquitin receptors. These multiply monoubiquitinated species 
are rapidly degraded by purified proteasomes.  
 In chapter IV, I examine the role of distinct E2 enzymes in APC/C-dependent proteolysis. 
I demonstrate that the chain-extending E2 UBE2S and long Lys11-linked ubiquitin assemblies are 
dispensable for cyclin B1 degradation, but become increasingly important with restriction of the 
number of ubiquitination sites.  Our findings support a model where through attachment of 
monoubiquitin to multiple lysine residues, and possibly elaboration of some short chains, 
UBCH10, or possibly members of the UBC4/5 family, cooperate with the APC/C to generate a 
robust proteolytic signal on cyclin B1. 
  
v 
Table of Contents: 
Title Page                                                                                                                                          i    
Copyright Notice                                                                                                                              ii 
Abstract                                                                                                                                            iii 
Table of Contents                                                                                                                              v 
List of Tables and Figures                                                                                                              vii  
Acknowledgements                                           ix 
 
Chapter I: Introduction                                                                                                                     1  
 Protein modification by ubiquitin                                                                                       2 
 Molecular players in ubiquitin-chain assembly and disassembly                                       4 
 Ubiquitin-signal topology and proteasome targeting                                                          8 
 The proteasome – a complex protein-degrading machinery                                              11 
 Orchestration of the cell cycle by the anaphase-promoting complex                                15  
 Role of ubiquitin-chain formation in cyclin B1 proteolysis                                              20 
 References                                                                                                                          25 
 
 
Chapter II: Development and characterization of the UbVS system                                             37       
             Abstract                                                                                                                             38 
             Introduction                                                                                                                       39 
 Results                                                                                                                               42 
 Discussion                                                                                                                         51 
 Methods                                                                                                                             54 
 References                                                                                                                         58 
 
 
 
Chapter III: APC/C-mediated multiple monoubiquitination provides an alternative degradation                 
             signal for cyclin B1                                                                                                            62 
           Abstract                                                                                                                              63 
            Introduction                                                                                                                        64 
 Results                                                                                                                                66 
 Discussion                                                                                                                          77 
 Methods                                                                                                                              82 
 References                                                                                                                          89 
  
 
 
Chapter IV: Role of E2 enzymes in APC/C-dependent proteolysis                                               93 
Abstract                                                                                                                              94 
             Introduction                                                                                                                        95 
 Results                                                                                                                                97 
 Discussion                                                                                                                        110 
 Methods                                                                                                                            115 
 References                                                                                                                        123 
  
vi 
Chapter V: Conclusions and Future Directions                                                                          127 
 Development of a system to study the role of ubiquitin linkage in  
   proteasomal targeting                                                                                                    128  
             Role of ubiquitin linkage and E2 enzymes in APC/C-mediated  
             Degradation                                                                                                                   131   
             References                                                                                                                     135  
 
 
 
Chapter VI: Appendix                                                                                                               137 
A. APC/C-mediated multiple monoubiquitylation provides an alternative degradation 
signal for cyclin B1                                                                                               138 
B. Analysis of the role of USP14 in cyclin B1 proteolysis in  
Xenopus extract                                                                                                     161 
C. Enhancement of proteasome activity by a small-molecule  
inhibitor of USP14                                                                                                184 
D. Pharmacologic inhibition of the anaphase-promoting complex 
induces a spindle checkpoint-dependent mitotic arrest in the  
absence of spindle damage                                                                                   223 
 
 
  
  
vii 
List of Tables and Figures: 
 
 
Chapter I: Introduction 
 
          Figure 1.1.  Schematic overview of ubiquitination                                                            5 
 
          Figure 1.2. The ubiquitin code                                                                                           9 
 
Figure 1.3. APC/C‐dependent proteolysis of cyclin B1                                                   21 
 
 
 
Chapter II: Development and characterization of the UbVS system 
 
Figure 2.1. N-terminal fragment of cyclin B1 is degraded in Xenopus extract 
in an APC/C- and proteasome-dependent fashion                                                            43  
 
Figure 2.2. Endogenous ubiquitin levels are limiting for degradation of an N- terminal 
fragment of human cyclin B1 in mitotic Xenopus extract                                                45 
 
Figure 2.3. Ubiquitin vinyl sulfone (UbVS) inhibits cycB1-NT proteolysis in a dose-
dependent fashion                                                                                                             47 
 
Figure 2.4. Ubiquitin vinyl sulfone (UbVS) inhibits cyclin B1 degradation by depleting 
available ubiquitin                                                                                                            49 
 
 
 
Chapter III: APC/C-mediated multiple monoubiquitylation provides an alternative degradation  
          signal for cyclin B1 
 
Figure 3.1. Ubiquitin-chain formation is not essential for cyclin B1 degradation 
in UbVS-treated Xenopus extract                                                                                    67 
  
Figure 3.2. Cyclin B1 proteolysis depends on Lys11-linked ubiquitin-chain formation 
only when the number of available lysine residues is restricted                                     69 
 
Figure 3.3. UBCH10 and APC/C catalyze rapid multiple monoubiquitination 
of cyclin B1 that is sufficient for binding ubiquitin receptors                                        73 
 
Figure 3.4. Multiply monoubiquitinated cyclin B1 is rapidly degraded by  
purified proteasomes and in Xenopus extract                                                                 75 
 
Figure 3.5. Model of cyclin B1 degradation in Xenopus cell-cycle extract                    80  
 
Chapter IV: Role of E2 enzymes in APC/C-dependent proteolysis 
 Figure 4.1. UBE2S is required for cyclin B1 proteolysis only when ubiquitination  
is constrained to a single lysine                                                                                       98 
  
viii 
 
Figure 4.2. Chain-elongating enzyme E2-25K does not enhance cyclin B1 ubiquitination 
catalyzed by Xenopus APC                                                                                            100 
 
Figure 4.3. Depletion of UBCH10 more significantly delays cyclin B1 degradation when 
ubiquitination is limited to a single lysine residue                                                         102 
 
Figure 4.4. UBC4 and APC/C catalyze multiple monoubiquitination of cyclin B1 that is 
sufficient for binding ubiquitin receptors                                                                       104 
 
Figure 4.5. Cyclin B1 multiply monoubiquitinated by UBC4 and APC/C is rapidly 
degraded by purified proteasomes and in Xenopus extract                                            106    
 
Figure 4.6. UBC4 partially rescues cyclin B1 degradation in Xenopus extract that is 
depleted of E2 enzymes                                                                                                 109 
  
ix 
Acknowledgments 
 
 First I would like to thank my advisor Dr. Randy King. He has been a truly great mentor 
in every aspect. Randy has been very supportive along every step of my graduate career. During 
the last five and a half years of work in the laboratory, Randy has exerted profound influence on 
me, which is not limited to my research projects, but also extends to my view of science. He has 
encouraged me to always identify and pursue important questions and has demonstrated to me 
how to tackle scientific questions in a systematic way.  He has also conveyed the importance of 
designing experiments in a rigorous way and has taught me to interpret data in a critical manner. 
His love for teaching and passion for science have been an inspiration to me. 
 I would like to thank the members of my dissertation advisory committee – Dr. Dan 
Finley, Dr. Sam Reck-Peterson and Dr. Jagesh Shah. They have always been very supportive and 
enthusiastic about my projects. Their guidance has been greatly valuable for the progress of my 
work. In spite of their busy schedules, they have always found time to discuss questions about 
this work or my professional growth.  
 I could have not asked for better colleagues in the laboratory. Although the makeup of the 
laboratory has changed over the years of my graduate work, all of my colleagues have been truly 
great scientists to work with and amazing friends. They have all been very supportive and always 
ready to help. I would like to give special thanks to Dr. Nathaniel Hathaway who was a graduate 
student at the time I joined the lab. Nate is a very talented scientist and a great teacher. Working 
closely with him, I learned a great deal and gathered the confidence that I can pursue the answers 
to important scientific questions. The degradation assays part of this project would not have been 
possible without the proteasomes Dr. Byung-Hoon Lee provided. Byung-Hoon, who has a joint 
appointment with the Finley lab, has been a great colleague. I am very happy to have worked with 
Dr. Katherine Sackton. She invested a great amount of time and efforts examining the stability of  
  
x 
different lysine mutants of cyclin B1 in human cells. Dr. Kathleen Pfaff has been very helpful 
with different aspects of my project. There are so many good things I can say about Dr. Frederic 
Sigoillot. In addition to sharing a lot about French culture and cuisine, he has been enthusiastic 
about sharing his knowledge and experience. Whether I had a question regarding formatting 
figures or needed help with a protein purification, he has been there for me. I would like to 
acknowledge Xing Zeng who is a classmate of mine and did his graduate work in the lab. I thank 
Xing for insightful discussions and collaboration on different aspects of our projects. Also, I 
would like to say that without the undergraduate students Lillian Zhao, Maia Anderson, Shantanu 
Gaur, the lab would not have so much fun.  
 I feel privileged to have done my graduate work in the Department of Cell Biology. I 
would like to give special thanks to our collaborators – Dr. Steve Gygi and Dr. Dan Finley, and 
the members of their laboratories. At the heart of this project has been work carried out by a 
talented scientist – Dr. Donald Kirkpatrick. Also, more recently my project has benefited 
significantly from collaborations with Dr. Mike Aguiar. It has been a pleasure to also work with 
scientists in Dr. Dan Finley‟s lab, in particular Dr. Suzanne Elsasser, Dr. Jessica Robert and Dr. 
Bradley Pearse. Their expertise in the proteasome field has been of great value to my research.   
 I would like to thank my friends and family for their unconditional love and support. 
Even thousands of miles away from home, I have been blessed to have my family‟s support along 
this long journey. This dissertation is dedicated to my parents -Rositssa and Varbin, and to my 
brothers – Matey and Lyubomir.   
  
1 
 
Chapter I: Introduction  
 
Nevena Dimova 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2 
Protein modification by ubiquitin 
 
Ubiquitination (also known as ubiquitylation) is a powerful mechanism for regulating 
essentially all aspects of cell physiology, including cell division, apoptosis, transcription, signal 
transduction and the modulation of diverse metabolic pathways (Ciechanover, 2005b; Johnson, 
2002; Kerscher et al., 2006; Pickart and Fushman, 2004).  The covalent attachment of ubiquitin 
(Ub) to substrate proteins is mediated by an enzymatic cascade that is tightly regulated in a spatial 
and temporal manner and is characterized by a high degree of specificity for the substrates it 
modulates. The best-studied result of this modification is the targeting of ubiquitin-tagged 
proteins for proteasomal degradation. Other important advances since the seminal work focused 
on understanding the energy-dependent proteolytic activity found in reticulocyte extracts 
(Ciechanover, 2005a; Ciechanover, 2005b; Ciechanover et al., 1984a; Hershko, 2005) were the 
discovery of non-degradative functions for ubiquitin and the discovery of ubiquitin-like proteins. 
How the ubiquitin signal assembled on a substrate is read by different downstream effectors and 
modulates the fate and/or function of the modified protein remains a central theme in the 
ubiquitin field. 
Ubiquitin is a small 76 amino-acid protein first purified during the isolation of 
thymopoietin by Goldstein and colleagues (Goldstein, 1974). The high evolutionary sequence 
conservation (Schlesinger and Goldstein, 1975; Wilkinson et al., 1986), likely unparalleled 
among known proteins, indicates the central role of ubiquitin-conjugation pathways to normal 
cell function. Even though this protein may not be as ubiquitous as was initially thought, the 
name aptly reflects its representation in a variety of cellular tissues and organisms (Goldstein, 
1974; Goldstein et al., 1975). Several ubiquitin-like proteins (UBLs) have also been identified, 
including NEDD8, SUMO and ISG15, which share a characteristic three-dimensional fold with 
ubiquitin but are otherwise distinct (Kerscher et al., 2006; Schulman and Harper, 2009). The 
overall structure of this ~8.5-kDa heat-stable protein is extremely compact and tightly-hydrogen 
bonded with only its C-terminal tail, which is accessed by enzymes, protruding from the molecule 
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(Vijay-Kumar et al., 1987). The stability of ubiquitin is likely further enhanced by the 
pronounced hydrophobic core (Vijay-Kumar et al., 1987). Subsequent work has indicated that the 
structural constraints required for proper conjugation or recognition of ubiquitin by downstream 
effectors are quite strict. Different surfaces revealed in the crystal structure of ubiquitin (Vijay-
Kumar et al., 1987) have been implicated in distinct cellular processes. The hydrophobic patch 
surrounding residues Leu8, Ile44 and Val70 is important for recognition of ubiquitin chains by 
proteasome-associated ubiquitin receptors and proteasome-mediated degradation (Beal et al., 
1996; Beal et al., 1998; Lam et al., 1997a; Sloper-Mould et al., 2001). The surface surrounding 
Ile44 has also been implicated in internalization of activated plasma-membrane receptors (Shih et 
al., 2000; Sloper-Mould et al., 2001). Residues Phe4 and Asp58 have been demonstrated to be 
critical for non-proteolytic functions of ubiquitin (Lee et al., 2006; Penengo et al., 2006; Shih et 
al., 2000; Sloper-Mould et al., 2001).  
An important breakthrough early in the field of ubiquitin research was the discovery that 
a single ubiquitin molecule can be covalently linked to histones, particularly to histones H2A and 
H2B (Hershko and Ciechanover, 1998). This and subsequent work revealed that, in most cases, 
ubiquitin is conjugated to substrates via an isopeptide bond between the activated carboxy-
terminal glycine (Gly76) of ubiquitin and an ε-amino group of a lysine (Lys) residue in a 
substrate (Ciechanover et al., 1984a; Ciechanover et al., 1980; Goldknopf and Busch, 1977; 
Hershko and Ciechanover, 1998; Hershko et al., 1981; Hunt and Dayhoff, 1977). In some cases, 
ubiquitin is conjugated to the α-amino group of the target substrate (Ciechanover and Ben-
Saadon, 2004; Hershko et al., 1984), and there are a few examples of attachment to threonine, 
serine or cysteine residues (Cadwell and Coscoy, 2005; Carvalho et al., 2007; Grou et al., 2008; 
Shimizu et al., 2010; Wang et al., 2007). Ubiquitin itself contains seven Lys residues, at positions 
6, 11, 27, 29, 33, 48, and 63, which can function as acceptor sites for another ubiquitin moiety 
during the assembly of ubiquitin chains. All seven potential ubiquitin-ubiquitin linkages have 
been found to exist in vivo (Peng et al., 2003; Xu et al., 2009). Because of the possible variations 
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in the sites and type of ubiquitination, the potential repertoire of ubiquitin signals is vast and an 
outstanding challenge for the ubiquitin field is to understand how these modifications dictate 
distinct fates of target proteins. 
 
 
Molecular players in ubiquitin-chain assembly and disassembly 
The organization of the ubiquitin-conjugation system is hierarchical. The enzymes 
involved in the cascade reaction of ubiquitin transfer onto substrates (Figure 1.1) were purified by 
Hershko, Ciechanover and colleagues (Ciechanover et al., 1982; Hershko et al., 1983). In the first 
step, the ubiquitin-activating enzyme (E1) forms a ternary complex consisting of E1-ubiquitin 
thioester with ubiquitin-AMP bound (Bedford et al., 2011; Ciechanover et al., 1984a; Hershko 
and Ciechanover, 1998).The activated ubiquitin is subsequently passed to one of a number of 
distinct ubiquitin-conjugating (E2) enzymes by transthiolation to a conserved cysteine (Cys) of 
the E2. The E2 proteins catalyze substrate modification in conjunction with a ubiquitin-protein 
ligase (E3). For the ~60 members of homologous to E6-AP C-terminus (HECT) family E3s, 
ubiquitin is shuttled from an E2 to a catalytic Cys in the HECT domain of the E3 before being 
attached to a substrate (Bedford et al., 2011; Hershko and Ciechanover, 1998; Kerscher et al., 
2006; Scheffner et al., 1995). Most E3s, however, contain a really interesting new gene (RING) 
domain or a structurally related U-box and act as scaffold, bringing a substrate and ubiquitin-
charged E2 in proximity and activating the E2 to transfer ubiquitin to a Lys residue in the 
substrate (Bedford et al., 2011; Kerscher et al., 2006; Pickart, 2001).  Ubiquitin chains nucleated 
on the substrate can be further elaborated by the activity of chain-elongating (E4) enzymes 
(Crosas et al., 2006; Koegl et al., 1999). Removal of ubiquitin groups which may modulate 
ubiquitin signaling is carried out by deubiquitinating enzymes (also referred to as deubiquitinases 
or DUBs) (Amerik and Hochstrasser, 2004; Finley, 2009; Komander et al., 2009; Lam et al., 
1997b; Nijman et al., 2005). By processing ubiquitin or ubiquitin-like gene products to yield the 
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free monomer form (Ozkaynak et al., 1987; Ozkaynak et al., 1984) and by recycling ubiquitin 
from existing conjugates (Komander et al., 2009), deubiquitinases play a critical role in ubiquitin 
homeostasis and the proper functioning of the ubiquitin-conjugation cascade. 
 
ATP AMP+PPi
E1 S~ E2
S~ 
E3
SubstrateUb
DUB
Figure 1.1 Schematic overview of ubiquitination. In the first step, a ubiquitin-activating
(E1) enzyme uses ATP to form a thioester bond between the Cys residue (denoted with
S) at its active site and the carboxyl terminus of ubiquitin (Ub). The activated ubiquitin
is then transferred to the Cys residue in the active site of a ubiquitin-conjugating (E2)
enzyme, which  in turn cooperates with ubiquitin-protein (E3) ligases to catalyze 
substrate modification. Removal of ubiquitin groups from substrates, which may 
modulate the downstream fate of a substrate and is important for maintaining steady-
state ubiquitin levels, is carried out by deubiquitinating enzymes or DUBs.
Ub Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
 
 
In contrast to the small number of E1 enzymes known to operate in the ubiquitin-
proteasome system (UPS) (Ciechanover et al., 1984b; Finley et al., 1984; Jin et al., 2007), there 
are at least 38 E2s encoded by the human genome (Ye and Rape, 2009). Active E2 enzymes 
possess a conserved core ubiquitin-conjugating (UBC) domain, which contains the catalytic Cys 
residue and interacts with E1s (Ye and Rape, 2009). After accepting ubiquitin transiently, E2s 
engage with a cognate E3 enzyme to catalyze substrate ubiquitination. A single ubiquitin ligase 
can work in conjunction with more than one E2 to ubiquitinate substrates, as seen for the 
anaphase-promoting complex/cyclosome (APC/C or APC) which interacts with members of the 
E-2C and UBC4/5 families of E2 enzymes (Kirkpatrick et al., 2006). Also, a sole E2 can function 
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with several different E3s – this is observed most dramatically with E2s from the UBC4/5 (also 
referred to as UBE2D) class (Brzovic et al., 2006; Garnett et al., 2009; Kirkpatrick et al., 2006). 
A central question in the field remains how the limited number of E2s pair up with the much 
greater number of putative ubiquitin ligases in a specific and regulated manner.  
Because of their role as the ultimate arbiters of substrate selection for ubiquitination, 
much of the initial work focused on E3s, and E2s were often viewed as simple carriers of 
activated ubiquitin with auxiliary roles. There is emerging evidence that contradicts this early 
image of E2s by revealing the complex interactions they carry out and important roles they have 
in substrate ubiquitination. Indeed, it is now evident that E2 enzymes can actively influence the 
linkage specificity and length of ubiquitin polymers. Ubiquitin-chain formation requires E3s to 
first nucleate chains by modifying a substrate lysine, and subsequently to elongate chains by 
targeting lysine residues in ubiquitin. To catalyze these complex reactions, the ubiquitin system 
has evolved different strategies. Some E2 enzymes such as yeast Cdc34 catalyzes both chain 
nucleation and elongation to form Lys48-linked chains on SCF substrates (Gazdoiu et al., 2007; 
Petroski and Deshaies, 2005; Saha et al., 2011). In contrast to Cdc34, some E2s appear to have 
dedicated roles in ubiquitin-chain initiation or elongation. An example that is particularly 
important to our work and will be discussed in further detail in a subsequent section is typified by 
yeast APC/C which uses Ubc4 to transfer ubiquitin onto Lys residues in cyclin B1 and Ubc1 to 
elaborate homotypic Lys48-linked ubiquitin chains (Rodrigo-Brenni and Morgan, 2007). In this 
context, regulating the availability of the two E2s is predicted to impact the outcome of the 
ubiquitination reaction. It is an interesting possibility that such a mechanism of APC/C activity 
with dependence on multiple E2 enzymes has evolved to more tightly regulate substrate 
modification and the ensuing cellular consequences.  
Synthesizing ubiquitin chains of a distinct topology is another intrinsic property of many 
E2 enzymes. To form specific ubiquitin-ubiquitin linkages, the E2 may orient the acceptor 
ubiquitin in a way that exposes the favored Lys residue to its active site (Eddins et al., 2006; 
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Petroski and Deshaies, 2005). Some E2s exhibit specificity for assembling free chains of a 
distinct linkage without the aid of an E3 and that linkage specificity is not altered by binding to 
their cognate E3s (Chen and Pickart, 1990; Wickliffe et al., 2011a). Because ubiquitinated 
substrates may be sorted into different pathways based on diverse polyubiquitin structures 
(Pickart and Fushman, 2004), E2s can be viewed as regulators of ubiquitin signaling owing to 
their capacity to build specific chains. It is important, however, to determine whether the 
assembly of ubiquitin chains of specific linkage simply reflects intrinsic properties of the E2 
rather than a requirement imposed by downstream effectors.     
Ubiquitin-conjugating enzymes may also influence the processivity of ubiquitination, 
defined as the number of ubiquitin molecules that are attached to substrates during a single 
binding to an E3 (Carroll and Morgan, 2002; Rape et al., 2006). Processivity of ubiquitination 
depends on the binding affinity of substrates as well as the availability and kinetic properties of 
E2 enzymes (Rape et al., 2006). Very processive substrates will acquire their functional ubiquitin 
tag in a single substrate-E3 binding event (Pierce et al., 2009; Rape et al., 2006). In contrast, more 
distributive substrates will continuously shuttle on and off the ligase complex in order to achieve 
their functional ubiquitination status and be potentially exposed to the activity of DUBs. Thus the 
processivity with which a substrate acquires its functional ubiquitin signal is likely to directly 
influence the downstream fate of the substrate. E2 enzymes have evolved different mechanisms to 
enhance the processivity of ubiquitination, including the binding of E3s using multiple 
independent binding sites to increase affinity, recognition of substrate and ubiquitin motifs, 
oligomerization of ubiquitin-charged E2s and pre-assembly of ubiquitin polymers on their active 
sites followed by en bloc transfer to the substrate (Ye and Rape, 2009).  
How do properties of E2 enzymes that determine the balance of multiple 
monoubiquitination versus assembly of ubiquitin chains of specific length and topology affect 
ubiquitin-receptor binding and proteasomal degradation of substrates? In the work presented in 
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this dissertation, we address this question in the context of APC-mediated proteolysis of cyclin 
B1. 
 
 
Ubiquitin-signal topology and proteasome targeting 
 Over a decade after the discovery of the ubiquitin pathway, it was realized that ubiquitin 
can be appended not only to different cellular proteins, but also to other ubiquitin moieties 
forming polyubiquitin structures (Chau et al., 1989; Hershko and Heller, 1985). This raised the 
question as to whether a unique ubiquitin tag signals destruction by the proteasome. Indeed, in the 
context of an engineered substrate Arg-βgal, the assembly of a polyubiquitin chain was critical 
for proteasomal degradation (Chau et al., 1989). In this context, lysine-to-arginine substitution at 
Lys48 of ubiquitin abrogated both ubiquitin-polymer formation and substrate proteolysis (Chau et 
al., 1989). Based on this and subsequent studies (Thrower et al., 2000), a model emerged where a 
polymer of 4 or more ubiquitin groups linked through Lys48 is required for efficient substrate 
degradation by the proteasome. Whether ubiquitin signals of different architecture were sufficient 
for proteasomal targeting was not addressed in these studies. Nevertheless, Lys48-linked chains 
became widely viewed as the canonical proteolytic signal. This model was further corroborated 
by work demonstrating that Lys48 of ubiquitin was important for bulk protein turnover and 
essential, albeit not sufficient, for proper cell-cycle progression in S. cerevisiae  (Finley et al., 
1994; Xu et al., 2009). The mitotic phenotype observed in UbK48R mutants where cells 
displayed two-lobed nuclei and remained arrested in medial nuclear division (Finley et al., 1994) 
is reminiscent of that observed upon deletion of the gene encoding the E2 Ubc1 (Rodrigo-Brenni 
and Morgan, 2007). For timely mitotic exit in these cells, the activity of the Lys48 chain-
extending E2 Ubc1 in promoting proteolysis of APC substrates was found critical (Rodrigo-
Brenni and Morgan, 2007). These and other studies underscore that the ubiquitin signal 
assembled on substrates is a function of the different E2-E3 complexes and poise the question 
  
9 
whether ubiquitin structures other than Lys48-linked chains can target substrates to the 
proteolytic machinery. Assigning the proteasomal signaling function to a specific Lys48-linked 
polymeric unit was a particularly attractive model as it also explained how a single ubiquitin can 
act as a functionally distinct signal in non-proteolytic processes. Similarly, to monoubiquitination 
and multiple monoubiquitination (Robzyk et al., 2000; Terrell et al., 1998), polymers assembled 
through Lys63 of ubiquitin have been implicated in mostly non-proteolytic roles (Deng et al., 
2000; Hofmann and Pickart, 1999; Pickart and Fushman, 2004; Spence et al., 2000; Spence et al., 
1995; Yang et al., 2009) (Figure 1.2). 
 
Protein trafficking,
DNA repair 
Modified from Ye et al, Nat MolCellBio 2009
Polyubiquitination : known functions
Targeting to the 26S proteasome
Substrate
K63
K63
K63
Substrate
K11
Substrate
K48
K48
K48 K11
K11
Substrate Substrate
Monoubiquitination or 
multiple monoubiquitination
Protein localization, protein interactions,
modulation of protein activity 
Figure 1.2 The ubiquitin code. Ubiquitin is usually conjugated to the ε-amino group of a lysine 
(Lys) residue in a substrate (Hershko and Ciechanover, 1998). Ubiquitin itself contains seven Lys 
residues, at positions 6, 11, 27, 29, 33, 48, and 63, which can function as acceptor sites for 
another ubiquitin moiety during the assembly of ubiquitin chains. In the classical model, a 
uniform K48-linked ubiquitin polymer is required for substrate recognition and destruction by 
the 26S proteasome (Chau et al., 1989; Thrower et al., 2000;  Finley et al., 1994). Work in more 
recent years has demonstrated that the repertoire of proteolytic signals may encompass chains 
of other linkage types, including K11-linked ubiquitin chains (Xu et al., 2009). Polymers built 
through K63 of ubiquitin have been suggested to have non-proteolytic roles in orchestrating 
different steps of DNA repair (Spence et al., 1995; Hofmann and Pickart, 1999) , kinase 
activation (Deng et al., 2000), protein trafficking (Pickart and Fushman, 2004; Yang et al., 2009) 
and translation (Spence et al., 2000). Similarly, the transfer of a single ubiquitin moiety to one 
(monoubiquitination) or to multiple sites (multiple monoubiquitination) in a substrate has long 
been implicated in mostly non-proteolytic processes, such as epigenetic control (Robzyk et al., 
2000) and receptor endocytosis (Terrell et al., 1998).
Ub Ub Ub Ub Ub
Ub
Ub
Ub
Ub Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
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 How can we detect different ubiquitin topologies and gain understanding of their 
functional significance in the cell? One approach has involved large-scale analyses and 
characterization of protein ubiquitination using quantitative mass-spectrometry techniques (Kim 
et al., 2011; Peng et al., 2003; Xu et al., 2009). Such studies have revealed a striking and 
unexpectedly high abundance of non-Lys48 ubiquitin linkages, especially Lys11 linkages (Peng 
et al., 2003; Xu et al., 2009). Moreover, Lys11-linked chains have been implicated in a broad 
range of physiological processes, including cell division and endoplasmic reticulum-associated 
degradation (ERAD) (Behrends and Harper, 2011; Wickliffe et al., 2011b; Xu et al., 2009).  A 
critical issue with these methodologies is that they are concentration-sensitive and thus better at 
identifying more abundant conjugates in the cell, while not detecting all short-lived proteins such 
as cell-cycle regulators (Peng et al., 2003). Also, while such analyses are integral to our 
understanding of the global ubiquitin landscape in the cell, they may not accurately reflect the 
behavior of individual proteins. For instance, no significant changes in total levels of Lys63 
linkages are observed upon proteasomal inhibition (Xu et al., 2009), even though these are 
capable of supporting degradation by the proteasome (Baboshina and Haas, 1996; Hofmann and 
Pickart, 2001). 
 Another approach to studying protein ubiquitination may be to integrate large-scale 
analyses with work detailing individual pathways. A method that has allowed significant progress 
in characterizing ubiquitin conjugates and mapping precise sites of ubiquitination is the absolute 
quantification of ubiquitin by mass spectrometry (Ub-AQUA) (Kirkpatrick et al., 2005; 
Kirkpatrick et al., 2006). This quantitative mass-spectrometry technique uses isotope-labeled 
internal standard peptides to quantify tryptic peptides that are derived from the digestion of any 
given sample. By comparison to the known amount of isotope-labeled standards, the exact 
amount of any given peptide in a sample can be quantitated. By applying the law of conservation 
of mass, one can use this method to quantify the absolute amount of any given substrate, 
ubiquitin, and the relative proportion of each of the seven potential ubiquitin-ubiquitin linkages. 
  
11 
In the work presented in this dissertation, we have combined analysis of processes reconstituted 
in vitro and Ub-AQUA analysis with studies in the Xenopus system to delineate how the E3 
ligase APC/C mediates ubiquitination and degradation of cyclin B1.  
 Studying the role of distinct ubiquitin topologies in protein breakdown in physiological 
settings has proven to be challenging. This can be attributed, in part, to the dynamic nature and 
fast kinetics of the ubiquitination and proteolytic events. Another factor that hinders our 
understanding of ubiquitin-mediated proteolysis has been the lack of methods allowing the 
ubiquitin pool available in a physiological setting to be modulated in a precise and controlled 
manner. Dominant-negative effects may be hard to observe when conducted in a background that 
contains wild-type ubiquitin. Meanwhile, ubiquitin homeostasis, through de novo protein 
synthesis and recycling from existing conjugates, is tightly regulated, rendering ubiquitin 
depletion hard to achieve. Thus, we need novel approaches for ubiquitin replacement to examine 
the effects of ubiquitin mutants on degradation in a physiological context. 
 
 
The proteasome - a complex protein-degrading machinery 
 The 26S proteasome, an intricate molecular machine of over 2.5 MDa, is the proteolytic 
arm of the UPS (Waxman et al., 1987). It functions primarily to degrade damaged, misfolded and 
short-lived regulatory proteins bearing ubiquitin modifications. The proteasome also regulates the 
state of cells by eliminating key cell-cycle regulators such as cyclins and securin. While existing 
in multiple forms, the proteasome is a composite of two major assemblies - the 28-subunit core 
particle (also known as the 20S particle) and the 19-subunit regulatory particle (also known as the 
19S particle or PA700) (Finley, 2009; Weissman et al., 2011).The catalytic activity of the 
proteasome is contained within the barrel-shaped structure of the core particle (Bedford et al., 
2011; Finley, 2009; Weissman et al., 2011).  
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 How does this complex machinery discern ubiquitin tags with proteolytic versus non-
proteolytic functions, ensuring substrates are not inadvertently degraded?  Entrance to the 
catalytic chamber is directed by factors within the regulatory particle, which recognize and 
process polyubiquitinated substrates (Finley, 2009; Weissman et al., 2011).  Another function of 
the 19S complex is to remove and recycle ubiquitin from proteolytic substrates concomitantly or 
prior to their translocation into the core. The third key function of this subcomplex is to promote 
substrate unfolding and translocation into the core (Finley, 2009; Weissman et al., 2011). The 19S 
particle is more heterogeneous and unstable as compared to the catalytic core with some of its 
components in sub-stoichiometric amounts and interchanging with the cytosol (Elsasser and 
Finley, 2005; Finley, 2009; Leggett et al., 2002; Schmidt et al., 2005). These findings have 
important implications about the adaptability of the proteasome in response to changing cellular 
signaling. In the work presented in this dissertation, we attempt to explore how the presence of 
proteasome-associated DUB activity may influence the recognition and degradation of a 
ubiquitin-tagged substrate. 
Once associated with proteasomal subunits, substrates may have their ubiquitin chains 
extensively remodeled through opposing ubiquitin-ligase and deubiquitinating activities (Crosas 
et al., 2006). Whether the delivery pathway to the proteasome influences the nature and extent of 
ubiquitin-polymer remodeling and how substrate specificity is enforced remain poorly 
understood. However, there is an emerging view that remodeling of the ubiquitin tag by the 
proteasome, during a kinetically defined time window, can influence the fate of substrates. 
Remodeling of the ubiquitin signal can, in part, be carried out by the three deubiquitinases found 
in mammalian proteasomes: RPN11, USP14, and UCH37 (Finley, 2009; Komander et al., 2009; 
Lee et al., 2010b). UCH37 and USP14 associate reversibly with the proteasome, whereas RPN11 
is a stoichiometric subunit (Finley, 2009). Essential for proteasome function (Finley, 2009; 
Verma et al., 2002; Yao and Cohen, 2002), the metalloenzyme RPN11 promotes substrate 
degradation by removing ubiquitin moieties, which may not be easily threaded through the 
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narrow translocation channel (Finley, 2009; Lander et al., 2012; Verma et al., 2002; Yao and 
Cohen, 2002).  
 The activity of UCH37 and USP14 may stimulate breakdown of some substrates, while 
antagonize that of others (Hanna et al., 2006; Jacobson et al., 2009; Lam et al., 1997b; Lee et al., 
2010a; Leggett et al., 2002). UCH37 has been implicated as an editing activity for the proteasome 
by selectively removing ubiquitin groups from oligoubiquitinated substrates and allowing them to 
escape degradation (Lam et al., 1997b). It remains to be determined, however, whether in the 
cellular context, UCH37 could provide a means for the proteolytic machinery to discriminate 
against substrates bearing multiple monoubiquitins or short ubiquitin chains. In contrast, USP14 
is thought to act on more heavily ubiquitinated substrates. By trimming of substrate-bound 
ubiquitin chains, USP14 has been suggested to potentially govern the degradation rates of 
numerous substrates (Hanna et al., 2006; Lee et al., 2010a). Unexpectedly, USP14 was also found 
to delay substrate degradation through a non-catalytic mechanism (Hanna et al., 2006; Lee et al., 
2010a). While these effects are not well understood, they may be related to the chain-trimming 
activity of USP14 and may also help the cell recycle ubiquitin especially under conditions of 
ubiquitin deficiency. Consistent with such a role, the expression of Ubp6 (the yeast orthologue of 
USP14) is upregulated and loading onto the proteasome elevated following depletion of free 
ubiquitin levels (Hanna et al., 2007). A number of important questions about the proteolytic 
machinery remain unresolved. Which proteins are substrates of the different DUBs on the 
proteasome and how substrate specificity and selectivity are enforced? Also, how do the number 
and spatial arrangement of ubiquitin monomers on a substrate affect its recognition and 
processing by the proteasome? 
 An important question is how ubiquitin-tagged proteins are correctly targeted to the 
proteasome holoenzyme for destruction. One potential solution to this complex problem is the 
recruitment of the ubiquitin-conjugation machinery in the vicinity in the proteasome. In fact, the 
E2 UBC4 (Chuang and Madura, 2005) and the APC (Seeger et al., 2003) (also N.D., R.W.K., 
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unpublished observations), among other enzymes (Finley, 2009), have been observed to directly 
associate with the proteasome. The functional significance of these interactions has not been 
elucidated, but they may allow ubiquitination and subsequent degradation to be spatially linked 
within the cell. An alternative pathway for target delivery to the proteasome may be dependent on 
the activity of ubiquitin-receptor proteins. The proteasome appears to recognize ubiquitinated 
substates via both intrinsic ubiquitin-receptor subunits and by transiently associating shuttling 
factors (Elsasser and Finley, 2005). Rpn10 (Deveraux et al., 1994; Elsasser and Finley, 2005; 
Young et al., 1998) and Rpn13 (Husnjak et al., 2008; Schreiner et al., 2008) are the two currently 
known intrinsic ubiquitin receptors, whereas Rad23, Dsk2, and Ddi1 (Elsasser and Finley, 2005) 
are shuttling proteins. 
The “shuttle” proteins are thought to function in capturing of ubiquitinated substrates 
remotely from the proteasome and escorting them to this complex. The ubiquitin-associated 
(UBA) domains in these proteins recognize the ubiquitin tag, whereas the ubiquitin-like (UBL) 
domains bind to the proteasome (Finley, 2009; Hicke et al., 2005; Schauber et al., 1998). In vitro 
studies suggest some ubiquitin-binding domains (UBDs) bind polyubiquitin preferentially to 
monoubiquitin, and may even exhibit preference for specific ubiquitin linkages (Hicke et al., 
2005). Supporting the view of Lys48-linked chains as the principal proteolytic signal, some 
studies suggest that proteasome-associated receptor proteins may preferentially recognize Lys48 
linkages (Raasi et al., 2004; Raasi and Pickart, 2003; Varadan et al., 2004). In a cellular context, 
it is likely that the specificity and affinity of binding may require that UBL/UBA proteins 
recognize binding determinants not only in the ubiquitin tag but also in the modified substrate. 
Substrate specificity (Verma et al., 2004) may be further enforced by subcellular localization of 
ubiquitin receptors or their interactions with E3 ubiquitin ligases. Importantly, ubiquitin receptors 
have the potential to recognize a vast array of ubiquitin signals through multiple UBDs joined by 
flexible linker regions (Kang et al., 2007; Wang et al., 2005) and by multimerization with other 
receptors (Kang et al., 2007; Kang et al., 2006). The presence of multiple ubiquitin-interacting 
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motifs in receptors such as RPN10 may provide additional avidity in recognition of targets, 
particularly those targets bearing either a polyubiquitin structure or multiple monoubiquitins 
(Finley, 2009; Harper and Schulman, 2006). 
In the work presented in this dissertation, we investigate whether ubiquitin receptors 
Rad23 and Rpn10 exert a requirement for ubiquitin-chain formation for binding to ubiquitinated 
cyclin B1. We also sought to understand whether the proteolytic machinery exerts a requirement 
for specific ubiquitin topologies for cyclin degradation. 
 
 
Orchestration of the cell cycle by the anaphase-promoting complex 
 Cyclins are a diverse family of proteins whose defining feature is that they bind and 
direct the activity of members of the cyclin-dependent kinase (CDK) family. Oscillations in their 
levels help to generate strictly controlled changes in the enzymatic activity of CDKs which 
modulate the phosphorylation state, and thereby the state of activation, of proteins that control 
cell-cycle processes. The M-phase cyclins typified by cyclin B in vertebrates (Clb1-4 in budding 
yeast) accumulate as the cell approaches mitosis, peaking at metaphase. The periodic rise and fall 
in cyclin levels and its striking disappearance at the end of each mitosis in early sea urchin 
embryos led to the discovery of this critical cell-cycle regulator (Evans et al., 1983). Subsequent 
studies found cyclin B to form a complex with CDK1 initially termed maturation promoting 
factor and now referred to as M-phase promoting factor (MPF) (Gautier et al., 1990; Gautier et 
al., 1988; Lohka et al., 1988). The activity of cyclin B1-CDK complexes is responsible for the 
striking cellular changes that lead to assembly of the mitotic spindle and the alignment of sister-
chromatid pairs on the spindle at metaphase. In addition to driving the cell to metaphase, the 
complex activates the system that degrades its cyclin subunit and orchestrates exit from both 
mitosis and meiosis (Glotzer et al., 1991; Hershko et al., 1991; Murray et al., 1989).  
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The Anaphase-Promoting Complex/Cyclosome (APC/C or APC) was identified in 
Xenopus and clam extracts as the cyclin B1 specific ubiquitin ligase responsible for MPF 
inactivation upon mitotic exit (King et al., 1995; Sudakin et al., 1995). The E3 ligase activities of 
Skp1-Cullin-F-box complex (SCF) family and the APC have long been recognized to be crucial 
to cell-cycle progression and regulation (Harper et al., 2002; Lipkowitz and Weissman, 2011; 
Peters, 2006; Skaar and Pagano, 2009). Consistent with this, the genetic inactivation of APC 
causes cell-cycle arrest in all species in which it has been investigated so far, ranging from yeast 
to mouse (Peters, 2006).  In addition to regulating mitosis and meiosis, the APC has been 
implicated in post-mitotic processes including dendrite formation in neurons, metabolic, and 
learning and memory processes (Barford, 2011b). 
The APC is a ~1.5 MDa complex, composed of at least 13 subunits (Peters, 2006). The 
size and unusual complexity of this E3 ubiquitin ligase has limited structural studies. The 
essential roles of APC constituent proteins pose further challenges in using native systems to 
study the complex. A recombinant expression system was recently generated that allowed the 
reconstitution of a functional APC in milligram quantities (Schreiber et al., 2011). This is exciting 
advance as the system may allow defined manipulation of APC complexes and facilitate studies 
of how APC subunits assemble and interact with co-activators, substrates and regulatory factors.  
APC-mediated coordination of cell-cycle progression is achieved through the temporal 
regulation of APC activity and substrate specificity. One aspect of temporal regulation of the 
ligase activity is achieved through a combination of two structurally related co-activators Cdc20 
and Cdc20 homolog 1 (Cdh1), coupled to protein phosphorylation.  The two co-activator subunits 
have opposing activity profiles. Cdc20 activates the APC at the onset of mitosis, when APC 
subunits are phosphorylated and Cdh1 activity is low owing to its CDK-mediated 
phosphorylation. After CDK activity is diminished during mitotic exit, Cdh1 forms a complex 
with APC, which ubiquitinates Cdc20, leading to APC
Cdc20
 inactivation. The co-activators help 
recruit substrates to the ligase complex. Indeed, multiple lines of evidence suggest that the co-
  
17 
activator directly bind APC substrates via its WD40-repeat domain so at least part of the function 
of the co-activator appears to be a substrate adaptor (Burton and Solomon, 2001; Buschhorn et 
al., 2011; da Fonseca et al., 2011; Kraft et al., 2005). The co-activators recognize two 
characteristic sequence elements found in APC substrates, namely a destruction box (D box; 
RxxLxxI/VxN) (Glotzer et al., 1991; King et al., 1996), and a KEN box (KENxxxN/D) (Pfleger 
and Kirschner, 2000; Pfleger et al., 2001). Whereas Cdc20 specifically recognizes the D-box 
motif, Cdh1 appears to prefer the KEN box, but also recognizes the D-box (Peters, 2006; Pfleger 
et al., 2001). 
The reversible association of co-activators with the APC presents one level of regulation 
of APC activity. Another level of APC control is provided by pseudo-substrate inhibitors such as 
early mitotic inhibitor 1 (Emi1). By preventing productive interactions of substrates with the 
catalytic module or interfering with recruitment of E2 enzymes (Barford, 2011b), such pseudo-
substrates can block APC-mediated ubiquitination and proteolysis. A similar concept of inhibition 
may apply to another critical APC regulatory system, the mitotic checkpoint complex (MCC) 
(Barford, 2011b; Kim and Yu, 2011). Consistent with this idea, elegant structural work reveals 
that checkpoint proteins inhibit APC catalysis at least in part by preventing substrate binding 
(Herzog et al., 2009).   
According to electron microscopy studies, APC/C complexes more commonly resemble 
an asymmetric triangular structure, composed of a platform and an arc lamp domain that together 
enclose a central cavity (Dube et al., 2005; Passmore et al., 2005). Apc1, together with Apc4 and 
Apc5, function as a scaffolding-like assembly subunit linking the catalytic module formed from 
Apc2, Apc11 and Apc10 (Doc1) with the TPR subunits Cdc16, Cdc23, Cdc27 found in the arc-
lamp domain (Barford, 2011b; Dube et al., 2005; Herzog et al., 2009; Schreiber et al., 2011; 
Thornton et al., 2006; Vodermaier et al., 2003). The tetratricopeptide repeats (TPR) found in 
APC/C subunits are 34-amino acid motifs that generate super-helical structures, facilitating 
protein-protein interactions (Barford, 2011a). 
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The catalytic core of the anaphase-promoting complex consists of Apc2 and Apc11. 
Apc2, a member of the cullin protein family, associates with the RING H2-finger domain in 
Apc11, which in turn recruits E2 ubiquitin-conjugating enzymes (Peters, 2006). Interestingly, 
Apc2-Apc11 alone can support ubiquitin ligation, albeit with diminished substrate specificity 
(Tang et al., 2001; Yu et al., 1998). Elegant structural work recently revealed that the cullin-
RING module was in close vicinity to the core APC/C subunit Apc10 (Doc1) (Buschhorn et al., 
2010; da Fonseca et al., 2011). Apc10 was earlier demonstrated to play a role in substrate 
recruitment to the ligase and processive substrate ubiquitination (Carroll et al., 2005; Carroll and 
Morgan, 2002; Passmore et al., 2003), but how it performs these functions remained poorly 
understood. In this context, a model emerging from recent studies suggests that Apc10 promotes 
processive substrate ubiquitination by forming part of a bipartite substrate receptor on the APC/C, 
composed of Apc10's ligand binding region (Au et al., 2002; Buschhorn et al., 2011; Carroll et 
al., 2005; Carroll and Morgan, 2002; Chao et al., 2012; da Fonseca et al., 2011; Wendt et al., 
2001) and the WD40 propeller domain of the co-activator protein (Buschhorn et al., 2011; da 
Fonseca et al., 2011; Kraft et al., 2005; Matyskiela and Morgan, 2009). Interestingly, substrate 
binding was found to induce conformational changes in Apc2-Apc11 (Buschhorn et al., 2011) 
which may be coupled with proper substrate recognition and efficient ubiquitin transfer to 
substrate residues.  
Another layer of interactions important for APC/C activity are those with E2 ubiquitin-
conjugating enzymes. Members of the UBC4/5 (King et al., 1995) and E-2C (Aristarkhov et al., 
1996; Townsley et al., 1997; Yu et al., 1996) families (in particular human UBCH5 and 
UBCH10, respectively) have long been recognized as E2 partners for the APC/C. While in a 
reconstituted system both classes of E2s can support APC/C-dependent ubiquitination (Garnett et 
al., 2009; Kirkpatrick et al., 2006; Mathe et al., 2004; Summers et al., 2008; Yu et al., 1996; Zeng 
et al., 2010), which E2 enzyme(s) work with the APC/C in vivo remains an open question. 
Genetic evidence from S. pombe and D. melanogaster supports the notion that members of the E-
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2C family, Ubc11 and Vihar, are most likely to be physiologically relevant (Mathe et al., 2004; 
Osaka et al., 1997) .Consistent with this, the spatiotemporal pattern of the E-2C protein Vihar 
distribution and proteolysis closely resembles that for cyclin B1 (Mathe et al., 2004) and a 
dominant-negative form of the enzyme results in stabilization of APC/C substrates (Townsley et 
al., 1997). Unlike in simpler model organisms, the importance of UBCH10 for mitosis in human 
cells has been disputed (Rape and Kirschner, 2004; Walker et al., 2008). An N-terminal extension 
found in UBCH10, but not in members of the UBC4/5 family, has been proposed to regulate the 
ubiquitination activity of the APC/C and the sensitivity of the ligase to checkpoint control 
(Summers et al., 2008).   
The set of distinct E2 ubiquitin-conjugating enzymes suspected to function in APC/C-
mediated catalysis was recently expanded. In budding yeast, Ubc1 functions as a supplementary 
E2 enzyme that elongates ubiquitin chains initiated by the proximally-acting E2 Ubc4 (Rodrigo-
Brenni and Morgan, 2007). In higher eukaryotes, it has been proposed that another E2 UBE2S is 
important in elaborating Lys11-linked ubiquitin chains on APC/C-substrates (Garnett et al., 2009; 
Williamson et al., 2009; Wu et al., 2010). In this model, UBCH10 is proposed to initiate 
monoubiquitination of the substrate, with UBE2S then extending Lys11-linked ubiquitin chains 
that signal degradation by the proteasome (Garnett et al., 2009; Jin et al., 2008; Williamson et al., 
2009; Wu et al., 2010). Consistent with this idea, depletion of UBE2S from Drosophila S2 cells 
results in a strong delay in a metaphase-like state and stabilization of cyclin B1 at the spindle 
poles, among other mitotic defects (Williamson et al., 2009). In contrast, UBE2S has a 
nonessential function in APC/C-mediated proteolysis of cyclin B1 during normal mitosis in 
human HeLa cells (Garnett et al., 2009). These findings imply instead that UBE2S becomes 
important for substrate proteolysis under conditions where APC/C activity is compromised such 
as during recovery from drug-induced spindle assembly checkpoint (SAC) activation. The spindle 
checkpoint detects inappropriate attachment and tension between chromosomal kinetochores and 
microtubules and delays segregation of sister chromatids by inhibiting APC-mediated 
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ubiquitination of securin and cyclin B1 (Kim and Yu, 2011; Musacchio and Salmon, 2007). 
Under such conditions of low APC/C activity, UBE2S may be priming APC/C molecules for 
rapid and processive ubiquitination of substrates and may be promoting degradation by enhancing 
the rate of ubiquitination relative to that of deubiquitination. A possible role of UBE2S in 
silencing the SAC has not been elucidated. Together these findings imply that the contribution of 
UBE2S and Lys11-linked chains in the degradation of APC/C substrates may be organism-and 
condition-specific, and that there may not be a uniform requirement for UBE2S in all systems or 
circumstances.   
 
 
Role of ubiquitin-chain formation in cyclin B1 proteolysis 
 Previous work revealed that in contrast to the SCF-ligase complex which cooperates with 
the E2 Cdc34 to assemble homogeneous Lys48-linked chains on substrates (Petroski and 
Deshaies, 2005), the APC works in conjunction with UBCH10 and UBCH5 and modifies cyclin 
B1 with chains of complex topology (Figure 1.3) (Kirkpatrick et al., 2006). Surprisingly, the 
ubiquitin signal assembled on cyclin B1 consists of ubiquitin-ubiquitin linkages through Lys11 
and Lys63 in addition to Lys48 (Kirkpatrick et al., 2006). Analysis of cyclin ubiquitination 
revealed a two-stage ubiquitination process, where initially the APC/C facilitates transfer of 
ubiquitin monomers to multiple lysine residues on cyclin B1, followed by extension of short 
ubiquitin chains (Kirkpatrick et al., 2006). Under conditions where the assembly of proteolytic 
signal is non-processive and requires rebinding to the ubiquitin ligase, this pathway, as opposed 
to the rapid elongation of a single chain, may allow the APC/C to more precisely control the 
spatiotemporal pattern of substrate proteolysis. In the context of cyclin B1, the short ubiquitin 
polymers generated by UBCH10 or UBC4 present an efficient proteolytic signal (Kirkpatrick et 
al., 2006). Interestingly, these assemblies are remodeled by the opposing activities of proteasome-
associated E4 chain-elongating enzyme Hul5 (KIAA10) and the deubiquitinase USP14 (Crosas et 
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al., 2006; Hanna et al., 2006; Leggett et al., 2002; You and Pickart, 2001). In these studies, 
perhaps the most surprising finding was that Lys48-linked ubiquitin polymers were dispensable 
for binding of modified cyclin B1 to ubiquitin receptors and rapid degradation by the proteasome 
(Kirkpatrick et al., 2006). As only few other substrates were known at the time to be degraded 
independent of Lys48-chain formation (Baboshina and Haas, 1996; Guterman and Glickman, 
2004; Hershko and Heller, 1985; Hofmann and Pickart, 2001), this in-depth analysis of cyclin B1 
set out the stage to explore the significance of different ubiquitin linkages in APC-mediated 
proteolysis.     
 
CDK1
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E2 (UBC4, 
UBCH10,                 
UBE2S 
26S Proteasome
E3: Anaphase-Promoting
Complex/Cyclosome (APC/C)
Cyclin B1
CDK1
Cyclin B1
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Figure 1.3 APC/C-dependent proteolysis of cyclin B1. The APC/C cooperates with ubiquitin-
conjugating enzymes from the E-2C and UBC4/5 families (in particular, human UBCH10 and 
UBCH5, respectively) to catalyze chain formation through three lysine residues of ubiquitin 
(K11, K48 and K63) (Kirkpatrick et al., 2006) . UBCH10 or UBCH5 builds multiple short 
ubiquitin chains on cyclin B1, which are sufficient to target the protein for degradation by 
the proteasome. In this context, K48-linked ubiquitin polymers are dispensable for binding 
of modified cyclin B1 to ubiquitin receptors and degradation by the proteasome (Kirkpatrick 
et al., 2006) . More recent work indicates that a second E2 enzyme, UBE2S, is important in 
elaborating K11-linked ubiquitin chains on APC/C-substrates (Garnett et al., 2009; 
Williamson et al., 2009; Wu et al., 2010). In this model, UBCH10 is proposed to initiate 
monoubiquitination of the substrate, with UBE2S then extending K11-linked ubiquitin 
chains that signal degradation by the proteasome. 
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The ability of the APC, in conjunction with the E2 UBCH10, to extend multiple short 
ubiquitin chains through lysines 11, 48 and 63 of ubiquitin in vitro (Kirkpatrick et al., 2005) 
raises the question as to whether Lys11-chain formation is indeed required for proteolysis of 
APC/C substrates, and if so, whether this requirement arises from a specific role of UBE2S, or 
because Lys11 is one of three sites used by UbcH10 (Jin et al., 2008; Kirkpatrick et al., 2005). 
Also, are any of these ubiquitin linkages functioning as the major degradative element? We 
sought to address these questions using Xenopus egg extracts as a model system. Studies of the 
role of ubiquitin topology in substrate turnover in Xenopus extract are hampered by the presence 
of endogenous ubiquitin. Seeking to understand whether APC/C-dependent proteolysis is strictly 
dependent upon polyubiquitination and whether the proteolytic machinery exerts a requirement 
for Lys11 or other Ub-Ub linkages to efficiently degrade cyclin B1, we developed a novel 
approach where Xenopus extracts are made largely dependent on exogenous ubiquitin. Treatment 
of Xenopus extract with ubiquitin-vinyl sulfone (UbVS), a general inhibitor of ubiquitin 
isopeptidases (Borodovsky et al., 2001), blocked cyclin B1 proteolysis in a manner that could be 
fully rescued by exogenous ubiquitin. For our analysis, we used full-length cyclin B1 and CDK1, 
expressed in insect cells and combined to produce MPF (Kirkpatrick et al., 2006). The studies 
with active MPF were nicely complemented with the use of an N-terminal fragment (1-88 amino 
acids) of cyclin B1 which we extensively characterized and found to mimic the ubiquitination and 
degradation patterns of the full-length protein. To quantitatively evaluate the role of different 
ubiquitin structures in targeting cyclin B1 for degradation, we expressed and purified 
35
S-labeled 
cyclin B1 and measured its proteolysis in Xenopus extract by monitoring release of radioactive 
soluble counts.  Surprisingly, using the UbVS system we found that Lys11-linked ubiquitin 
chains were not required for efficient cyclin B1 degradation. Furthermore, we were fascinated 
with the robust rates of proteolysis a chain-terminating ubiquitin (Ub
triR
), which blocks all 
possible sites of chain elongation by UBCH10, UBC4/5, and UBE2S, supported. 
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 Cyclin B1 has some particularly interesting features that may play a role in regulating its 
localization in the cell and interactions with other proteins, as well as its stability. The function of 
accepting ubiquitin appears to be fulfilled by lysine residues found in the non-conserved regions 
neighboring the degron (Glotzer et al., 1991; King et al., 1996). Positioned in the vicinity of the 
D-box or KEN-box motif, the TEK box has been proposed as a new interaction motif directing 
the chain-initiation event (Jin et al., 2008). However, the potential contribution of the lysine 
residue found in this motif to proteolysis of different APC substrates remains to be addressed and 
may provide a better understanding of how the integrity of the motif is essential to UBCH10-
dependent conjugation and proteasomal degradation (Jin et al., 2008). For cyclin B1, the 
unstructured N-terminal region upstream of the cyclin box provides a platform containing 18 
lysine residues; 15 of these lysine residues are located within the first 88 amino acids close to the 
destruction box. Intriguingly, there are patterns of lysine clustering that appear to be fairly well 
conserved in different species and whose significance has not been elucidated. We hypothesized 
that the lysine profile of cyclin B1 provides a platform upon which a proteolytic signal consisting 
of multiple monoubiquitins or short ubiquitin chains can be assembled, obviating the need for the 
formation of long Lys11-linked ubiquitin chains. In the work presented in this dissertation, we 
examined how cyclin B1 proteolysis is influenced by the number of available ubiquitination sites. 
To this end, we generated a series of cyclin mutants containing lysine-to-arginine substitutions at 
particular residues guided by mass spectrometry analysis of the ubiquitination sites in the 
substrate. Our findings suggested that ubiquitin-chain formation is not essential for cyclin B1 
proteolysis, unless the number of available lysine residues is restricted and that multiple 
monoubiquitination constitutes an efficient proteolytic signal in this context.  
 What the ubiquitination status of cyclin B1 upon its docking at the proteasome is and 
what ubiquitin requirements the proteolytic machinery itself may be imposing on the APC for 
efficient degradation of cyclin B1 have remained poorly understood. To further evaluate the 
relevance of different chain structures as a targeting signal for degradation, we sought to 
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reconstitute different steps of the pathway in vitro.  In ubiquitination reconstituted with 
recombinant E1, E2s, and ubiquitin, the APC/C, immunopurified from mitotic Xenopus extracts 
where it is activated by Cdc20, can rapidly attach mono-ubiquitin to multiple lysines in cyclin B1. 
Cyclin modified with 4 or more ubiquitin moieties on distinct lysines was recognized by various 
ubiquitin receptors.  Consistent with experiments in Xenopus extract, multiply monoubiquitinated 
cyclin B1 species were efficiently degraded by purified human proteasomes in the absence of the 
proteasome-associated deubiquitinating enzyme USP14. Surprisingly, we found that USP14 
suppressed degradation of multiply monoubiquitinated cyclin B1 to a similar extent as that of 
polyubiquitinated species, suggesting that USP14 can efficiently remove monoubiquitin. 
However, such deubiquitinating activity did not appear to strongly antagonize proteasome 
function in Xenopus extract as our findings presented in this dissertation suggest. We further 
pursued identification of deubiquitinating enzyme(s) that may modulate the rate of cyclin 
degradation in the Xenopus extract. 
 In conclusion, in chapter II we present our work on developing and characterizing the 
UbVS system. This includes work detailing the behavior of an N-terminal fragment of cyclin B1 
and our approach to quantitatively analyze its degradation. In the study presented in chapter III 
we sought to evaluate the role of different ubiquitin linkages in cyclin B1 proteolysis. We 
demonstrate that conjugation of ubiquitin moieties to multiple lysine residues of cyclin B1 
provides an alternative degradation pathway for cyclin B1 that does not require chain extension 
by the Lys11-specific E2 enzyme UBE2S. Lys11-ubiquitin chain formation becomes essential 
only when the number of available lysine residues in cyclin B1 is restricted. We postulate that 
high local density of ubiquitin, whether attached as monomers along the substrate or linked to 
each other in a polymer, is sufficient to target a substrate for proteolysis.  In chapter IV we further 
examine the relative contribution of different E2 enzymes for APC/C-mediated ubiquitination and 
degradation in the Xenopus extract. 
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Abstract 
 
Covalent attachment of ubiquitin to proteins regulates a myriad of cellular processes by 
influencing activity, localization and stability of substrates. Ubiquitin can be appended to proteins 
as single moieties or as ubiquitin polymers of specific length and linkage type. The widely 
accepted view supported by early studies was that Lys63-linked ubiquitin polymers have non-
proteolytic roles, whereas Lys48-linked assemblies serve as the principal signal for substrate 
degradation by the 26S proteasome. While appealing in its simplicity, it is now evident that this 
model does not reflect the wealth of information different ubiquitin signals encode. Recent work 
has revealed that the proteasome has the capacity to recognize and degrade substrates bearing 
ubiquitin modifications other than homogenous Lys48-linked ubiquitin chains. In this study, we 
establish and characterize a novel approach to studying the role of ubiquitin-chain synthesis in 
targeting of substrates to the proteasome. Global inhibition of deubiquitinases with ubiquitin 
vinyl sulfone (UbVS) rendered Xenopus egg extracts dependent on exogenous ubiquitin to 
promote cyclin B1 proteolysis. Detailed characterization of the system suggested that it can be a 
valuable approach in defining the role of ubiquitin-chain formation in APC/C-dependent 
ubiquitination and degradation.  
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Introduction 
 
Ubiquitin is a highly conserved 76 amino-acid protein which can be conjugated 
posttranslationally to other proteins via an isopeptide linkage between its carboxy-terminal 
glycine and, most typically, the ε-amino group of a lysine (Lys) in a substrate (Ciechanover et al., 
1984; Ciechanover et al., 1980; Goldknopf and Busch, 1977; Hershko and Ciechanover, 1998; 
Hershko et al., 1981; Hunt and Dayhoff, 1977). Ubiquitin itself contains seven Lys residues, at 
positions 6, 11, 27, 29, 33, 48, and 63, allowing the assembly of ubiquitin polymers and a diverse 
array of ubiquitin signals (Pickart and Fushman, 2004). Posttranslational modification by 
ubiquitin is utilized in many cellular pathways, but the role of ubiquitin in selective, intracellular 
protein degradation remains its best-understood function. In the classical model, a chain of four 
ubiquitin molecules linked through Lys48 is required for efficient recognition and degradation by 
the 26S proteasome (Chau et al., 1989; Finley et al., 1994; Thrower et al., 2000). The 
development of novel mass spectrometry techniques (Kirkpatrick et al., 2005; Kirkpatrick et al., 
2006; Peng et al., 2003; Xu et al., 2009) and biochemical reagents (Matsumoto et al., 2010; 
Newton et al., 2008) has been vital to recent work demonstrating that the repertoire of proteolytic 
signals may encompass chains of other linkage types, including Lys11-linked ubiquitin chains 
(Baboshina and Haas, 1996; Garnett et al., 2009; Jin et al., 2008; Matsumoto et al., 2010; 
Williamson et al., 2009; Wu et al., 2010; Xu et al., 2009) or short chains of mixed linkage 
(Kirkpatrick et al., 2006). Congruent with the widely accepted view that ubiquitin-polymer 
structure is required for high-affinity binding to the proteasome, the attachment of a single 
ubiquitin to one (monoubiquitination) or to multiple sites (multiple monoubiquitination) has been 
implicated in mostly non-proteolytic processes. 
The cell cycle must proceed in an orderly fashion to maintain genomic integrity and to 
prevent dysregulated proliferation. Fundamental to this is the precisely timed destruction of key 
regulators, including cyclins, cyclin-dependent kinase inhibitors and securin. Many of these 
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regulators are substrates of the anaphase-promoting complex/cyclosome (APC/C or APC), a 
multisubunit RING E3 ubiquitin ligase. In an event critical for anaphase entry, the APC/C and 
cognate E2 ubiquitin-conjugating enzymes catalyze the ubiquitination of cyclin B1 targeting it to 
the 26S proteasome for degradation (Barford, 2011; Glotzer et al., 1991; Harper et al., 2002; 
Hershko et al., 1991; Peters, 2002; Peters, 2006). The ubiquitin signal assembled on cyclin B1 in 
vitro was previously revealed to comprise of monoubiquitin appended to multiple distinct lysines 
in the substrate, as well as some short chains linked through Lys11, Lys48 and Lys63 
(Kirkpatrick et al., 2006). While starkly different from canonical proteolytic signals consisting of 
a single homogeneous ubiquitin chain, the ubiquitin signal built on cyclin B1 supports rapid 
degradation by the 26S proteasome (Kirkpatrick et al., 2006).  More recent studies have 
implicated a role of the Lys11-linkage specific E2 UBE2S and chain synthesis it promotes in 
APC/C-dependent proteolysis (Garnett et al., 2009; Matsumoto et al., 2010; Wickliffe et al., 
2011a; Wickliffe et al., 2011b; Williamson et al., 2009; Wu et al., 2010; Ye and Rape, 2009). At 
least in some biological contexts, however, turnover of APC/C substrates and normal mitosis can 
occur in the absence of UBE2S or Lys11-linked polyubiquitination (Garnett et al., 2009; Jin et al., 
2008). 
Dissecting the contribution of different ubiquitin linkages to proteasomal recognition and 
degradation in intricate systems such as whole cells or cellular extracts is complicated in part by 
the pool of endogenous ubiquitin. Maintenance of steady-state ubiquitin levels is crucial in 
physiological settings and is regulated at multiple levels, the most important of which are de novo 
synthesis of ubiquitin (Simon et al., 1999; Watt and Piper, 1997) and ubiquitin recycling 
mediated by deubiquitinating enzymes (Finley, 2009; Hanna et al., 2007). Such pathways pose 
challenges to studying the role of ubiquitin topology in proteasomal targeting and their robustness 
renders it a non-trivial task to induce ubiquitin deficiency. To gain better understanding of the 
role of specific ubiquitin linkages in cyclin B1 proteolysis, we developed and characterized a 
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novel approach where Xenopus extracts are made largely dependent on exogenous ubiquitin by 
restricting the recycling of endogenous ubiquitin.  
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Results 
 
Developing a quantitative assay to measure cyclin proteolysis in Xenopus cell-cycle extract 
 
 The heterogeneous nature of the ubiquitin signal built on cyclin B1 in Xenopus extract 
renders visualization of ubiquitinated species by western blot analysis challenging. Furthermore, 
the ubiquitin tag assembled on substrates may not promote their degradation. To assess the 
contribution of different ubiquitin linkages specifically in cyclin B1 turnover, we developed a 
quantitative assay to measure cyclin B1 degradation products. We metabolically labeled an N-
terminal fragment of cyclin B1 with 
35
S in E. coli, purified the protein, and measured its 
proteolysis in Xenopus extract by monitoring release of trichloroacetic-acid (TCA) soluble 
counts. 
We first examined whether this N-terminal fragment of cyclin B1, similar to the full-
length protein, was degraded in an APC/C-dependent fashion. When added to interphase extract, 
a state in which the APC/C is inactive, cycB1-NT remained stable, but was rapidly degraded 
upon entry of extract into mitosis (Figure 2.1a). Furthermore, pre-treatment of mitotically-
arrested extract with a small-molecule inhibitor of the APC/C TAME (Zeng and King, 2012; 
Zeng et al., 2010) (Figure 2.1b) or concomitant addition of identical unlabeled N-terminal 
fragment largely stabilized the radiolabeled cycB1-NT (Figure 2.1d), consistent with a 
requirement for APC/C-mediated ubiquitination to stimulate substrate degradation. In contrast, 
proteolysis was not effectively competed by a destruction-box (D-box) mutant (Figure 2.1d). 
Interestingly, these competition experiments revealed differing efficiencies of inhibition, 
suggesting cyclin B1 fragments from different species may bind the APC with different affinities. 
Difference in binding affinities may stem from the sequence variation distinguishing the D-box 
motif of the sea urchin protein from that of the human cyclin B1. Alternatively, sea urchin cyclin 
B1 is relatively lysine-poor in its N-terminal domain, containing only 10 lysine residues, raising  
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an interesting possibility that this relative defect in binding to the APC may stem from the lower 
number of ubiquitination sites neighboring the D-box. Nevertheless, the degradation of both 
human and sea urchin cycB1-NT in extract was proteasome-dependent, as addition of the 
proteasome inhibitor MG262 blocked this process (Figure 2.1c; data not shown).   
 
 
Endogenous ubiquitin levels are limiting for degradation of an N-terminal fragment of 
cyclin B1 in mitotic Xenopus extract 
 
To evaluate the role of different ubiquitin-chain topologies in cyclin degradation in the 
Xenopus system, we first determined the consequences of adding excess wild-type or mutant 
ubiquitin to mitotic extract. Using ubiquitin-aqua (Ub-AQUA) (Kirkpatrick et al., 2005; 
Kirkpatrick et al., 2006) measurements, we calculated that free ubiquitin is present at 5-10 μM 
concentration in Xenopus extracts (D. Kirkpatrick and N. Hathaway, unpublished observations). 
When added at 44 μM final concentration, wild-type ubiquitin substantially accelerated 
degradation, decreasing the half-life of the substrate from 25 minutes in untreated extract to 
approximately 15 minutes in the presence of additional ubiquitin (Figure 2.2a). Ubiquitin mutants 
containing a single lysine-to-arginine substitution at position 48 (Ub
48R
) or 63 (Ub
63R
) stimulated 
degradation almost as well as wild-type ubiquitin, consistent with the idea that these linkages are 
not essential for degradation.  Surprisingly, a ubiquitin containing a lysine-to-arginine mutation at 
position 11 (Ub
11R
) also stimulated degradation when added to extract, although the effect was 
not as dramatic as for wild-type ubiquitin.  Similar results were obtained with a ubiquitin variant 
bearing arginine residues at all three positions, Lys11, 48 and 63 (Ub
triR
), simultaneously. Similar 
trends were observed when the amount of ubiquitin was increased approximately 2.5-fold to 116 
μM (Figure 2.2b). These results were unexpected, as mass spectrometry analysis indicated that 
elimination of all three principal sites (Lys11, Lys48 and Lys63) of ubiquitin-ubiquitin linkage by  
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the APC, as in Ub
triR
, rendered ubiquitin incapable of supporting chain formation in reconstituted 
reactions (data not shown). In contrast, methylated ubiquitin (Ub
me
) slowed proteolysis below the 
rate observed in untreated extract, but even when added at high concentration, the degree to 
which it suppressed degradation was modest.  The capacity of chain-terminating ubiquitin to 
support robust cyclin proteolysis in mitotic Xenopus extract raised the question of whether 
ubiquitin-chain synthesis is essential in this pathway.  
 
 
The UbVS system – a novel approach to studying the role of ubiquitin topology in 
proteasomal targeting 
 
 Analysis of ubiquitin-mediated proteolysis in complex systems such as Xenopus extracts 
is hampered by the pool of endogenous ubiquitin which can be incorporated into the ubiquitin 
signal assembled on a substrate. In Xenopus extracts, endogenous ubiquitin levels appeared to be 
limiting for the proteolysis of cycB1-NT as addition of ubiquitin accelerated this process. To 
restrict ubiquitin availability further, we sought to suppress ubiquitin-chain disassembly, in 
essence, locking endogenous ubiquitin into existing conjugates. We reasoned that inhibition of 
ubiquitin recycling will render the degradative capacity of Xenopus extracts dependent on added 
ubiquitin. To test this idea, we added ubiquitin-vinyl sulfone (UbVS), a general inhibitor of 
ubiquitin isopeptidases (Borodovsky et al., 2001), to mitotic Xenopus extract. Ubiquitin-vinyl 
sulfone inhibited cyclin proteolysis in a dose-dependent fashion, such that 10 μM suppressed 
degradation only partially, whereas 20 µM UbVS inhibited degradation by at least 90-95% 
(Figure 2.3a; data for full-length cyclin B1 not shown). Inhibition of cyclin proteolysis could be 
fully rescued by addition of wild-type ubiquitin at the end of the pre-incubation, concomitantly 
with substrate addition (Figure 2.3b). However, while increasing concentrations of UbVS failed 
to influence appreciably the degree of substrate stabilization, those appeared to slightly dampen  
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the ability of 44 μM of wild-type ubiquitin to restore degradation (Figure 2.3b). The robust 
stabilization of the N-terminal fragment of human cyclin B1, as well as that of the full-length 
protein, achieved with 20 µM UbVS prompted us to use this concentration of UbVS for all 
subsequent experiments where we sought to make the system dependent on exogenous ubiquitin.   
We found that the degree of degradation rescue in UbVS-treated extracts depended on the 
concentration of added ubiquitin (Figure 2.4a). When ubiquitin was supplemented at 20 μM 
concentration, degradation proceeded at a rapid rate for the first 15 minutes of the reaction, and 
then plateaued, presumably due to depletion of free ubiquitin. Consistent with this idea, a two-
fold increase in the concentration of ubiquitin supported rapid proteolysis for 30 minutes, leading 
to complete degradation of the substrate (Figure 2.4a). To confirm that the substrate behavior 
observed under these conditions is consistent with the known properties of the ubiquitin-
proteasome system, we examined how mutations in functional surfaces of ubiquitin impacted its 
capacity to rescue degradation in a UbVS-treated extract.  Forms of ubiquitin bearing point 
mutations in one of the hydrophobic patch residues (L8A, I44A, or V70A) were not capable of 
supporting proteolysis (Figure 2.4b), as predicted given the importance of the hydrophobic patch 
in recognition of ubiquitin chains by proteasome-associated ubiquitin receptors (Beal et al., 1996; 
Beal et al., 1998; Lam et al., 1997). In contrast, mutations that interfere with non-proteolytic 
functions of ubiquitin (F4A (Shih et al., 2000; Sloper-Mould et al., 2001) or D58A (Lee et al., 
2006; Penengo et al., 2006)) supported rapid proteolysis, at rates comparable to wild-type 
ubiquitin (Figure 2.4b). Importantly, the rate of degradation in UbVS-treated extracts 
supplemented with wild-type ubiquitin was identical to that observed when adding a similar 
concentration of ubiquitin to untreated extracts, yielding a half-life of approximately 15 minutes 
in both cases (Figure 2.2a; Figure 2.4a). These findings suggest that UbVS-sensitive 
deubiquitinating enzymes are unlikely to present a major kinetic barrier to cyclin B1 degradation 
and instead suggest that the major role of these deubiquitinating enzymes may be to maintain a 
pool of free ubiquitin available to the conjugation machinery. Analysis of ubiquitin conjugates  
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and thioesters in extract under these conditions revealed that inhibition of isopeptidase activity 
with 20 μM UbVS led to near complete discharge of E2~Ub thioesters („~‟ represents a thioester 
bond between the active-site cysteine of an E2 and the C-terminal glycine of ubiquitin) (Figure 
2.4d, e). These trends paralleled the gradual disappearance of ubiquitinated species in the extract 
(Figure 2.4c). Addition of exogenous ubiquitin restored charging of E2 enzymes and formation of 
ubiquitin conjugates in the extract. Importantly, addition of wild-type ubiquitin to UbVS-treated 
extract led to reduction in UBCH10, but not UBCH5, levels (Figure 2.4d, e), suggesting that 
deubiquitinases may actively oppose UBCH10 degradation in Xenopus extracts. 
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Discussion 
 
In our studies, we sought to evaluate how the nature of the ubiquitin signal constructed on 
cyclin B1 influences its degradation by the 26S proteasome. The manner in which cyclin B1 is 
ubiquitinated, however, leads to a heterogeneous mixture of conjugates of different ubiquitin 
mass which can be difficult to visualize by western analysis. Furthermore, western analysis may 
not distinguish between ubiquitin intermediates en route to the proteasome and those bearing a 
non-proteolytic ubiquitin tag. Thus, to evaluate the role of different ubiquitin linkages in 
proteasomal targeting of cyclin B1, we developed a quantitative assay to measure cyclin B1 
degradation products. Here, we describe a novel approach where Xenopus extracts are made 
largely dependent on exogenous ubiquitin, allowing analysis of the role of ubiquitin-chain 
formation in APC-dependent proteolysis of cyclin B1. 
Several studies have attempted to examine the role of ubiquitin-chain topology in 
proteasomal degradation by adding mutant ubiquitin to extracts (Hershko et al., 1991; Jin et al., 
2008; Wu et al., 2010) or by injecting the ubiquitin into cells (Jin et al., 2008). Jin and colleagues 
found that ubiquitin incapable of forming Lys11 linkages (Ub
11R
) delayed early cell divisions 
when injected into Xenopus tropicalis embryos (Jin et al., 2008). However, the specific 
mechanism of delay and rates of degradation of APC substrates were not directly addressed. 
Therefore, it is possible that injection of Ub
11R
 perturbs other processes required for division of 
early embryos. In contrast, we found that adding such modified forms of ubiquitin typically 
accelerated degradation, with the exception of methylated ubiquitin. A possible explanation for 
the lack of effect of chain-terminating ubiquitins, such as Ub
11R 
or Ub
triR
, is that any added 
ubiquitin must compete with the endogenous ubiquitin pool. Therefore, dominant-negative effects 
may be difficult to observe when conducted in a background that contains wild-type ubiquitin. 
Alternatively, our data suggest that despite their potential effects on chain termination, these 
ubiquitins are indeed capable of contributing to a signal that can promote degradation.  
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Intriguingly, the stimulatory effect of ubiquitin addition was more pronounced for an N-
terminal fragment of cyclin B1 (cycB1-NT) relative to full-length cyclin B1 (data shown in 
chapter II and III). One possible explanation for this difference is that the N-terminal fragment 
binds to APC with lower affinity compared to the full-length protein, imposing a requirement for 
higher levels of ubiquitin-charged E2 for efficient degradation. Such a phenomenon would be 
reminiscent of the implicated role of a complex formation with a CDK partner and a Cks protein 
for cyclin recruitment to the phospho-APC/C and efficient degradation (van Zon et al., 2010; 
Wolthuis et al., 2008). Also, our work indicates that cyclin B N-termini from different species 
may have different affinities for the APC/C. An interesting question is whether the lysine profile 
of these proteins influences the stability of interaction with the E2-E3 complex. Sea urchin cyclin 
B, having fewer lysines in its N-terminal domain that can be targeted by proximally-acting E2 
such as UBCH10, may dissociate from the APC/C more rapidly and therefore require more 
processive ubiquitination such as catalyzed by the chain-extending Ubc1 (Chen and Pickart, 
1990; Rodrigo-Brenni and Morgan, 2007) or UBE2S (Garnett et al., 2009; Williamson et al., 
2009; Wu et al., 2010) for its timely destruction. Further experiments will be necessary to better 
understand these interesting aspects of the behavior of the system.  
Our analysis uncovered a strong dependence of the rate of cyclin proteolysis on the levels 
of free ubiquitin in extract. Addition of exogenous ubiquitin stimulated degradation, whereas 
inhibition of ubiquitin recycling suppressed degradation. Such a relationship between ubiquitin 
availability and APC-dependent proteolysis has not been previously appreciated, and it leads to 
the interesting possibility that control of ubiquitin availability may be a new mechanism by which 
the rate of APC substrate degradation could be controlled. Future experiments are required to 
examine whether and how ubiquitin availability may be controlled by cell-cycle regulatory 
mechanisms. Supplementing UbVS-treated extracts with ubiquitin restores cyclin proteolysis to 
levels seen in non-treated extract. This finding indicates there may be no requirement for UbVS-
sensitive deubiquitination to support cyclin degradation, beyond a role in maintaining levels of 
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free ubiquitin. Interestingly, as long as ubiquitin is supplied to sufficient levels, the rate of cyclin 
degradation is no faster in a UbVS-treated extract relative to a non-treated extract. This may 
indicate that there are few, if any, UbVS-sensitive DUBs that actively antagonize cyclin B1 
degradation in mitotic extracts. Alternatively, for deubiquitinating enzymes to be able to 
antagonize degradation, it may be crucial that the rate of ubiquitination be constrained by 
restricting availability of free ubiquitin or by rendering ubiquitin transfer less processive.  
UbVS-treated extracts provide an opportunity to rigorously examine the degradative 
function of different ubiquitin-ubiquitin linkages. While the role of UbVS-sensitive DUBs in this 
process cannot be ascertained using this approach, systematic analysis is likely to provide clues 
about potential contribution. In the context of cyclin B1, UbVS-sensitive deubiquitination did not 
appear to appreciably oppose proteasomal targeting. However, APC substrates may be 
differentially sensitive to the action of such deubiquitinating enzymes and the UbVS approach 
may allow for this idea to be directly tested. In this regard, the APC was previously suggested to 
establish temporal order of destruction of its targets based on relative differences in the 
processivity of ubiquitination (Rape et al., 2006). How deubiquitination may modulate the 
ubiquitin signal APC builds on various substrates and potentially have an active role in 
establishing the correct sequence of proteasomal targeting have not been clarified. The UbVS 
system may provide an avenue to examine how the balance of ubiquitination and deubiquitination 
influences the temporal order of degradation of APC substrates.
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Methods 
Antibodies and biochemical reagents 
Proteins were separated by SDS-PAGE on NuPAGE 4-12% or 12% Bis-Tris gels 
(Invitrogen), followed by wet transfer to PVDF. Sources of antibodies for immunoblotting were 
as follows: anti-cyclin B1 (Ab-2; RB-008-P, Neomarkers), anti-UBCH10 (A-650, Boston 
Biochem and AB3861, Millipore), anti-UBCH5 (A-615; Boston Biochem), anti-ubiquitin (P4D1; 
sc-8017; Santa Cruz Biotechnology). Secondary antibodies used include anti-goat IgG-HRP (sc-
2020; Santa Cruz Biotechnology), anti-rabbit IgG-HRP (NA934; GE Healthcare), and anti-mouse 
IgG-HRP (NA931; GE Healthcare). MG262 (I-120), Ub
me 
and ubiquitin mutants except for 
Ub
(11+48)R
, Ub
(11+63)R
 and Ub
triR 
were purchased from Boston Biochem. TAME (T4626) and 
ubiquitin (U6253) were purchased from Sigma. 
 
Preparation of recombinant proteins 
Ubiquitin mutants Ub
(11+48)R
, Ub
(11+63)R
 and Ub
(11+48+63)R 
(referred to as Ub
triR
) were 
generated by introducing arginine codons (AGA and AGG) at the indicated sites through PCR-
mediated mutagenesis of the human ubiquitin sequence (cloned in pET3a with ampicillin 
resistance, the kind gift of C.M. Pickart). Plasmids were verified by sequencing and the purified 
proteins analyzed by mass spectrometry. To ensure efficient arginine incorporation, BL21 (DE3) 
cells were co-transformed with pJY2, developed by Pickart lab (You et al., 1999), which carries 
T7 lysozyme (LysS) and a gene encoding tRNAUCU
Arg
. Cultures were grown at 37 °C to an 
attenuance (D) of ~ 0.5 at 600 nm, and induced with 100 μM IPTG at D600 nm = 0.6 at 25 ˚C for 5 
h. Cells were ruptured by sonication in QA lysis buffer (50 mM HEPES (pH 7.7), 100 mM KCl, 
protease-inhibitor cocktail, 5 mM 2-mercaptoethanol, 10 µg ml
-1
 DNase). Lysozyme was added 
to 1 mg ml
-1 
concentration and lysate was incubated with rotation at 4 °C for 15 min. Following 
sonication, cell lysates were clarified by centrifugation and the resulting supernatants applied to a 
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Q column. The flow-through containing ubiquitin was concentrated and purified by size-
exclusion chromatography. Fractions containing ubiquitin were typically > 95% pure. 
To generate full-length cyclin B-CDK1 complex, human cyclin B1 and CDK1 
baculoviruses were used as described previously (Kirkpatrick et al., 2006). Baculovirus was 
added to Sf9 cells and cyclin B1 expression was allowed for 2.5 days. CDK1 was expressed 
separately in Sf9 cells and then combined with lysate from cells expressing cyclin B1 to allow 
formation of complex, which was then purified through Ni-NTA affinity and gel filtration 
chromatography.  
        CycB1-NT (1-88 amino acids of human cyclin B1) , containing an HA tag at the N 
terminus and a 6xHis tag at the C terminus was generated using PCR amplification with forward 
primer (5‟-CCA GGA CCA TGG GTT ACC CAT ACG ATG TTC CAG ATT ACG CTG GCT 
CGA TGG CGC TCC GAG TCA CG-3‟) and reverse primer (5‟-GGG AGC CTC GAG CTA 
GGG AGC GTG ATG GTG ATG GTG ATG CAT AGG TAC CTT TTC AAG AGG-3‟). The 
resulting PCR product was digested with NcoI and XhoI for subcloning into pET28a. Plasmids 
were verified by restriction enzyme mapping and sequencing. For 
35
S labeling in Escherichia  
coli, cultures (50 ml) were grown at 37 ˚C to D600 nm =  0.8, then collected  by centrifugation 
(3,700g for 15 min, at 4 
o
C) and resuspended in modified M9 medium (50 ml final volume). After 
resuspension in modified M9 medium, cells were allowed to grow for additional 15 min at 37 °C 
before 5 mCi of Easy Tag
TM
 L-[35S]-Methionine (NEG709A005MC; Perkin Elmer) was added. 
Expression was induced with 0.5 mM IPTG for 2.5 h at 37 
o
C. Cells were ruptured in 5 ml g
-1
 of 
pellet guanidine-HCl lysis buffer (pH 8.0) and lysates rotated at 24 °C until the lysate became 
slightly translucent; approximately 45 min. Lysates were clarified by centrifugation and cycB1-
NT was purified using Ni-NTA affinity chromatography (Qiagen). Eluted protein was desalted 
into XB buffer (100 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, pH 7.8 with KOH), 
supplemented 2% glycerol, protease inhibitors and phenylmethylsulfonyl fluoride, and stored at – 
20 °C.  
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Preparation of Xenopus egg extract  
Interphase Xenopus egg extract was prepared from eggs laid overnight according to the 
protocol of Murray (Murray, 1991) with the exception that eggs were activated with 2 μg/ml 
calcium ionophore (A23187, free acid form, Calbiochem) for 30 min prior to the crushing spin. 
Extract was frozen in liquid nitrogen and stored at -80 ºC. Interphase extract was induced to enter 
mitosis by addition of non-degradable cyclin B, which activates CDK1 and stimulates mitotic 
phosphorylation, resulting in APC/C activation. A fusion of the maltose-binding protein (MBP) 
to Xenopus cyclin B lacking its N-terminal 90 amino acids (MBP-Δ90) (Salic and King, 2005) 
was expressed in E. coli by inducing cultures at an D600nm=0.6 with 300 μM 
isopropylthiogalactoside (IPTG) for 5 h at room temperature. Purification was carried out 
following New England BioLabs (NEB) protocol. To make mitotic extract, MBP- Δ90 was added 
to interphase extract generally at ~ 20 μg ml-1 and incubated at 22-24 ºC for 45-60 min. 
 
Cyclin B1 degradation in Xenopus egg extract 
Degradation assays where non-ubiquitinated cyclin B1 was added to extract were 
generally performed in 40 μl total volume per reaction condition, with extract constituting 75-
80% of that volume. For experiments with TAME and MG262, extracts were pre-treated with 
relevant compound or dimethyl sulfoxide (DMSO) for 15 min at 24 °C, with agitation (1,250 
r.p.m.). For assays containing no UbVS, extracts were supplemented with ubiquitin as indicated 
or buffer (for untreated sample) concomitantly with ~200-250 nM substrate. For experiments 
with UbVS, interphase or mitotic extracts were treated with UbVS for 30 min at 24 °C, with 
agitation (1,250 r.p.m.) before addition of ubiquitin and cyclin B1. Extracts contained 100 μg ml-1 
cycloheximide to prevent re-incorporation of free labeled amino acid. For competition assays, 
unlabeled competitor was added concomitantly with radiolabeled cyclin B1 and degradation was 
initiated. Degradation experiments were performed at 24 °C, with agitation (1,250 r.p.m.), with 
samples withdrawn at indicated times. Samples for proteolysis of unlabeled full-length cyclin B1-
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CDK1 complex were combined with SDS sample buffer and subjected to SDS-PAGE and 
immunoblot analysis using anti-cyclin B1 polyclonal antibody (Ab-2, Neomarkers). In 
degradation assays with 
35
S-labeled cycB1-NT, reactions (3 μl per time point) were quenched 
with 97 μl of 20% trichloroacetic acid (TCA) (in H2O), vortexed and incubated on ice ≥ 30 min 
before centrifugation at 14,000g, at 4 °C. A fraction (50%) of sample supernatants was combined 
with NaOH to neutralize the acid and added to Ultima Gold scintillation fluid (6013327, Perkin 
Elmer). The radioactivity in the samples was measured by scintillation counting using a Packard 
scintillation counter. Proteolysis was measured by release of TCA soluble counts and is plotted as 
the percentage of input radiolabeled cyclin B1 protein. 
Ubiquitin dynamics in Xenopus extract were examined by anti-ubiquitin western blot 
analysis. Levels of specific E2s in Xenopus extract were examined by western blot analysis. 
Samples of extract removed at the indicated times were mixed with DTT-containing sample 
buffer and boiled to examine total endogenous levels of specific E2 enzymes.  To analyze levels 
of ubiquitin-charged endogenous ubch10 (ubch10~Ub) or ubch5 (ubch5~Ub), aliquots were 
removed at the indicated times and quenched with non-reducing sample buffer.  
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Abstract 
 
The Anaphase-Promoting Complex/Cyclosome (APC/C or APC) regulates progression 
through mitosis by orchestrating the ubiquitination of cell-cycle regulators such as cyclin B1 and 
securin. Although Lys48-linked ubiquitin chains represent a canonical signal targeting proteins 
for degradation by the proteasome, they are not required for the degradation of cyclin B1 in a 
reconstituted system. Recently, Lys11-linked ubiquitin chains have been implicated in 
degradation of APC/C substrates, but the Lys11-chain forming E2 UBE2S is not essential for 
mitotic exit. Together these findings raise important questions about the nature of the ubiquitin 
signal that targets APC/C substrates for degradation. Here, using a reconstituted system and 
Xenopus egg extracts, we demonstrate that multiple monoubiquitination of cyclin B1, catalyzed 
by UBCH10 or UBC4/5, is sufficient to target cyclin B1 for destruction by the proteasome. 
However, elaboration of Lys11-linked polymers becomes increasingly important when the 
number of ubiquitinatable lysines in cyclin B1 is restricted. We therefore define a novel 
proteolytic signal in the ubiquitin-proteasome pathway that confers flexibility in the requirement 
for particular E2 enzymes in modulating the rate of ubiquitin-dependent proteolysis.  
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Introduction 
 
Protein ubiquitination regulates many aspects of cell physiology, including protein 
degradation. A uniform Lys48-linked ubiquitin polymer was the first signal identified to target 
substrates for destruction by the 26S proteasome (Chau et al., 1989; Finley et al., 1994; Thrower 
et al., 2000). Recent work has demonstrated that the repertoire of proteolytic signals encompasses 
chains of other linkage types, including Lys11-linked ubiquitin chains (Baboshina and Haas, 
1996; Garnett et al., 2009; Jin et al., 2008; Matsumoto et al., 2010; Williamson et al., 2009; Wu et 
al., 2010; Xu et al., 2009) and short chains of mixed linkage types (Kirkpatrick et al., 2006). In 
contrast, polymers built through Lys63 of ubiquitin have non-proteolytic roles in DNA repair 
(Hofmann and Pickart, 1999; Spence et al., 1995), kinase activation (Deng et al., 2000), protein 
trafficking (Pickart and Fushman, 2004; Yang et al., 2009) and translation (Spence et al., 2000). 
Similarly, the transfer of a single ubiquitin moiety to one (monoubiquitination) or to multiple 
sites (multiple monoubiquitination) in a substrate has been implicated in mostly non-proteolytic 
processes (Robzyk et al., 2000; Terrell et al., 1998), although multiple monoubiquitination can 
target receptor tyrosine kinases (RTKs) to the lysosome (Haglund et al., 2003; Huang et al., 2006; 
Mosesson et al., 2003). More recently, multiple monoubiquitination has been shown to control 
proteasomal processing of the p105 NF-kB precursor to the shorter p50 subunit (Kravtsova-
Ivantsiv et al., 2009). To date, multiple monoubiquitination has not been coupled with rapid and 
complete proteolysis of a proteasome substrate. 
  The E3 ligase activities of the Skp1-Cullin-F-box complex (SCF) family and the 
Anaphase-Promoting Complex/Cyclosome (APC/C or APC) have long been recognized to be 
essential for cell-cycle progression (Harper et al., 2002; Peters, 2006; Skaar and Pagano, 2009). 
Unlike the SCF, which cooperates with the E2 Cdc34 to assemble uniform Lys48-linked ubiquitin 
polymers on substrates (Petroski and Deshaies, 2005), the APC/C works in conjunction with 
UBCH10 (also known as E-2C) and enzymes of the UBC4/5 family to catalyze chain formation 
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through three lysine residues of ubiquitin (Lys11, Lys48 and Lys63) (Kirkpatrick et al., 2006). 
UBCH10 builds multiple short ubiquitin chains on cyclin B1, which are sufficient to target the 
protein for degradation by the proteasome (Kirkpatrick et al., 2006). In this context, Lys48-linked 
ubiquitin polymers are dispensable for binding of modified cyclin B1 to ubiquitin receptors and 
degradation by the proteasome (Kirkpatrick et al., 2006). More recent work suggests that the 
assembly of proteolytic signal on APC/C substrates may occur in two stages. In budding yeast, 
Ubc4 initiates ubiquitin conjugation, whereas Ubc1 elongates ubiquitin chains (Rodrigo-Brenni 
and Morgan, 2007). Similarly, in metazoans, UBCH10 has been proposed to initiate 
monoubiquitination of the substrate, followed by UBE2S-dependent extension of Lys11-linked 
ubiquitin chains (Garnett et al., 2009; Williamson et al., 2009; Wu et al., 2010). Consistent with 
this idea, depletion of UBE2S from Drosophila S2 cells results in a strong delay in a metaphase-
like state and stabilization of cyclin B1 at the spindle poles, among other mitotic defects 
(Williamson et al., 2009). In contrast, UBE2S is not essential for normal mitosis in human HeLa 
cells and is largely dispensable for timely proteolysis of cyclin B1 in this context (Garnett et al., 
2009). These findings imply that UBE2S may not be uniformly required for mitosis, but rather 
may be important for substrate proteolysis under conditions where APC/C activity is 
compromised such as during recovery from drug-induced spindle-assembly checkpoint (SAC) 
activation (Garnett et al., 2009).   
 The ability of the APC/C, in conjunction with the E2 UBCH10 to extend multiple short 
ubiquitin chains through lysines 11, 48 and 63 of ubiquitin in vitro (Kirkpatrick et al., 2006) 
raises the question as to whether long homotypic ubiquitin-chain formation is indeed required for 
proteolysis of APC/C substrates. Even if ubiquitin chains are important, it remains unclear 
whether this requirement arises from a specific role of UBE2S, or through the chain-forming 
activity of UBCH10 (Jin et al., 2008; Kirkpatrick et al., 2006). However, it has been challenging 
to study the role of specific ubiquitin linkages in substrate turnover in cellular extracts due to the 
presence of endogenous ubiquitin. Using a novel approach in which Xenopus extracts are made 
  
66 
largely dependent on exogenous ubiquitin, we sought to understand whether APC/C-catalyzed 
proteolysis is strictly dependent upon polyubiquitination and whether the proteolytic machinery 
exerts a requirement for Lys11 or other ubiquitin linkages to efficiently degrade cyclin B1. 
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Results 
Inhibiting ubiquitin-chain formation has only a modest effect in stabilizing cyclin B1 in 
Xenopus extract 
  
We previously showed that by suppressing deubiquitinating activity with ubiquitin-vinyl 
sulfone (UbVS) we can impose a state of ubiquitin deficiency in Xenopus extract that strongly 
stabilized cyclin B1 (chapter II). Addition of physiologically relevant concentrations of wild-type 
ubiquitin fully rescued cyclin degradation, as measured by the production of acid-soluble 
radioactive counts. Using this system, we next tested the ability of chain-terminating ubiquitin 
mutants to restore proteolysis of 
35
S-labeled N-terminal fragment of human cyclin B1 (cycB1-
NT) in UbVS-treated extracts. Different Ub mutants containing a single lysine-to-arginine 
substitution at position 11 (Ub
11R
), 48 (Ub
48R
), or 63 (Ub
63R
), or at all three positions 
simultaneously (Ub
triR
) restored cycB1-NT proteolysis under these conditions, albeit with 
different kinetics. Addition of wild-type ubiquitin, Ub
48R
, and Ub
63R
 rescued degradation most 
efficiently, showing a half-life of approximately 15 minutes (Figure 3.1a). After 20 minutes, the 
rate of degradation slowed substantially, likely a consequence of ubiquitin depletion in the UbVS-
treated extract, as supplementation with additional ubiquitin restored degradation to the initial 
rate (Figure 3.1b). Extracts supplemented with Ub
11R
 or Ub
triR
 degraded substrate only somewhat 
more slowly. These results were unexpected, as mass spectrometric analysis indicated that 
elimination of all three principal sites of Ub-Ub linkage by the APC/C rendered Ub incapable of 
forming ubiquitin chains in reconstituted reactions (data not shown). Even addition of Ub
me
 
supported degradation, with a half-life of approximately 30 minutes. We next assessed how 
constraining the topology of ubiquitin chains to a single lysine residue would affect degradation 
of cycB1-NT (Figure 3.1c). Addition of Ub
K11only
 or Ub
K48only
 to UbVS-treated extract restored 
cycB1-NT proteolysis, but with slower kinetics compared to wild-type ubiquitin. We were 
surprised that Ub
K11only
 did not support robust degradation, as previous reports indicated that it  
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can efficiently support APC/C-dependent ubiquitination (Jin et al., 2008; Williamson et al., 2009; 
Wu et al., 2010). One possibility is that mutation of Lys6 of ubiquitin may have an inhibitory 
effect on proteasomal degradation (Shang et al., 2005). We therefore tested the effect of 
restricting chain formation to one of the three principle sites of ubiquitin-ubiquitin attachment 
mediated by UBCH10 by mutating the remaining two (data not shown). In these experiments, 
Ub
(48+63)R
 stimulated degradation efficiently, consistent with the ability of Lys11 linkages to 
support degradation (Figure 3.1d). Ubiquitin forms supporting Lys48 and Lys63 linkages 
(Ub
(11+63)R 
and Ub
(11+48)R
, respectively) and Ub
triR
 supported proteolysis with somewhat slower 
kinetics. Together these findings indicate that even when deubiquitinating enzymes are inhibited, 
the ability to construct Lys11-linked chains provides a kinetic advantage for degradation, 
although the advantage is modest. In principle this advantage could arise from the utilization of 
Lys11 as one of three sites (in addition to Lys48 and Lys63 of ubiquitin) in chain-forming 
reactions catalyzed by UBCH10, or from a role of UBE2S, which elongates ubiquitin chains 
exclusively through Lys11 linkages.  
 
 
Ubiquitin chains are required for cyclin B1 degradation only when the number of available 
lysine residues in cyclin B1 is restricted   
 
 To rule out the possibility that our results thus far were influenced by use of an N-
terminal fragment of cyclin B1, we examined proteolysis of full-length wild-type cyclin B1 
bound to CDK1 by immunoblotting (Figure 3.2c, left panel). Addition of Ub
11R
 or Ub
triR
 
stimulated degradation, albeit at slightly reduced rates relative to wild-type ubiquitin. Ubiquitin
me
 
also supported substantial degradation of cyclin B1, although a small fraction of the protein 
accumulated in a triply-ubiquitinated species. Higher molecular-weight forms were not observed, 
possibly because they were targeted for degradation by the proteasome.   
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                Cyclin B1 contains 18 lysine residues in its unstructured N-terminal region upstream of 
the cyclin box; 15 of these lysine residues are located within the first 88 amino acids close to the 
destruction box (Figure 3.2a), providing a platform upon which a proteolytic signal consisting of 
multiple monoubiquitins or short ubiquitin chains can be assembled. To examine whether 
reducing the number of lysines in cyclin B1 renders its proteolysis dependent on ubiquitin-chain 
formation, we measured degradation of cyclin B1 mutants that contained either one or four 
ubiquitinatable lysine residues in the first 115 amino acids at position 64 only (cyc
K64only
) or at 
positions 59, 63, 64, and 67 (cyc
K59,63,64,67only
) (Figure 3.2b; Figure 3.2c, right panel; Figure 3.2d). 
We chose these positions as mass spectrometry studies indicated that these lysine residues 
become ubiquitinated early in the course of reconstituted ubiquitination reactions (D. K., N. H., 
unpublished observations). Cyc
K64only
 was degraded rapidly in untreated Xenopus extract, and was 
fully stabilized in UbVS-treated extract. However, unlike the case for wild-type cyclin B1, Ub
11R   
was not able to efficiently stimulate the degradation of cyc
K64only
. Similar results were obtained 
with Ub
triR
. Interestingly, Ub
me
 did not rescue degradation, but instead caused quantitative 
accumulation in a monoubiquitinated form.  These results contrast strikingly with the behavior of 
wild-type cyclin B1, where the majority of the protein was degraded upon addition of Ub
me
.  
 We next determined whether restoration of a limited number of lysine residues could 
enable degradation in the presence of chain-terminating ubiquitins (Figure 3.2d). Surprisingly, 
cyc
K59,63,64,67only
 was degraded somewhat more slowly than cyc
K64only
 in untreated extract, for 
reasons that remain unclear and may include posttranslational modifications within this lysine 
cluster that are inhibitory to APC-dependent proteolysis. Addition of Ub
11R
 partially restored 
degradation of cyc
K59,63,64,67only
 in a UbVS-treated extract. The most striking difference was 
observed in extracts supplemented with Ub
me
. Whereas cyc
K64only
 accumulated quantitatively in a 
monoubiquitinated form, cyc
K59,63,64,67only
 was unstable, although a fraction of the protein 
accumulated in mono- and di-ubiquitinated species. We conclude that when deubiquitinating 
enzymes are inhibited, the attachment of single ubiquitin molecules to multiple lysine residues in 
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cyclin is sufficient to target the substrate for degradation. Strict dependence on elaboration of 
ubiquitin chains appears to occur only when the number of available substrate lysines is 
restricted.  
 
Multiple monoubiquitination can target cyclin B1 for efficient degradation in a 
reconstituted system and in Xenopus extract 
 
 We next assessed whether the effects of different ubiquitin mutants on proteolysis 
paralleled their effects on ubiquitin conjugation using a reconstituted system. In APC/C reactions 
reconstituted with 100 nM UBCH10, we found that elimination of Lys48 or 63 of ubiquitin had 
no effect on the mass of conjugates generated in 15-minute reactions, consistent with the fact that 
these mutations had little effect on degradation in UbVS-treated extracts (Figure 3.3a, top panel). 
Interestingly, elimination of Lys11 reduced the mass of conjugates formed, consistent with the 
previously reported preference of UBCH10 for synthesizing Lys11 linkages (Jin et al., 2008; 
Kirkpatrick et al., 2006). These differences became more pronounced in longer ubiquitination 
reactions (Figure 3.3a, bottom panel). In the presence of ubiquitin types that do not support 
ubiquitin-polymer assembly (Ub
triR
 and Ub
me
), the maximal extent of substrate modification (5-6 
ubiquitins per cyclin B1 molecule) was observed at early time-points and remained unchanged in 
longer reactions (Figure 3.3a), implying that there likely is a limited subset of preferred 
ubiquitination sites in cyclin B1. A time-course of ubiquitination with either wild-type Ub or 
Ub
triR
 (Figure 3.3b) revealed that, at physiologically relevant E2 concentrations, the conjugation 
of ubiquitin monomers to distinct lysines in cyclin B1 occurs with rapid kinetics. Furthermore, 
conjugates bearing 4 or more ubiquitin moieties were capable of binding proteasome-associated 
ubiquitin-receptors (Deveraux et al., 1994; Elsasser et al., 2004; Elsasser and Finley, 2005; 
Finley, 2009; Isasa et al., 2010; Matiuhin et al., 2008; Peth et al., 2010; Rao and Sastry, 2002; 
Riedinger et al., 2010) including Rpn10 (Figure 3.3c, d) and Rad23 (Figure 3.3e, f), in a manner  
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that depended on their ubiquitin-interaction domains. For conjugates of a similar molecular mass, 
substrate ubiquitinated with Ub
triR
 bound to receptors more efficiently than substrate ubiquitinated 
with Ub
me
. Given that Ub-AQUA analysis indicates that these forms of ubiquitin suppress 
ubiquitin-chain formation with similar efficiency, this finding suggests that methylation of 
ubiquitin may compromise its affinity for ubiquitin receptors. We found similar binding patterns 
with cyclin B1-ubiquitin conjugates generated with UBC4 as the E2 (discussed in chapter IV).  
Together these results indicate that multiple monoubiquitination occurs rapidly and can result in a 
productive signal for binding ubiquitin receptors.    
 We next sought to determine whether multiple monoubiquitination can target cyclin B1 
for degradation in a reconstituted system. To this end, full-length cyclin B1-CDK1 complex was 
ubiquitinated with UBCH10, in conjunction with wild-type or chain-terminating ubiquitin. The 
resulting conjugates were incubated with purified human proteasomes that were washed with high 
salt concentrations to eliminate USP14, a deubiquitinating enzyme that can antagonize cyclin B1 
degradation in vitro (Hanna et al., 2006; Lee et al., 2010). These proteasomes, which retain the 
deubiquitinating enzymes RPN11 and UCH37 (Lee et al., 2010), rapidly degraded 
polyubiquitinated cyclin B1, generated with UBCH10 (Figure 3.4a). While conjugates formed 
with Ub
triR
 or lysine-less ubiquitin (Ub
K0
) were efficiently degraded, those generated with 
methylated ubiquitin were degraded less rapidly, consistent with the defect in the ability of these 
conjugates to bind ubiquitin receptors (Figure 3.3c, e). Similar trends were observed for cyclin B1 
species ubiquitinated with UBC4 as the E2 (discussed in chapter IV). The extent of conjugate 
proteolysis was quantitated using radiolabeled full-length cyclin B1, in complex with unlabeled 
CDK1, and was found to closely correlate with the fraction of input cyclin B1 bearing three or 
more ubiquitin molecules (data not shown). Degradation of cyclin B1 in the reconstituted system 
was confirmed to be both APC/C- and ubiquitin-dependent (data not shown). Interestingly, 
analogous experiments performed with radiolabeled cycB1-NT pre-ubiquitinated by UBCH10 
(Figure 3.4b) revealed that degradation of multiply monoubiquitinated cyclin B1 was sensitive to  
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addition of the deubiquitinating enzyme USP14 (Figure 3.4c). This effect was reversed by IU1, 
an inhibitor of the catalytic activity of USP14 (Lee et al., 2010) (data not shown). Together these 
results indicate that purified proteasomes can efficiently degrade a multiply monoubiquitinated 
cyclin B1 and that USP14 can deubiquitinate this substrate to suppress degradation.  
 To determine whether multiple monoubiquitination could target the protein for 
degradation under conditions of physiological concentrations of proteasomes and in the presence 
of relevant DUB activities, we used the same ubiquitinated species from those analyzed in Figure 
3.4b and added them to interphase Xenopus extract, a state in which the APC/C is inactive (Figure 
3.4d). Conjugates generated with Ub
triR
 or Ub
me
 were degraded rapidly with initial rates very 
similar to that observed for conjugates generated with wild-type ubiquitin. However, a fraction of 
the conjugates generated with methylated ubiquitin were degraded less efficiently, likely because 
they were insufficiently ubiquitinated to be recognized by the proteasome. Similar results were 
obtained when the ubiquitin conjugates were introduced into extracts that were supplemented 
with excess non-ubiquitinated unlabeled competitor to prevent any potential APC/C-mediated 
ubiquitination (data not shown) or to extracts that had been immunodepleted of APC/C (data 
shown in chapter IV). Together these findings further indicate that Xenopus extracts can rapidly 
degrade a cyclin substrate bearing multiple ubiquitin monomers attached to distinct lysine 
residues.  
 Pre-treatment of extract with UbVS, at a concentration identical to that used to deplete 
free ubiquitin, had little ability to accelerate degradation of conjugates generated with wild-type 
ubiquitin or with Ub
triR
, but modestly enhanced degradation of species modified with Ub
me
 
(Figure 3.4d). Deubiquitination appears to exert little effect on degradation of these pre-
ubiquitinated species, perhaps because deubiquitinating enzymes such as USP14 are present at 
much lower levels in Xenopus extracts than in our reconstituted system. Consistent with this idea, 
addition of an inhibitor of USP14, IU1, failed to accelerate degradation of cyclin B1 in Xenopus 
extracts (data not shown).   
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Discussion 
 
In this study, we have evaluated the role of ubiquitin-chain topology in targeting cyclin 
B1 for degradation in a reconstituted system, as well as in mitotic Xenopus cell-cycle extracts. 
Our study was motivated by recent findings suggesting that Lys11 linkages, mediated by the 
chain-forming E2 enzyme UBE2S, may be important for APC/C-dependent proteolysis. 
However, our earlier work suggested that APC/C, solely in conjunction with the E2 enzyme 
UBCH10 or the enzyme UBC4/5, can build a ubiquitin signal that is sufficient for degradation by 
purified proteasomes (Kirkpatrick et al., 2006). Here we provide a resolution to this paradox, 
demonstrating that conjugation of ubiquitin to multiple lysine residues of cyclin B1 provides an 
alternative degradation signal for cyclin B1 that does not require extension of Lys11-linked 
ubiquitin polymers. Lysine11-linked ubiquitin-chain formation becomes essential only when the 
number of available lysine residues in cyclin B1 is restricted.  
Dominant negative effects of different ubiquitin types may be difficult to observe when 
examined in a background that contains wild-type ubiquitin. Using UbVS to inhibit 
deubiquitinases and their capacity to recycle ubiquitin, we were able to impose a state of ubiquitin 
deficiency in extract that strongly stabilized cyclin B1. Supplementing UbVS-treated extracts 
with ubiquitin rescues the proteasomal degradation of cyclin. As opposed to addition of excess 
ubiquitin, this approach allowed us to examine the functional significance of different linkages at 
physiological concentrations of ubiquitin. Under such conditions, any kinetic advantage specific 
ubiquitin linkages may confer in protein degradation may be ascertained and more easily 
uncovered.   
The UbVS system enabled us to define the role of different ubiquitin-chain topologies in 
targeting cyclin B1 for degradation in Xenopus extracts. In agreement with earlier work in a 
reconstituted system (Kirkpatrick et al., 2006), Lys48 ubiquitin-ubiquitin linkages were not 
required for efficient cyclin proteolysis in UbVS-treated extract. Surprisingly in the light of recent 
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studies (Jin et al., 2008; Williamson et al., 2009; Wu et al., 2010), ubiquitin incapable of forming 
Lys11 linkages (Ub
11R
) also supported very robust degradation of cyclin B1 (Dimova et al., 
2012). Importantly, we found that chain-terminating ubiquitins (Ub
triR
 and lysine-less ubiquitin), 
which greatly diminish chain elongation by UBCH10, UBC4/5, and UBE2S, also support robust 
rates of cyclin proteolysis. Methylated ubiquitin was somewhat less capable of supporting rapid 
cyclin degradation, which may reflect less efficient recognition by ubiquitin receptors and the 
proteasome due to modification of Lys6 of ubiquitin (Shang et al., 2005). However, upon 
restriction of ubiquitination to a single lysine residue in cyclin as in cyc
K64only
, chain-terminating 
ubiquitins were no longer able to stimulate substrate degradation and cyclin accumulated as 
mono- and di-ubiquitinated species. Together these findings suggest that ubiquitin-chain 
formation is not essential for cyclin proteolysis, unless the number of available ubiquitination 
sites in the substrate is restricted.  
Utilizing a reconstituted system, we demonstrated that UBCH10 can rapidly append 
mono-ubiquitin to multiple lysines in cyclin. Species bearing 4 or more ubiquitin moieties on 
distinct lysines were recognized by ubiquitin receptors. Based on these findings, we propose that 
the presence of multiple lysines in cyclin B1 that are in close proximity to one another has the 
potential for generating a high density of mono-ubiquitin that promotes receptor binding. In such 
an arrangement, the hydrophobic patches on distinct ubiquitin units may be available to form 
contacts with various ubiquitin-binding domains (UBDs). Whether particular spacing of 
ubiquitinated lysine residues is essential for recognition by ubiquitin receptors remains unknown. 
In our pull-down experiments, there may be some enhanced avidity resulting from a dimeric GST 
moiety positioning two ubiquitin-associated domains (UBAs) in close proximity (Sims et al., 
2009). However, the rapid destruction of multiply monoubiquitinated species by purified 
proteasomes and in Xenopus extracts implies that this substrate must have sufficient affinity for 
proteasome-associated ubiquitin receptors.  
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The capacity of purified proteasomes to rapidly degrade multiply monoubiquitinated 
cyclin B1 was significantly attenuated by USP14, suggesting that USP14 can efficiently remove 
monoubiquitin, as well as trim Ub chains. However, such deubiquitinating activity did not appear 
to strongly antagonize proteasome function in Xenopus extract, as treatment of extract with UbVS 
or the USP14-specific inhibitor IU1 did not appreciably enhance turnover of pre-ubiquitinated 
cyclin. Although present in Xenopus extracts (N.V.D., R.W.K., unpublished data), levels of 
USP14 associated with proteasomes in extract may be insufficient to impede proteolysis. 
Together, these findings suggest the proteasome does not impose a requirement for ubiquitin-
chain formation for efficient proteolysis of cyclin B1, even when DUBs are not inhibited by 
UbVS. This study further strengthens the view that the proteasome has the capacity to recognize 
and degrade substrates bearing ubiquitin modifications distinct from the canonical Lys48-linked 
polyubiquitin chains (Baboshina and Haas, 1996; Guterman and Glickman, 2004; Hershko and 
Heller, 1985; Hofmann and Pickart, 2001). The early work of Hershko and Heller demonstrated 
that methyl-ubiquitin addition to reticulocyte extracts can support the proteolysis of 
125
I-labeled 
lysozyme, but overall rates of degradation were slow, with ~12% of input substrate degraded 
within an hour (Hershko and Heller, 1985). While conjugation of mono-ubiquitin can promote 
degradation of the model substrate Pax 3 (Boutet et al., 2007), the kinetics of degradation are 
slow, with a half-life of 3.5 h. In contrast, multiple monoubiquitination of cyclin B1 provides a 
robust degradation signal.  
Previously, we demonstrated that in conjunction with UBCH10 or UBC4/5 enzymes, the 
APC generates a proteolytic signal on cyclin comprised of Lys11 and Lys63, in addition to Lys48 
ubiquitin linkages (Kirkpatrick et al., 2006). In this context where chains are nucleated on 
multiple substrate lysines, it cannot not be ruled out that distinct chains consisting of a series of 
identical linkages such as Lys11(Lys11(Lys11))) (Kirkpatrick et al., 2006) are assembled and 
function as the major degradative signal. This question has become increasingly important in the 
light of recent studies suggesting that synthesis of Lys11-linked polymers is central to APC-
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dependent proteolysis (Williamson et al., 2009; Wu et al., 2010). Such a model is not consistent 
with our findings where ubiquitin incapable of forming Lys11 linkages (Ub
11R
) or supporting 
chain-elongation (Ub
triR
) allows robust cyclin proteolysis in UbVS-treated extracts. Based on our 
findings in Xenopus extract and in a reconstituted system, we propose that through conjugation of 
monoubiquitin to multiple lysine residues, and possibly elaboration of some short chains, 
UBCH10, or possibly members of the UBC4/5 family, cooperates with the APC/C to generate a 
sufficient proteolytic signal on cyclin B1 (Figure 3.5). Our findings lend strong support to the 
idea that high local density of ubiquitin, independent of linkage, is sufficient to target a substrate 
for proteolysis. Upon restriction of available lysine residues, however, such ubiquitin density may 
not be attainable through the conjugation of monoubiquitin. In this context, ubiquitin moieties 
will have to be added to the end of a growing chain rather than to a lysine residue in the substrate 
in order to achieve the threshold necessary for proteolysis. Consistent with this idea, ubiquitin-
chain formation becomes essential for proteasomal degradation when the number of available 
lysine residues in cyclin B1 is restricted.  An important question is whether in this context the 
activity of the inherently less processive UBCH10 is sufficient to promote efficient ubiquitination 
and targeting to the proteasome, or whether there is a greater dependence on chain-elongation by 
the Lys11-specific E2 UBE2S (Garnett et al., 2009; Wickliffe et al., 2011; Williamson et al., 
2009; Wu et al., 2010).  
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Methods 
Antibodies and biochemical reagents 
Proteins were separated by SDS-PAGE on NuPAGE 4-12% or 12% Bis-Tris gels 
(Invitrogen), followed by wet transfer to PVDF. Sources of antibodies for immunoblotting were 
as follows: anti-cyclin B1 (Ab-2; RB-008-P, Neomarkers), anti-Cdc27 (610455, BD Transduction 
Laboratories), anti-UBCH10 (A-650, Boston Biochem; AB3861, Millipore), anti-UBE2S (N-14; 
sc-131354, Santa Cruz Biotechnology), anti-UBCH5 (A-615; Boston Biochem), anti-ubiquitin 
(P4D1; sc-8017; Santa Cruz Biotechnology). Secondary antibodies used include anti-goat IgG-
HRP (sc-2020; Santa Cruz Biotechnology), anti-rabbit IgG-HRP (NA934; GE Healthcare), and 
anti-mouse IgG-HRP (NA931; GE Healthcare). Antibodies for immunoprecipitation or 
immunodepletion included: anti-Cdc27 (AF3.1; sc-9972) and anti-UBE2S (N-14; sc-131354) 
from Santa Cruz Biotechnology; anti-UBCH10 (gift from H. Yu, UT Southwestern, USA); and 
for control depletions, normal rabbit (sc-2027) and normal goat (sc-2028) IgG, both from Santa 
Cruz Biotechnology. UBE2S antibodies were coupled to UltraLink immobilized protein A/G 
beads (53132, Pierce). UBCH10 and CDC27 antibodies were coupled to Affiprep protein A beads 
(156-0006, Bio-Rad). Ubiquitin agarose (U-405), UbVS (U-202), MG262 (I-120), Ub
me 
and 
ubiquitin mutants except for Ub
(11+48)R
, Ub
(11+63)R
 and Ub
triR 
were purchased from Boston 
Biochem. TAME (T4626) and ubiquitin (U6253) were purchased from Sigma. 
 
Preparation of recombinant proteins 
Ubiquitin mutants Ub
(11+48)R
, Ub
(11+63)R
 and Ub
(11+48+63)R 
(referred to as Ub
triR
) were 
generated by introducing arginine codons (AGA and AGG) at the indicated sites through PCR-
mediated mutagenesis of the human ubiquitin sequence (cloned in pET3a with ampicillin 
resistance, the kind gift of C.M. Pickart). Plasmids were verified by sequencing and the purified 
proteins analyzed by mass spectrometry. To ensure efficient arginine incorporation, BL21 (DE3) 
cells were co-transformed with pJY2, developed by Pickart lab (You et al., 1999), which carries 
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T7 lysozyme (LysS) and a gene encoding tRNAUCU
Arg
. Cultures were grown at 37 °C to an 
attenuance (D) of ~ 0.5 at 600 nm, and induced with 100 μM isopropylthiogalactoside (IPTG) at 
D600 nm = 0.6 at 25 ˚C for 5 h. Cells were ruptured by sonication in QA lysis buffer (50 mM 
HEPES (pH 7.7), 100 mM KCl, protease-inhibitor cocktail, 5 mM 2-mercaptoethanol, 10 µg ml
-1
 
DNase). Lysozyme was added to 1 mg ml
-1 
concentration and lysate was incubated with rotation 
at 4 °C for 15 min. Following sonication, cell lysates were clarified by centrifugation and the 
resulting supernatants applied to a Q column. The flow-through containing ubiquitin was 
concentrated and purified by size-exclusion chromatography. Fractions containing ubiquitin were 
typically > 95% pure. 
To generate full-length cyclin B-CDK1 complex, human cyclin B1 and CDK1 
baculoviruses were used as described previously (Kirkpatrick et al., 2006).  To generate mutants 
of cyclin B1, DNA fragments encoding the N-terminal 124 amino acids of wild-type human 
cyclin B1 (5'-
AACCGGTCCGAAACCGTCGACATGTCGCATCACCATCACCATCACGGCTC 
GATGGCGCTCCGAGTCACGCGTAACTCGAAAATTAATGCTGAAAATAAAGCGAAAA
TCAACATGGCAGGCGCCAAGCGCGTTCCTACGGCACCGGCGGCAACCTCCAAACCCG
GGCTGAGGCCAAGAACAGCTCTTGGGGACATTGGTAACAAAGTCAGTGAACAGCTA
CAGGCCAAAATGCCTATGAAAAAAGAAGCAAAACCTTCAGCTACCGGTAAAGTCAT
TGATAAAAAACTACCAAAACCTCTTGAAAAGGTACCTATGCTGGTGCCAGTGCCAGT
GTCTGAGCCAGTGCCAGAGCCAGAACCTGAGCCAGAACCTGAGCCTGTTAAAGAAG
AAAAACTTTCGCCTGAGCCTATTTTGGTTGATACTGCTAGCAATA-3') or the same 
region of the protein with arginine substitutions at all lysine residues (cyc
allR
; 5'- 
AACCGGTCCGAAACCGTCGACATGTCGCATCACCATCACCATCACGGCTC 
GATGGCGCTCCGAGTCACGCGTAACTCGAGAATTAATGCTGAAAATAGAGCGAGAA
TCAACATGGCAGGCGCCAGGCGCGTTCCTACGGCACCGGCGGCAACCTCCAGACCCG
GGCTGAGGCCAAGAACAGCTCTTGGGGACATTGGTAACAGAGTCAGTGAACAGCTA
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CAGGCCAGAATGCCTATGAGAAGAGAAGCAAGACCTTCAGCTACCGGTAGAGTCAT
TGATAGAAGACTACCAAGACCTCTTGAAAGGGTACCTATGCTGGTGCCAGTGCCAGT
GTCTGAGCCAGTGCCAGAGCCAGAACCTGAGCCAGAACCTGAGCCTGTTAGAGAAG
AAAGACTTTCGCCTGAGCCTATTTTGGTTGATACTGCTAGCAATA-3') preceded by 6 x  
His tag were synthesized (GenScript). Using restriction enzyme digestion with NheI and RsrII, 
fragments were subcloned into pFASTBac containing the carboxy terminus (125-433 amino 
acids) of cyclin B1. To generate cyc
K64only
, primers 5'- 
TCCAGACCCGGGCTGAGGCCAAGAACAGCTCTTGGGGACATTGGTAACAGAGTCAG
TGAACAGCTACAGGCC-3' and 5' –
AATGACTCTACCGGTAGCTGAAGGTCTTGCTTCTTTTCTCATAGGCATTCTGGCCTGT
AGCTGTTCACTGAC - 3' were used for an extension reaction and the resulting fragments 
cloned into XmaI and AgeI cleavage sites of pFASTBac carrying full-length cyc
allR
. Plasmids 
were verified by restriction enzyme mapping and sequencing. Baculoviruses were generated 
according to the Bac-to-Bac manual (Invitrogen). Wild-type cyclin B1 was 
35
S-labeled in Sf9 
cultures with resuspending cells (1.5 x 10
6
 cells ml
-1
) in media containing 10% SF-900 II SFM 
and 90% SF-900 II SFM without methionine or cysteine (both from Invitrogen) to increase radio-
label uptake. Baculovirus was added to cells, along with 50 µCi of 
35
S-labelled methionine and 
cysteine (NEG772; Perkin Elmer), and cyclin B1 expression was allowed for 2.5 days. CDK1 
was expressed separately in Sf9 cells without radiolabeling and then combined with lysate from 
cells expressing cyclin B1 to allow formation of complex, which was then purified through Ni-
NTA affinity and gel filtration chromatography.  
        CycB1-NT (1-88 amino acids of human cyclin B1) , containing an HA tag at the N 
terminus and a 6xHis tag at the C terminus was generated using PCR amplification with forward 
primer (5'-CCA GGA CCA TGG GTT ACC CAT ACG ATG TTC CAG ATT ACG CTG GCT 
CGA TGG CGC TCC GAG TCA CG-3') and reverse primer (5'-GGG AGC CTC GAG CTA 
GGG AGC GTG ATG GTG ATG GTG ATG CAT AGG TAC CTT TTC AAG AGG-3'). The 
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resulting PCR product was digested with NcoI and XhoI for subcloning into pET28a. Plasmids 
were verified by restriction enzyme mapping and sequencing. For 
35
S labeling in Escherichia  
coli, cultures (50 ml) were grown at 37 ˚C to D600 nm =  0.8, then collected  by centrifugation 
(3,700g for 15 min, at 4 
o
C) and resuspended in modified M9 medium (50 ml final volume). After 
resuspension in modified M9 medium, cells were allowed to grow for additional 15 min at 37 °C 
before 5 mCi of Easy Tag
TM
 L-[35S]-Methionine (NEG709A005MC; Perkin Elmer) was added. 
Expression was induced with 0.5 mM IPTG for 2.5 h at 37 
o
C. Cells were ruptured in 5 ml g
-1
 of 
pellet guanidine-HCl lysis buffer (pH 8.0) and lysates rotated at 24 °C until the lysate became 
slightly translucent; approximately 45 min. Lysates were clarified by centrifugation and cycB1-
NT was purified using Ni-NTA affinity chromatography (Qiagen). Eluted protein was desalted 
into XB buffer (100 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, at pH 7.8 with 
KOH), supplemented 2% glycerol, protease inhibitors and phenylmethylsulfonyl fluoride, and 
stored at – 20 °C.  
Maltose-binding protein (MBP)-tagged E1 was expressed in E. coli inducing cultures at 
D600 nm = 0.6 with 300 μM IPTG for 5 h at room temperature. Purification was carried out using a 
standard MBP purification protocol. For expression of His-tagged UBCH10 and His-tagged 
UBC4, bacterial cultures were induced at D600 nm = 0.6 at 37 ˚C with 500 μM IPTG for 4 h. The 
enzymes were purified through Ni-NTA affinity and gel-filtration chromatography. PET28a 
expressing human wild-type UBE2S was provided by M. Kirschner (Harvard Medical School, 
USA). Cultures were grown to D600 nm = 0.4 and induced with 500 μM IPTG at 37 ˚C for 4 h. His-
UBE2S was purified by Ni-NTA purification.     Glutathione-S-transferase (GST)-fusion proteins 
for Rpn10 and Rad23, as well as their sub-domains, were purified essentially as reported 
previously (Elsasser et al., 2004; Elsasser et al., 2002). Recombinant E2-25K (UbcH1) was 
purchased from Boston Biochem (SP-200). 
 
Preparation of Xenopus egg extract  
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Interphase Xenopus egg extract was prepared from eggs laid overnight according to the 
protocol of Murray (Murray, 1991) with the exception that eggs were activated with 2 μg ml-1 
calcium ionophore (A23187, free acid form, Calbiochem) for 30 min prior to the crushing spin. 
Extract was frozen in liquid nitrogen and stored at -80 ºC. Interphase extract was induced to enter 
mitosis by addition of non-degradable cyclin B, which activates CDK1 and stimulates mitotic 
phosphorylation, resulting in APC/C activation. A fusion of the maltose-binding protein (MBP) 
to Xenopus cyclin B lacking its N-terminal 90 amino acids (MBP-Δ90) (Salic and King, 2005) 
was expressed in E. coli by inducing cultures at an D600nm=0.6 with 300 μM 
isopropylthiogalactoside (IPTG) for 5 h at room temperature. Purification was carried out 
following New England BioLabs (NEB) protocol. To make mitotic extract, MBP- Δ90 was added 
to interphase extract generally at ~ 20 μg ml-1 and incubated at 22-24 ºC for 45-60 min. 
 
Reconstitution of ubiquitination and degradation of cyclin B1 
Ubiquitination reactions were carried out essentially as described previously (Kirkpatrick 
et al., 2006) for the indicated times. Briefly, for each 30 µl reaction, APC/C was immunopurified 
from 600 µl of mitotic Xenopus egg extract by incubation for 1 h at 4 °C with 12 µg of anti-
Cdc27 antibodies (AF3.1, Santa Cruz Biotechnology) immobilized onto 30 µl of Affiprep Protein 
A beads (156-0006, Bio-Rad). Following incubation with extract, beads were washed quickly (to 
minimize loss of associated APC/C co-activator Cdc20) three times with XB containing 500 mM 
KCl (10 mM potassium HEPES, pH 7.7, 500 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2), two times 
with XB same content as above, except with 100 mM KCl), and then three times with reaction 
buffer (20 mM Tris, pH 7.5, 100 mM KCl, 2.5 mM MgCl2, 2 mM ATP).  Ubiquitination reaction 
were carried out at 24 °C with agitation at 1500 r.p.m and contained APC/C on 30 µl beads, and 
30 µl of a mix containing recombinant MBP-human E1 (1.3 µM), His-tagged UBCH10 or UBC4 
(100 nM – 4 μM) as the E2 enzyme, wild-type or different forms of ubiquitin (118-145 μM), and 
450-500 nM cyclin B1-CDK1 or cycB1-NT. For ubiquitin-receptor binding and degradation 
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assays, reaction supernatants were combined with the first 20 µl of reaction buffer wash. For 
analysis of cyclin B1 ubiquitination with different ubiquitins, entire reactions were processed for 
immunoblotting or autoragiography. Dried gels were analyzed by phosphorimaging (Bio-Rad 
PMI); quantification was carried out with Quantity One software (Bio-Rad). 
For binding experiments with ubiquitin receptors, cyclin B1-CDK1 was pre-ubiquitinated 
with purified Xenopus APC/C, UBCH10 (3 μM), and ubiquitin (118 μM) for 90 min. 
Approximately 7-8 μg of “bait” protein immobilized onto Glutathione-Sepharose 4B resin (GE 
Healthcare) was mixed with 4 μl of pre-synthesized ubiquitin-cyclin B1 conjugates and incubated 
for 1 h at 4 ˚C with agitation in the presence of 100 μg ml-1 BSA and 0.1 % Tween 20. 
Supernatants were collected and mixed with the first wash to make the flow-through fraction. 
Beads were washed twice and diluted with SDS sample buffer to analyze the bound fraction. 
Equivalent amounts of input (I), flow-through (FT) and bound (B) fractions were subjected to 
SDS-PAGE and western blot analysis using anti-cyclin B1 polyclonal antibody (Ab-2, 
Neomarkers). 
For degradation assays with purified proteasomes, human proteasomes (10-20 nM, 
concentrations as indicated), purified as reported previously (Lee et al., 2010) but non-UbVS 
treated, were added to cyclin B1-Ubn in buffer (50 mM Tris-HCl (pH 7.5), 5 mM MgCl2 and 5 
mM ATP) (Lee et al., 2010) and incubated at 24 °C. For “0 min” time-point, substrate and 
proteasome mixtures were individually added to SDS sample buffer to prevent a time-lag from 
mixing. Aliquots withdrawn at indicated times were combined with SDS sample buffer and 
subjected to SDS-PAGE/immunoblot analysis using anti-cyclin B1 polyclonal antibody (Ab-2, 
Neomarkers).  
 
Cyclin B1 degradation in Xenopus egg extract 
Degradation assays with non-ubiquitinated cyclin B1 were carried out by adding ~ 200-
250 nM of cyclin B1 in 40 μl reactions, with extract constituting 75-80% of the total volume. Pre-
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treatment of extract with TAME or MG262 was done at 24 °C for 15 min. For assays containing 
no UbVS, extracts were supplemented with ubiquitin as indicated or buffer (for untreated sample) 
concomitantly with substrate. UbVS treatment was carried out for 30 min at 24 ˚C, with agitation 
(1,250 r.p.m.) before addition of ubiquitin and cyclin B1. Extracts contained 100 μg ml-1 of 
cycloheximide to prevent reincorporation of free labeled amino acid. For competition assays, 
unlabeled competitor was added concomitantly with radiolabelled cyclin B1 and degradation was 
initiated. Degradation experiments were carried out at 24 °C, with agitation. Samples for 
proteolysis of unlabeled cyclin B1-CDK1 were processed for anti-cyclin B1 immunoblot using 
anti-cyclin B1 polyclonal antibody (Ab-2, Neomarkers). In degradation assays with 
35
S-labelled 
cycB1-NT, reactions (3 μl per time point) were quenched with 97 μl of 20% TCA (in H2O), 
vortexed and incubated on ice ≥ 30 min before centrifugation at 14,000g, at 4 °C for 30 min. A 
fraction (50%) of sample supernatants was combined with NaOH to neutralize the acid and added 
to Ultima Gold scintillation fluid (6013327, Perkin Elmer). The radioactivity in the supernatant 
was measured by scintillation counting. Acid-soluble counts were compared to total radioactive 
counts and results were graphed as percent soluble radioactive counts.  
For degradation of pre-ubiquitinated cycB1-NT in extract, interphase extract was pre-
treated with UbVS or buffer for 30 min at 24 °C with agitation and supplemented with 100 μg ml-
1
 cycloheximide. In experiments with USP14 inhibitor IU1, IU1 or dimethylsulphoxide (DMSO) 
was added to extract for 15 min at 24 ˚C before addition of substrate. Where proteolysis was 
evaluated in the presence of unlabeled cycB1-NT, extract was mixed with unlabeled competitor 
and 
35
S cycB1-NT-Ubn concomitantly. Extract (~14 μl) was added to 4 μl of cycB1-NT-Ubn 
conjugates for each time point. Degradation mixtures were incubated at 24 °C, 1250 r.p.m. for 
indicated times. Reactions were quenched with 107 μl of 20% TCA, vortexed and incubated on 
ice ≥ 30 min before centrifugation at 14,000g, at 4 °C for 30 min. A fraction of supernatants was 
combined with NaOH and Ultima Gold scintillation fluid (6013327, Perkin Elmer). 
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To deplete APC/C, 100 μl of interphase extract was mixed 2 μg of anti-Cdc27 antibody 
coupled to 5 μl of Affiprep Protein A beads and incubated at 4 °C for 3 h. APC/C depletion was 
confirmed by anti-Cdc27 western blot analysis. Approximately 10 μl of pre-ubiquitinated 
radiolabelled cyclin B1 was added to 90 μl of APC/C- depleted extract. Reactions were incubated 
at 22 °C for the indicated times and stopped by the addition of an equal volume of chilled 2% 
perchloric acid (PCA) (in H2O) making a new final volume of 200 μl. Reactions were then 
incubated on ice for ≥30 min and centrifuged at 15,000 r.p.m. for 10 min, at 4 °C. A fraction of 
supernatants was mixed with Tris Base and Ultima Gold scintillation fluid (6013327, Perkin 
Elmer) and the radioactivity was measured by scintillation counting. 
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Abstract 
 
The Anaphase-Promoting Complex/Cyclosome (APC/C or APC) regulates progression 
through mitosis by orchestrating the ubiquitination of cell-cycle regulators such as cyclin B1 and 
securin. Recent reports have implicated Lys11-linked ubiquitin chains in degradation of APC/C 
substrates, but the Lys11 chain-forming E2 UBE2S is not essential for mitotic exit. In Xenopus 
cell-cycle extracts, conjugation of ubiquitin to multiple lysine residues of cyclin B1 provides an 
alternative degradation signal for cyclin B1 that does not require chain extension. Here, we 
evaluate the relative contribution of different E2 enzymes to APC activity and demonstrate that 
the chain-elongating activity of UBE2S is dispensable for cyclin degradation unless the number 
of ubiquitinatable lysines in cyclin B1 is restricted. 
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Introduction 
 
 
 Covalent attachment of ubiquitin to proteins controls the stability, localization or 
activation status of myriad cellular proteins and thereby constitutes a powerful mechanism for 
regulating almost all aspects of cell physiology (Behrends and Harper, 2011; Kerscher et al., 
2006). Ubiquitination of substrates requires the concerted actions of an ubiquitin-activating 
enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin ligase (E3) (Hershko and 
Ciechanover, 1998; Kerscher et al., 2006). A view emerging from recent structural and 
mechanistic studies invokes E2 enzymes to play an active role in determining the length and 
topology of ubiquitin assemblies, as well as the processivity of ubiquitination, thereby influencing 
the downstream fate of the substrate (Behrends and Harper, 2011; Chen and Pickart, 1990; Eddins 
et al., 2006; Garnett et al., 2009; Hofmann and Pickart, 1999; Petroski et al., 2007; Rodrigo-
Brenni and Morgan, 2007; Wickliffe et al., 2011a; Williamson et al., 2009; Ye and Rape, 2009).  
 The Anaphase-Promoting Complex/Cyclosome (APC/C or APC) is a multi-subunit E3 
ubiquitin ligase that initiates anaphase and mitotic exit by ubiquitinating regulatory proteins, 
including cyclin B1 and securin, to target them for destruction by the 26S proteasome (Barford, 
2011; Harper et al., 2002; Peters, 2002; Peters, 2006). Biochemical studies in frog and clam 
oocytes originally showed that two different E2 enzymes, Ubc4 and UbcX, or E-2C, can 
independently support APC activity (Aristarkhov et al., 1996; Yu et al., 1996).  In conjunction 
with either E2, X. laevis APC was found to modify cyclin B1 with ubiquitin chains linked 
through multiple lysine residues of ubiquitin (Lys11 and Lys63, in addition to Lys48) 
(Kirkpatrick et al., 2006). In this context, uniform Lys48-linked ubiquitin chains were found 
dispensable for binding of ubiquitinated cyclin B1 to ubiquitin-receptor proteins and robust 
degradation by the 26S proteasome (Kirkpatrick et al., 2006). A model emerging from more 
recent work challenges the view that a single E2 enzyme is sufficient to support the assembly of 
proteolytic tag on APC substrates and instead suggests that this process requires the sequential 
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action of two distinct E2 enzymes (Rodrigo-Brenni and Morgan, 2007). In metazoans, the 
conjugating enzyme UBE2S promotes processive Lys11-linked chain-extension after the initial 
monoubiquitination or short-chain formation by UBCH10 (Barford, 2011; Behrends and Harper, 
2011; Garnett et al., 2009; Wickliffe et al., 2011a; Wickliffe et al., 2011b; Williamson et al., 
2009; Wu et al., 2010; Ye and Rape, 2009). Consistent with this model, depletion of both 
UBCH10 and UBE2S causes mitotic arrest and stabilization of APC substrates (Williamson et al., 
2009). While important for APC activity in Drosophila S2 cells (Williamson et al., 2009), 
UBE2S was not found to be essential for normal mitosis in human HeLa cells and is largely 
dispensable for timely proteolysis of cyclin B1 in this context (Garnett et al., 2009). Together 
these findings imply that the contribution of UBE2S and long polyubiquitin chains in the 
degradation of APC substrates may be organism- and condition-specific, and that there may not 
be a uniform requirement for UBE2S in all systems or circumstances.   
Our recent study revealed that conjugation of ubiquitin to multiple lysine residues of 
cyclin B1 provides an alternative degradation signal for cyclin B1 that does not require chain 
elongation (discussed in chapter III). However, chain formation becomes essential for substrate 
proteolysis when the number of ubiquitination sites in cyclin B1 is restricted. Here we sought to 
examine whether this requirement for chain formation arises from a specific role of UBE2S or 
through the chain-forming activity of UBCH10.    
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Results 
Analysis of the role of chain-elongating E2 UBE2S in cyclin B1 degradation  
 
 The ability of Ub
11R
 and chain-terminating ubiquitins to support reasonably efficient 
proteolysis of cyclin B1 in Xenopus extract raised a question as to whether the E2 enzyme 
UBE2S is important for APC activity in this context. To assess the role of UBE2S in cyclin B1 
proteolysis, we immunodepleted the protein and measured how this affected the kinetics of cyclin 
degradation. Antibodies efficiently depleted the UBE2S protein, as observed by the absence of 
signal following 25-fold enrichment of E2 enzymes on Ub agarose (Figure 4.1a, lanes 4-6), 
without affecting levels of the APC/C or the E2 UBCH10. UBE2S depletion caused only a 
modest increase in the half-life of cycB1-NT as compared to control-depleted extract (Figure 
4.1b). This effect was reversed by adding back 10 nM of the recombinant enzyme, implying that 
the delay was specifically due to loss of UBE2S activity.  
 We hypothesized that perhaps UBE2S is not essential for rapid degradation of cyclin B1 
because this substrate contains multiple lysine residues that can serve as sites of attachment of 
short ubiquitin chains generated by UBCH10. If this hypothesis is correct, then restricting the 
number of available lysine residues should make degradation more dependent on UBE2S. We 
therefore examined the effect of UBE2S depletion on the rates of degradation of cyc
K64only
 
compared to that of wild-type cyclin B1 (Figure 4.1c). As we observed for cycB1-NT, the 
degradation of full-length wild-type cyclin B1 was largely unaffected by depletion of UBE2S 
(Figure 4.1c, top and bottom left panels). In contrast, the proteolysis of cyc
K64only
 was highly 
sensitive to the depletion of UBE2S (Figure 4.1c, top and bottom right panels), and addition of 
recombinant UBE2S fully restored degradation. Supplementing control-depleted mitotic extract 
with 10 nM of recombinant UBE2S had little effect on the turnover of wild-type cyclin B1 
(Figure 4.1b and 4.1c top left panel), but slightly stimulated degradation of cyc
K64only
 (Figure 4.1c,  
  
100 
  
101 
top right panel). Together these findings indicate that UBE2S is indeed present in Xenopus extract 
at sufficient levels to support cyclin proteolysis, but becomes essential only when the number of 
ubiquitinatable lysine residues in cyclin B1 is restricted.  
 
 
Role of chain-extending enzyme E2-25K in APC-mediated ubiquitination 
 
 Similarly to UBE2S, in budding yeast another ubiquitin-conjugating enzyme Ubc1 has 
been shown to stimulate processive ubiquitin-chain extension on APC substrates carrying pre-
attached ubiquitins (Rodrigo-Brenni and Morgan, 2007). The human homolog of Ubc1, E2-25K 
was also found to promote higher extent of polyubiquitination when added to assays containing 
human APC and UBCH10. Motivated by these findings, we sought to examine whether E2-25K 
has any effect on the extent or pattern of cyclin ubiquitination catalyzed by Xenopus APC using 
reconstituted ubiquitination assays. Consistent with studies showing that this E2 cannot initiate 
conjugation, but rather elongates nascent ubiquitin chains (Rodrigo-Brenni and Morgan, 2007; 
Wu et al., 2010), E2-25K did not catalyze cyclin ubiquitination on its own (Figure 4.2). 
Unexpectedly, when E2-25K was added to the assay together with UBC4, the number of 
conjugated Ub molecules per cyclin remained largely unaffected (Figure 4.2; data not shown). 
Similarly, we found no effect of the chain-elongating activity of E2-25K when combined with 
UBCH10 (Figure 4.2). To rule out the possibility that the apparent lack of contribution of E2-25K 
resulted from competition for ubiquitin charging or binding to the APC/C, we added the 
proximally-acting E2s UBCH10 and UBC4 at nanomolar concentrations concomitantly with 
increasing the E2-25K concentration approximately tenfold to 10 μM. Under these conditions, the 
catalytically active E2-25K had no appreciable effect on cyclin B1 ubiquitination (data not 
shown). 
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Analysis of the role of UBCH10 in APC activity in Xenopus extract 
 
The lack of requirement for UBE2S activity and ubiquitin-chain formation for efficient 
proteolysis of cyclin B1 in Xenopus extract suggest that UBCH10, or perhaps enzymes of the 
UBC4/5 family, are sufficient to support APC/C-dependent degradation in this context. We next 
examined how recruitment of the E2 UBCH10 contributes to the function of mitotically activated 
APC. To quantitatively evaluate a requirement for UBCH10-mediated ubiquitination in targeting 
cyclin to the proteasome, we immunodepleted the protein and measured how this affected levels 
of 
35
S-labeled cycB1-NT. Antibodies efficiently depleted the UBCH10 protein, as observed by 
the absence of signal following 20-fold enrichment of E2 enzymes on ubiquitin agarose (Figure 
4.3a). UBCH10 depletion with two different antibodies (Figure 4.3a; data not shown) caused a 
modest increase in the half-life of cycB1-NT as compared to control-depleted extract (Figure 
4.3b), but failed to stabilize the substrate which would be expected if UBCH10 were required for 
substrate degradation in this context. The delay in degradation was rescued by addition of 50 nM 
of recombinant UBCH10. In analogous experiments, proteolysis of full-length cyclin B1-CDK1 
complex was largely unaffected by depletion of UBCH10 (Figure 4.3c). In contrast with wild-
type cyclin B1, depletion of UBCH10 more significantly delayed turnover of the single-lysine 
(cyc
K64only
) cyclin B1 (Figure 4.3c), an effect reversed by the addition of 50 nM of recombinant 
UBCH10. The lack of requirement for UBCH10 in cyclin B1 degradation indicates that other E2 
enzymes in the extract may be sufficient to prime APC molecules for substrate ubiquitination. 
Members of the UBC4/5 family, which have been demonstrated to cooperate with the APC in 
vitro (Garnett et al., 2009; Kirkpatrick et al., 2006; Mathe et al., 2004; Summers et al., 2008; Yu 
et al., 1996; Zeng et al., 2010), are the best candidates for such a role. We therefore sought to 
examine the role of this class of E2s in cyclin B1 destruction. 
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UBC4 cooperates with the APC to assemble an efficient proteolytic signal on cyclin B1 
 
             To evaluate a potential role for enzymes from the UBC4/5 class in cyclin B1 degradation, 
we assessed whether effects of different ubiquitin mutants on proteolysis in Xenopus extract 
(discussed in chapter III) paralleled their effects on UBC4-catalyzed conjugation in a 
reconstituted system. Elimination of Lys11 or 63 of ubiquitin had no effect on the overall pattern 
or extent of substrate ubiquitination, whereas elimination of Lys48 slightly reduced the mass of 
conjugates, consistent with the preference of UBC4 for forming Lys48 linkages (Kirkpatrick et 
al., 2006) (Figure 4.4a). In the presence of chain-terminating ubiquitin types such as methylated 
ubiquitin and Ub
triR 
(ubiquitin containing lysine-to-arginine substitutions at all three sites Lys11, 
48 and 63 simultaneously), UBC4, similarly to UBCH10 (discussed in chapter III), was capable 
of appending ubiquitin monomers to distinct lysine residues on cyclin. The maximal extent of 
ubiquitination achieved with UBC4 under these conditions appeared higher relative to that seen 
with UBCH10 (Figure 4.4a; data shown in chapter III). Together these findings indicate that 
UBC4 can facilitate ubiquitination on more cyclin B1 lysine residues than UBCH10, consistent 
with previous work (Garnett et al., 2009; Kirkpatrick et al., 2006).  
 Ubiquitin assemblies elaborated by UBC4 in the presence of wild-type ubiquitin were 
recognized by proteasome-associated ubiquitin receptors (Deveraux et al., 1994; Elsasser et al., 
2004; Elsasser and Finley, 2005; Finley, 2009; Isasa et al., 2010; Matiuhin et al., 2008; Peth et al., 
2010; Rao and Sastry, 2002; Riedinger et al., 2010) including Rpn10 (Figure 4.4b) and Rad23 
(Figure 4.4d), consistent with previous findings (Kirkpatrick et al., 2006). Importantly, multiply 
monoubiquitinated substrate was also capable of binding to both receptors. For conjugates of a 
similar molecular mass, substrate ubiquitinated with Ub
triR
 bound to receptors more efficiently 
than substrate ubiquitinated with Ub
me
, a difference more pronounced in binding to Rad23. In 
contrast to species bearing a higher number of ubiquitin groups, unmodified and 
oligoubiquitinated cyclin B1 had much lower affinity for ubiquitin receptors.  As observed  
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previously (data shown in chapter III) (Kirkpatrick et al., 2006), all binding was dependent on the 
integrity of the receptor domains recognizing ubiquitin (Figure 4.4c, e). 
 Since UBC4 mediated transfer of monoubiquitin to multiple substrate residues and 
generated a ubiquitin signal that was recognized by ubiquitin receptors, we sought to determine 
whether multiple monoubiquitination catalyzed by UBC4 can target cyclin B1 for degradation. 
To this end, full-length cyclin B1-CDK1 complex was ubiquitinated with UBC4, in conjunction 
with wild-type or chain-terminating ubiquitin. The resulting species were incubated with human 
proteasomes, purified as reported previously (Lee et al., 2010) and containing the 
deubiquitinating enzymes RPN11 and UCH37, but no USP14. The deubiquitinase USP14 was 
previously shown to attenuate the capacity of the proteasome to rapidly degrade cyclin-ubiquitin 
species in vitro, presumably by trimming poly-ubiquitin chains assembled on substrate residues 
(Hanna et al., 2006; Lee et al., 2010). In agreement with previous findings (Crosas et al., 2006; 
Hanna et al., 2006; Lee et al., 2010), these USP14-deficient proteasomes rapidly degraded cyclin 
B1 that was polyubiquitinated by UBC4-APC (Figure 4.5a). While conjugates formed with Ub
triR 
or lysine-less ubiquitin (Ub
K0
) were also degraded rapidly, those generated with methylated 
ubiquitin (Ub
me
) were degraded more slowly. This observation parallels the effects of these 
mutant ubiquitins in Xenopus extract (discussed in chapter III) and is consistent with the defect in 
the ability of cyclin B1-Ub
me
 to bind ubiquitin receptors (Figure 4.4b, d). We previously 
quantitated the extent of substrate proteolysis using 
35
S-labeled full-length cyclin B1 and found 
that it closely correlated with the percentage of cyclin B1 modified with three or more ubiquitin 
moieties (data not shown). Together these results indicate that purified proteasomes do not 
impose a requirement for long ubiquitin polymers and can efficiently degrade multiply 
monoubiquitinated cyclin B1. 
 We extended the analysis of these multiply monoubiquitinated species by measuring their 
degradation under conditions where different ubiquitin receptors, deubiquitinating enzymes and 
the proteolytic machinery are present at physiological concentrations. To this end, we added  
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radiolabeled full-length cyclin B1 pre-ubiquitinated by UBC4 (Figure 4.5b) to interphase 
Xenopus extract that had been immunodepleted of the APC (Figure 4.5c). The extent and kinetics 
of degradation of species formed with Ub
triR
 were very similar to those for conjugates formed 
with wild-type ubiquitin. Conjugates generated with Ub
me
 were degraded slightly less efficiently. 
Together these results further support the view that Xenopus extracts can rapidly degrade a cyclin 
substrate bearing multiple ubiquitin groups attached to distinct lysine residues even when 
deubiquitination is not inhibited. 
 
 
Role of UBC4/5 enzymes in cyclin B1 degradation in Xenopus extract 
 
 The modest stabilization of cyclin B1 observed in UBCH10-depleted extracts (Figure 
4.3b) raises the possibility that additional E2 enzymes may support APC catalysis in this context. 
Based on this and previous work (Hanna et al., 2006; Kirkpatrick et al., 2006; Lee et al., 2010), 
members of the UBC4/5 class appear to be the best candidates for such a role. We sought to 
deplete the extract of these enzymes and assess the effect on cyclin degradation. To this end, we 
screened five different commercially available antibodies against UBC4/5. Despite extensive 
optimization of assay conditions, we were unable to achieve significant depletion of UBC4/5 in 
order to evaluate their role in cyclin proteolysis. We therefore took an alternative approach in 
addressing this question. Using ubiquitin covalently coupled to agarose beads via primary amines 
allowing for a fully functional C-terminus, we attempted to deplete the extract of proteins that 
have an affinity for ubiquitin, including ubiquitin-activating enzyme (E1), ubiquitin-conjugating 
enzymes (E2s), ubiquitin ligases (E3s) and ubiquitin C-terminal hydrolases (UCHs). Unlike 
immunodepletion experiments which address necessity, ubiquitin-agarose depletions have the 
potential to reveal sufficiency of particular E2 enzymes in cyclin degradation.  
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To quantitatively assess the effect of depleting the enzymatic machinery that targets 
cyclin B1 for degradation in mitotic Xenopus extracts, we measured the proteolysis of a purified, 
35
S-labeled cycB1-NT. In parallel, we examined the levels of UBC4/5, UBCH10 and UBE2S 
enzymes, as well as the APC, by western analysis. Interestingly, even trace levels of different E2 
enzymes known to work in conjunction with the APC (Aristarkhov et al., 1996; Jin et al., 2008; 
King et al., 1995; Mathe et al., 2004; Rodrigo-Brenni and Morgan, 2007; Townsley et al., 1997; 
Williamson et al., 2009; Yu et al., 1996) were sufficient to support cyclin proteolysis. We found 
that while four rounds of incubation with ubiquitin agarose led to significant depletion of UBC4/5 
and UBCH10, as observed by western blotting (Figure 4.6a), cycB1-NT degradation remained 
largely unaffected (data not shown). Increasing the rounds of ubiquitin-agarose depletion to six 
rendered the extract incapable of promoting cyclin degradation (Figure 4.6b), consistent with 
complete depletion of E2 enzymes (Figure 4.6a). To rescue proteolysis in depleted extracts, 
recombinant E1, ubiquitin, ATP and the E2 enzyme of interest were added back. Addition of 
ubiquitin-activating enzyme (E1) and ubiquitin alone did not restore degradation, indicating that 
the relevant E2 machinery had been depleted below the threshold required to support proteolysis 
(Figure 4.6b). We found that supplementing the depleted extract with 100 nM (data not shown) or 
250 nM (Figure 4.6b) of recombinant UBC4 partially rescued proteolysis. Similar trends were 
observed even when the concentration of recombinant UBC4 was increased to 3 μM (data not 
shown). In contrast, under these conditions, addition of 250 nM of recombinant UBCH10 restored 
degradation to levels observed in undepleted extract (Figure 4.6b). Together these findings imply 
that another member of the UBC4/5 family may be a preferred E2 partner of the APC in Xenopus 
egg extract. Future experiments are required to determine whether other members of the UBC4/5 
family may be more efficient at priming APC substrates for proteasomal degradation. 
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Discussion 
 
Here we have evaluated the role of E2 enzymes in supporting APC activity in Xenopus 
cell-cycle extracts. Our study was motivated by recent reports suggesting that the assembly of 
Lys11-linked ubiquitin chains, mediated by the E2 enzyme UBE2S, may be essential for APC-
dependent proteolysis. However, we found that the proteolytic machinery in Xenopus extract and 
in the reconstituted system does not impose a requirement for chain formation to efficiently 
degrade ubiquitinated cyclin and that the elaboration of Lys11-linked chains becomes essential 
only when the number of ubiquitinatable residues in cyclin B1 is restricted. Here we provide 
evidence that the chain-forming E2 UBE2S is dispensable for cyclin proteolysis, unless the 
number of available lysine residues in cyclin B1 is restricted, and evaluate how proximally-acting 
E2s UBCH10 and UBC4 may promote substrate degradation. 
Our previous work revealed that chain-terminating ubiquitins support efficient 
proteolysis of cyclin B1 in Xenopus extracts (discussed in chapter III). Utilizing a reconstituted 
system, we demonstrated that multiply monoubiquitinated species generated with either UBCH10 
or UBC4 are efficiently degraded by purified proteasomes. These findings raise the possibility 
that through conjugation of monoubiquitin to distinct lysines in cyclin, and possibly the 
elaboration of short chains, either of these E2 may promote APC-dependent proteolysis of cyclin 
B1 in Xenopus extracts. Consistent with such a model, UBCH10 supported robust APC catalysis 
when added to ubiquitin-agarose depleted extract. Interestingly, the importance of UBCH10 in 
substrate degradation appears to increase with elimination of available ubiquitin-acceptor sites in 
cyclin B1. Nevertheless, the effects seen upon UBCH10 depletion were not very dramatic. These 
findings were surprising in the light of a previous report showing that an N-terminal fragment of 
human cyclin B1 is stabilized upon UBCH10 depletion, arguing that UBCH10 is required for 
cyclin proteolysis in  Xenopus extract (Tang et al., 2001). An important question the authors did 
not address, which may provide an explanation for these findings, was whether the antibody 
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efficiently and specifically depleted the UBCH10 protein, without affecting the levels of E2 
enzymes from the UBC4/5 family. As the core ubiquitin-conjugating (UBC) domains of these 
E2s share a high degree of sequence homology (Osaka et al., 1997; Summers et al., 2008; Ye and 
Rape, 2009), it may be non-trivial to avoid unintended co-depletion. 
Evidence from simpler model organisms indicates that E-2C family members are most 
likely to be biologically relevant as E2 partners of the APC (Mathe et al., 2004; Osaka et al., 
1997). These models do not rule out the possibility that members of the UBC4/5 family, or 
possibly other E2s, influence APC -dependent proteolysis in Xenopus extracts. Our earlier work 
suggested that APC, solely in conjunction with the E2 UBC4, can generate polyubiquitinated 
cyclin B1 that is rapidly degraded by purified proteasomes (Crosas et al., 2006; Hanna et al., 
2006; Kirkpatrick et al., 2006; Lee et al., 2010). These findings, together with the lack of 
substrate stabilization in UBCH10-depleted extract, led us to investigate a potential contribution 
of UBC4/5 to cyclin proteolysis in this system. Furthermore, we sought to determine whether 
UBCH10 and UBC4/5 enzymes are functionally redundant in creating multiple 
monoubiquitination sufficient for cyclin proteolysis.  
Utilizing a reconstituted system, we demonstrated that UBC4 can catalyze transfer of 
ubiquitin monomers to multiple lysine residues in cyclin, consistent with previous studies 
(Garnett et al., 2009; Kirkpatrick et al., 2005). Experiments with chain-terminating ubiquitin 
revealed higher number of substrate monoubiquitination sites in reactions catalyzed by UBC4, as 
compared to UBCH10 (discussed in chapter III). An interesting question is whether this more 
extensive multiple monoubiquitination and the apparent lower threshold of modification required 
for binding at least some ubiquitin receptors translates into more efficient degradation of UBC4-
generated cyclin B1-Ubn by the proteasome. Quantitative analysis of degradation with purified 
proteasomes (discussed in chapter III) revealed no such enhanced rate, or extent, of degradation 
of UBC4-generated conjugates. The capacity of purified proteasomes to rapidly degrade multiply 
monoubiquitinated species generated with either UBC4 or UBCH10 (data shown in chapter III) 
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further strengthens our proposition that the proteasome does not impose a requirement for 
ubiquitin-chain formation for efficient proteolysis of cyclin B1. 
Unlike the E-2C enzymes, members of the UBC4/5 class have been regarded as 
promiscuous E2s (Summers et al., 2008; Ye and Rape, 2009) with no essential role in APC -
mediated catalysis. Consistent with this view, Summers and colleagues found that addition of 
UBCH10, but not UBCH5 (a member of the UBC4/5 family), to extracts from nocodaloze-
arrested HeLa cells was required and sufficient to activate the APC and mediate destruction of 
securin and cyclin B1 (Summers et al., 2008). However, the simultaneous addition of excess 
ubiquitin allowed UBCH5 to catalyze destruction of APC substrates in this context, presumably 
by increasing the levels of ubiquitin-charged UBCH5 above the threshold required to stimulate 
APC activity (Summers et al., 2008). Due to technical limitations, we were unable to 
immunodeplete UBC4/5 and investigate potential functional redundancy between UBCH10 and 
UBC4/5 enzymes, explaining the partial effects in UBCH10-depleted extracts. Utilizing the 
ubiquitin-agarose depletion strategy, we examined whether UBC4/5 enzymatic activity supports 
cyclin proteolysis. Strikingly, E2s from the UBC4/5 and E-2C families had to be completely 
depleted in order to abolish substrate turnover in Xenopus extract. The incomplete rescue 
achieved with UBC4 under these conditions may imply that another member of the UBC4/5 class 
is a preferred APC partner. A limitation of the ubiquitin-agarose depletion approach is that 
multiple factors, which may impact substrate proteolysis directly or indirectly, become depleted 
(as revealed by mass spectrometry analysis) making it difficult to ascertain the contribution of 
UBC4/5 enzymes. It is possible that following multiple rounds of depletion, the extracts become 
deficient of components, such as ubiquitin receptors, which may be important for UBC4/5-driven 
pathways.  
Recent studies have proposed that the Lys11-specific chain-elongating E2 UBE2S has a 
critical role in the efficient ubiquitination and degradation of APC substrates in Xenopus, 
Drosophila, and humans (Williamson et al., 2009; Wu et al., 2010). We found that UBE2S 
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depletion of Xenopus egg extract had no impact on degradation of wild-type cyclin B1, but 
significantly slowed substrate proteolysis when ubiquitination was restricted to a single site.  
These trends closely paralleled the effects of adding chain-terminating ubiquitins to UbVS-treated 
Xenopus extract (discussed in chapter III).  Our findings are consistent with a report suggesting 
that UBE2S is largely dispensable for cyclin B1 degradation in normal mitosis in human HeLa 
cells (Garnett et al., 2009). In contrast, UBE2S was found to be more important for substrate 
degradation when APC activity is compromised as upon activation of the spindle assembly-
checkpoint (Garnett et al., 2009). The lack of requirement for UBE2S activity and long Lys11-
linked ubiquitin chains for robust degradation of cyclin B1 in Xenopus extracts may be a 
consequence of higher levels of active UBCH10 and APC than seen in other biological contexts 
(Garnett et al., 2009; Williamson et al., 2009), as well as the availability of multiple lysine 
residues in cyclin B1 that can serve as ubiquitin acceptor sites. Our observations favor the idea 
that the increased importance of UBE2S seen with limiting the number of ubiquitination sites 
reflects the ability of this E2 to extend long polymers with high processivity rather than a major 
degradative role of Lys11 linkages it forms. In this context, UBCH10 or UBC4/5 enzymes appear 
to be less efficient in rapidly elongating individual ubiquitin chains that would facilitate 
proteasomal recognition and substrate breakdown. We anticipate that the relative contribution of 
UBCH10 and UBE2S in degradation of different APC substrates may vary. Human cyclin B1 is 
lysine-rich in its N-terminal domain, containing 18 lysine residues, whereas cyclin A2 has 12 
lysine residues in the same region, which may make the latter protein more dependent on the 
chain-elongating enzyme UBE2S for degradation. Similarly, S. cerevisiae Clb2 is relatively 
lysine-poor in its N-terminal domain, containing only 6 lysine residues, potentially explaining the 
importance of a chain-elongating E2 in this system (Rodrigo-Brenni and Morgan, 2007). A 
greater dependence on chain-elongating E2s may impact the sensitivity of different substrates to 
deubiquitination. In this regard, cyclin A2 degradation during interphase is specifically impeded 
by the deubiquitinating enzyme USP37 (Huang et al., 2011), but this enzyme does not appear to 
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antagonize cyclin B1 degradation. An interesting future question is how the balance between 
multiple monoubiquitination and ubiquitin-chain formation affects sensitivity of degradation to 
deubiquitinating enzymes. Finally, our work raises the interesting possibility that the degree of 
dependence on UBE2S could be regulated by post-translational modification of the substrate. For 
example, acetylation is known to affect degradation of the spindle-checkpoint protein BubR1 
(Choi et al., 2009). By restricting the number of ubiquitinatable lysine residues, acetylation could 
increase the dependence of degradation pathways on UBE2S-catalyzed chain formation.  
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Methods 
 
Antibodies and biochemical reagents 
Proteins were separated by SDS-PAGE on NuPAGE 4-12% or 12% Bis-Tris gels 
(Invitrogen), followed by wet transfer to PVDF. Sources of antibodies for immunoblotting were 
as follows: anti-cyclin B1 (Ab-2; RB-008-P, Neomarkers), anti-Cdc27 (610455, BD Transduction 
Laboratories), anti-UBCH10 (A-650, Boston Biochem; AB3861, Millipore), anti-UBE2S (N-14; 
sc-131354, Santa Cruz Biotechnology), anti-UBCH5 (A-615; Boston Biochem), anti-ubiquitin 
(P4D1; sc-8017; Santa Cruz Biotechnology). Secondary antibodies used include anti-goat IgG-
HRP (sc-2020; Santa Cruz Biotechnology), anti-rabbit IgG-HRP (NA934; GE Healthcare), and 
anti-mouse IgG-HRP (NA931; GE Healthcare). Antibodies for immunoprecipitation or 
immunodepletion included: anti-Cdc27 (AF3.1; sc-9972, Santa Cruz Biotechnology), anti-
UBE2S (N-14; sc-131354, Santa Cruz Biotechnology), anti-UBCH10 (gift from H. Yu, UT 
Southwestern, USA); and for control depletions, normal rabbit IgG (sc-2027, Santa Cruz 
Biotechnology) and normal goat IgG (sc-2028, Santa Cruz Biotechnology) were used. UBE2S 
antibodies were coupled to UltraLink immobilized protein A/G beads (53132, Pierce). UBCH10 
and CDC27 antibodies were coupled to Affiprep protein A beads (156-0006, Bio-Rad). Ubiquitin 
agarose (U-405), MG262 (I-120), Ub
me 
and ubiquitin mutants except for Ub
(11+48)R
, Ub
(11+63)R
 and 
Ub
triR 
were purchased from Boston Biochem. Ubiquitin (U6253) were purchased from Sigma. 
 
Preparation of recombinant proteins 
Ubiquitin mutants Ub
(11+48)R
, Ub
(11+63)R
 and Ub
(11+48+63)R 
(referred to as Ub
triR
) were 
generated by introducing arginine codons (AGA, AGG) at the indicated sites through PCR-
mediated mutagenesis of the human ubiquitin sequence (cloned in pET3a with ampicillin 
resistance, the kind gift of C.M. Pickart). Plasmids were verified by sequencing and the purified 
proteins analyzed by mass spectrometry. To ensure efficient arginine incorporation, BL21 (DE3) 
cells were co-transformed with pJY2, developed by Pickart lab (You et al., 1999), which carries 
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T7 lysozyme (LysS) and a gene encoding tRNAUCU
Arg
. Cultures were grown at 37 °C to an 
attenuance (D) of ~ 0.5 at 600 nm, and induced with 100 μM isopropylthiogalactoside (IPTG) at 
D600 nm = 0.6 at 25 ˚C for 5 h. Cells were ruptured by sonication in QA lysis buffer (50 mM 
HEPES (pH 7.7), 100 mM KCl, protease-inhibitor cocktail, 5 mM 2-mercaptoethanol, 10 µg ml
-1
 
DNase). Lysozyme was added to 1 mg ml
-1 
concentration and lysate was incubated with rotation 
at 4 °C for 15 min. Following sonication, cell lysates were clarified by centrifugation and the 
resulting supernatants applied to a Q column. The flow-through containing ubiquitin was 
concentrated and purified by size-exclusion chromatography. Fractions containing ubiquitin were 
typically > 95% pure. 
To generate full-length cyclin B1-CDK1 complex, human cyclin B1 and CDK1 
baculoviruses were used as described previously (Kirkpatrick et al., 2006).  To generate mutants 
of cyclin B1, DNA fragments encoding the N-terminal 124 amino acids of wild-type human 
cyclin B1 (5´-
AACCGGTCCGAAACCGTCGACATGTCGCATCACCATCACCATCACGGCTC 
GATGGCGCTCCGAGTCACGCGTAACTCGAAAATTAATGCTGAAAATAAAGCGAAAA
TCAACATGGCAGGCGCCAAGCGCGTTCCTACGGCACCGGCGGCAACCTCCAAACCCG
GGCTGAGGCCAAGAACAGCTCTTGGGGACATTGGTAACAAAGTCAGTGAACAGCTA
CAGGCCAAAATGCCTATGAAAAAAGAAGCAAAACCTTCAGCTACCGGTAAAGTCAT
TGATAAAAAACTACCAAAACCTCTTGAAAAGGTACCTATGCTGGTGCCAGTGCCAGT
GTCTGAGCCAGTGCCAGAGCCAGAACCTGAGCCAGAACCTGAGCCTGTTAAAGAAG
AAAAACTTTCGCCTGAGCCTATTTTGGTTGATACTGCTAGCAATA-3´) or the same 
region of the protein with arginine substitutions at all lysine residues (cyc
allR
; 5´- 
AACCGGTCCGAAACCGTCGACATGTCGCATCACCATCACCATCACGGCTC 
GATGGCGCTCCGAGTCACGCGTAACTCGAGAATTAATGCTGAAAATAGAGCGAGAA
TCAACATGGCAGGCGCCAGGCGCGTTCCTACGGCACCGGCGGCAACCTCCAGACCCG
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GGCTGAGGCCAAGAACAGCTCTTGGGGACATTGGTAACAGAGTCAGTGAACAGCTA
CAGGCCAGAATGCCTATGAGAAGAGAAGCAAGACCTTCAGCTACCGGTAGAGTCAT
TGATAGAAGACTACCAAGACCTCTTGAAAGGGTACCTATGCTGGTGCCAGTGCCAGT
GTCTGAGCCAGTGCCAGAGCCAGAACCTGAGCCAGAACCTGAGCCTGTTAGAGAAG
AAAGACTTTCGCCTGAGCCTATTTTGGTTGATACTGCTAGCAATA-3´) preceded by 6 x  
His tag were synthesized (GenScript). Using restriction enzyme digestion with NheI and RsrII, 
fragments were subcloned into pFASTBac containing the carboxy terminus (125-433 amino 
acids) of cyclin B1. To generate cyc
K64only
, primers 5'- 
TCCAGACCCGGGCTGAGGCCAAGAACAGCTCTTGGGGACATTGGTAACAGAGTCAG
TGAACAGCTACAGGCC-3' and 5'-
AATGACTCTACCGGTAGCTGAAGGTCTTGCTTCTTTTCTCATAGGCATTCTGGCCTGT
AGCTGTTCACTGAC- 3' were used for an extension reaction and the resulting fragments cloned 
into XmaI and AgeI cleavage sites of pFASTBac carrying full-length cyc
allR
. Plasmids were 
verified by restriction enzyme mapping and sequencing. Baculoviruses were generated according 
to the Bac-to-Bac manual (Invitrogen). Wild-type cyclin B1 was 
35
S-labeled in Sf9 cultures with 
resuspending cells (1.5 x 10
6
 cells ml
-1
) in media containing 10% SF-900 II SFM and 90% SF-
900 II SFM without methionine or cysteine (both from Invitrogen) to increase radio-label uptake. 
Baculovirus was added to cells, along with 50 µCi of 
35
S-labeled methionine and cysteine 
(NEG772; Perkin Elmer), and cyclin B1 expression was allowed for 2.5 days. CDK1 was 
expressed separately in Sf9 cells without radiolabeling and then combined with lysate from cells 
expressing cyclin B1 to allow formation of complex, which was then purified through Ni-NTA 
affinity and gel filtration chromatography.  
        CycB1-NT (1-88 amino acids of human cyclin B1) , containing an HA tag at the N 
terminus and a 6xHis tag at the C terminus was generated using PCR amplification with forward 
primer (5´-CCA GGA CCA TGG GTT ACC CAT ACG ATG TTC CAG ATT ACG CTG GCT 
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CGA TGG CGC TCC GAG TCA CG-3´) and reverse primer (5´-GGG AGC CTC GAG CTA 
GGG AGC GTG ATG GTG ATG GTG ATG CAT AGG TAC CTT TTC AAG AGG-3´). The 
resulting PCR product was digested with NcoI and XhoI for subcloning into pET28a. Plasmids 
were verified by restriction enzyme mapping and sequencing. For 
35
S labeling in Escherichia  
coli, cultures (50 ml) were grown at 37 ˚C to D600 nm =  0.8, then collected  by centrifugation 
(3,700g for 15 min, at 4 
o
C) and resuspended in modified M9 medium (50 ml final volume). After 
resuspension in modified M9 medium, cells were allowed to grow for additional 15 min at 37 °C 
before 5 mCi of Easy Tag
TM
 L-[35S]-Methionine (NEG709A005MC; Perkin Elmer) was added. 
Expression was induced with 0.5 mM IPTG for 2.5 h at 37 
o
C. Cells were ruptured in 5 ml g
-1
 of 
pellet guanidine-HCl lysis buffer (pH 8.0) and lysates rotated at 24 °C until the lysate became 
slightly translucent; approximately 45 min. Lysates were clarified by centrifugation and cycB1-
NT was purified using Ni-NTA affinity chromatography (Qiagen). Eluted protein was desalted 
into XB buffer (100 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, at pH 7.8 with 
KOH), supplemented 2% glycerol, protease inhibitors and phenylmethylsulfonyl fluoride, and 
stored at – 20 °C.  
Maltose-binding protein (MBP)-tagged E1 was expressed in E. coli inducing cultures at 
D600 nm = 0.6 with 300 μM IPTG for 5 h at room temperature. Purification was carried out using a 
standard MBP purification protocol. For expression of His-tagged UBCH10 and His-tagged 
UBC4, bacterial cultures were induced at D600 nm = 0.6 at 37 ˚C with 500 μM IPTG for 4 h. The 
enzymes were purified through Ni-NTA affinity and gel-filtration chromatography. Glutathione-
S-transferase (GST)-fusion proteins for Rpn10 and Rad23, as well as their sub-domains, were 
purified essentially as reported previously (Elsasser et al., 2004; Elsasser et al., 2002). 
Recombinant E2-25K (UbcH1) was purchased from Boston Biochem (SP-200). 
 
Preparation of Xenopus egg extract  
  
121 
Interphase Xenopus egg extract was prepared from eggs laid overnight according to the 
protocol of Murray (Murray, 1991) with the exception that eggs were activated with 2 μg ml-1 
calcium ionophore (A23187, free acid form, Calbiochem) for 30 min prior to the crushing spin. 
Extract was frozen in liquid nitrogen and stored at -80 ºC. Interphase extract was induced to enter 
mitosis by addition of non-degradable cyclin B, which activates CDK1 and stimulates mitotic 
phosphorylation, resulting in APC activation. A fusion of the maltose-binding protein (MBP) to 
Xenopus cyclin B lacking its N-terminal 90 amino acids (MBP-Δ90) (Salic and King, 2005) was 
expressed in E. coli by inducing cultures at an D600nm=0.6 with 300 μM IPTG for 5 h at room 
temperature. Purification was carried out following New England BioLabs (NEB) protocol. To 
make mitotic extract, MBP-Δ90 was added to interphase extract generally at ~ 20 μg ml-1 and 
incubated at 22-24 ºC for 45-60 min. 
 
Reconstitution of ubiquitination and degradation of cyclin B1 
Ubiquitination reactions were carried out essentially as described previously (Kirkpatrick 
et al., 2006) for the indicated times. Briefly, for each 30 µl reaction, APC was immunopurified 
from 600 µl of mitotic Xenopus egg extract by incubation for 1 h at 4 °C with 12 µg of anti-
Cdc27 antibodies (AF3.1, Santa Cruz Biotechnology) immobilized onto 30 µl of Affiprep Protein 
A beads (156-0006, Bio-Rad). Following incubation with extract, beads were washed quickly (to 
minimize loss of associated APC co-activator Cdc20) three times with XB containing 500 mM 
KCl (10 mM potassium HEPES, pH 7.7, 500 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2), two times 
with XB (same content as above, except with 100 mM KCl), and then three times with reaction 
buffer (20 mM Tris, pH 7.5, 100 mM KCl, 2.5 mM MgCl2, 2 mM ATP).  Ubiquitination reaction 
were carried out at 24 °C with agitation at 1500 r.p.m and contained APC on 30 µl beads, and 30 
µl of a mix containing recombinant MBP-human E1 (1.3 µM), His-tagged UBCH10 or UBC4 
(100 nM – 4 μM), and E2-25K (concentration as indicated) as the E2 enzyme, wild-type or 
different forms of ubiquitin (118-145 μM), and 450-500 nM cyclin B1-CDK1 or cycB1-NT. For 
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ubiquitin-receptor binding and degradation assays, reaction supernatants were combined with the 
first 20 µl of reaction buffer wash. For analysis of cyclin B1 ubiquitination with different 
ubiquitins, entire reactions were processed for immunoblotting or autoradiography. Dried gels 
were analyzed by phosphorimaging (Bio-Rad PMI); quantification was carried out with Quantity 
One software (Bio-Rad). 
For binding experiments with ubiquitin receptors, cyclin B1-CDK1 was pre-ubiquitinated 
with purified Xenopus APC, UBC4 (3 μM), and ubiquitin (118 μM) for 90 min. Approximately 7-
8 μg of “bait” protein immobilized onto Glutathione-Sepharose 4B resin (GE Healthcare) was 
mixed with 4 μl of pre-synthesized ubiquitin-cyclin B1 conjugates and incubated for 1 h at 4 ˚C 
with agitation in the presence of 100 μg ml-1 BSA and 0.1 % Tween 20. Supernatants were 
collected and mixed with the first wash to make the flow-through fraction. Beads were washed 
twice and diluted with SDS sample buffer to analyze the bound fraction. Equivalent amounts of 
input (I), flow-through (FT) and bound (B) fractions were subjected to SDS-PAGE and western 
blot analysis using anti-cyclin B1 polyclonal antibody (Ab-2, Neomarkers). 
For degradation assays with purified proteasomes, human proteasomes (10-20 nM, 
concentrations as indicated), purified as reported previously (Lee et al., 2010) but non-UbVS 
treated, were added to cyclin B1-Ubn in buffer (50 mM Tris-HCl (pH 7.5), 5 mM MgCl2 and 5 
mM ATP) (Lee et al., 2010) and incubated at 24 °C. For 0 min time-point, substrate and 
proteasome mixtures were individually added to SDS sample buffer to prevent a time-lag from 
mixing. Aliquots withdrawn at indicated times were combined with SDS sample buffer and 
subjected to SDS-PAGE and immunoblot analysis using anti-cyclin B1 polyclonal antibody (Ab-
2, Neomarkers).  
 
Cyclin B1 degradation in Xenopus egg extract 
To deplete APC, 100 μl of interphase extract was mixed 2 μg of anti-Cdc27 antibody 
coupled to 5 μl of Affiprep Protein A beads and incubated at 4 °C for 3 h. APC depletion was 
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confirmed by anti-Cdc27 western blot analysis. Approximately 10 μl of pre-ubiquitinated 
radiolabeled cyclin B1 was added to 90 μl of APC-depleted extract. Reactions were incubated at 
22 °C for the indicated times and stopped by the addition of an equal volume of chilled 2% 
perchloric acid (PCA) (in H2O) making a new final volume of 200 μl. Reactions were then 
incubated on ice for ≥30 min and centrifuged at 15,000 r.p.m. for 10 min, at 4 °C. A fraction of 
supernatants was mixed with Tris Base and Ultima Gold scintillation fluid (6013327, Perkin 
Elmer) and the radioactivity was measured by scintillation counting. 
 
Immunodepletion of E2 enzymes 
 For UBE2S immunodepletion, 10 μg of anti-UBE2S antibody (N-14, Santa Cruz 
Biotechnology) or control goat IgG antibody (Santa Cruz Biotechnology) was bound to 25 µl 
UltraLink Immobilized Protein A/G (Pierce) and incubated with 250 µl extract at 4 °C for ~ 1 h. 
For UBCH10 immunodepletion, 100 μl of anti-UbcX antibody or an equivalent amount of control 
rabbit IgG coupled to Affiprep protein A support was used to deplete 170 μl extract. Following 
incubation, samples were briefly centrifuged and supernatants constituting E2- or control-
depleted extracts removed carefully without disturbing resin. Samples of depleted extract were 
centrifuged again to ensure no resin was present. Cyclin B1-CDK1 (~200 nM) was added to E2- 
or control-depleted extract and analysis of the time course of degradation was carried out at 24 ˚C 
(1,250 r.p.m.). The equivalent of 1 μl of extract was analyzed by SDS-PAGE and anti-cyclin B1 
immunoblot analysis. Depletion of UBE2S and UBCH10 was confirmed by western blotting 
using anti-UBE2S and anti-UBCH10, respectively. To confirm the efficiency of E2 depletion, 
extract was incubated with ubiquitin agarose, at a ratio of ~10:1 (extract/ resin). Ubiquitin agarose 
was pre-washed four times with 1x energy mix (for 20x stock: 150 mM creatine phosphate, 20 
mM ATP, 2 mM EGTA and 20 mM  MgCl2 , at pH 7.7) in XB buffer (100 mM KCl). Extract and 
2x energy mix were added to ubiquitin agarose and incubated with agitation at 24 ˚C for 45 min. 
Samples were centrifuged, extract was removed and ubiquitin agarose was washed once with a 
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tenfold volume of 1x energy mix in XB. Bound proteins were eluted by boiling in SDS sample 
buffer and analyzed by immunoblotting. 
 
Ubiquitin-agarose depletion of Xenopus extract 
Ubiquitin (Ub) agarose (concentration of Ub was 10 mg ml
-1
 or 1.2 mM) was pre-washed 
four times with 1x energy mix (for 20x stock: 150 mM creatine phosphate, 20 mM ATP, 2 mM 
EGTA and 20 mM  MgCl2 , at pH 7.7) in XB buffer (100 mM KCl). To pre-washed Ub agarose, 
added mitotically arrested Xenopus extract and 2x energy mix (20x stock) at a ratio of ~2:1 
(extract/ resin), and incubated with agitation (1,250 r.p.m) at 24 °C for 7 min. Following 
incubation, centrifuged sample at 2,000 r.p.m. for 30 sec to return resin to bottom of the tube. The 
resulting supernatant is transferred to a new tube containing Ub agarose, repeating the steps 
described above for a total of 7 rounds of depletion. Samples of supernatant following each round 
of depletion were combined with SDS sample buffer and levels of proteins analyzed by 
immunoblotting. Proteins bound to Ub agarose were eluted by boiling in SDS sample buffer and 
analyzed by immunoblotting. 
Ub agarose-depleted extracts were supplemented with 0.9 μM human or Xenopus laevis 
E1 enzyme (kind gift of Brenda Schulman), ~120 μM wild-type ubiquitin, E2 enzymes (100 nM – 
3 μM), as indicated, and 1x energy mix. 35S-labeled cycB1-NT (~200-250 nM) was added to Ub 
agarose-depleted or undepleted extract and analysis of the time course of degradation was carried 
out at 24 ˚C (1,250 r.p.m.). At indicated times, reactions (3 μl per time point) were quenched with 
97 μl of 20 % TCA, vortexed and incubated on ice (≥ 30 min) before centrifugation at 14,000g 
for 30 min at 4 °C. The radioactivity in the supernatant was measured by scintillation counting. 
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 The Anaphase-Promoting Complex/Cyclosome (APC/C or APC) is a multi-subunit ligase 
complex that initiates anaphase and mitotic exit by ubiquitinating cell-cycle regulators, including 
cyclin B1. Here, we sought to understand the role of ubiquitin-chain formation in APC catalysis 
and proteasomal targeting. Our work provides strong evidence that the proteolytic machinery 
does not exert a requirement for Lys11 or other ubiquitin-ubiquitin linkages for efficient 
degradation of ubiquitinated cyclin B1. Utilizing a reconstituted system and Xenopus cell-cycle 
extracts, we demonstrate that multiple monoubiquitination can indeed be coupled to robust 
proteolysis, at least in the context of cyclin B1. Upon restriction of the ubiquitin-acceptor sites in 
cyclin B1, Lys11-linked ubiquitin polymers elaborated by the E2 UBE2S become increasingly 
important for substrate proteolysis. The existence of two distinct degradative pathways driven by 
multiple monoubiquitination vs. ubiquitin-chain formation has important implications for how 
APC activity may be coupled to, and regulated by, distinct E2 enzymes. Our findings explain how 
the presence of multiple ubiquitin-acceptor sites confers flexibility in the requirement for 
particular E2 enzymes in modulating the rate of ubiquitin-dependent proteolysis. 
 
 
Development of a system to study the role of ubiquitin linkage in proteasomal targeting  
 
 
 Chapter II of this dissertation presents a novel approach we developed to gain better 
understanding of the importance of different ubiquitin-chain topologies in promoting substrate 
degradation by the 26S proteasome. To investigate the nature of the ubiquitin signal targeting 
cyclin B1 for proteolysis, a system for the expression and purification of radiolabeled N-terminal 
fragment of the protein was established, which was critical to our ability to examine cyclin 
degradation in a rigorous and quantitative manner. Analysis of APC -mediated ubiquitination and 
degradation with purified proteasomes provided us with strong confidence that the behavior of 
  
131 
the N-terminal fragment of human cyclin B1 (amino acids 1-88) (referred to as cycB1-NT) 
closely resembled that of the full-length protein.  
 The problem of ubiquitin-chain formation and function has been challenging to study in 
physiologically relevant systems due to the presence of endogenous ubiquitin. Development of 
strategies for effective blockade of the regulatory pathways maintaining ubiquitin levels is a non-
trivial task and for that reason manipulation of the endogenous ubiquitin pool in any model 
system is difficult. One experimental approach to studying the role of specific ubiquitin-ubiquitin 
linkages, or lack thereof, in proteasomal targeting has been the addition of mutant ubiquitin in 
excess to endogenous ubiquitin (Hershko et al., 1991; Jin et al., 2008; Wu et al., 2010). However, 
the contribution of specific ubiquitin-chain topologies in proteasomal degradation may be 
difficult to ascertain when conducted in a background that contains wild-type ubiquitin. 
Importantly, alteration of ubiquitin levels as upon adding exogenous ubiquitin may influence 
pairing of a specific E3 ubiquitin ligase with ubiquitin-conjugating enzymes, potentially 
impacting different aspects of substrate ubiquitination and/or the downstream fate of modified 
proteins. In this regard, excess added ubiquitin was found to increase the fraction of ubiquitin-
charged UBCH5, thereby promoting a functional interaction of this promiscuous E2 with APC in 
mitotic cell extracts (Summers et al., 2008).  These findings emphasize the need for methods 
where no gross fluctuations in the available ubiquitin pool are introduced. In the UbVS system, 
recycling of endogenous ubiquitin from existing conjugates is inhibited and wild-type ubiquitin is 
supplemented at levels just sufficient to restore degradation. Thereby we were able to examine 
the functional significance of distinct ubiquitin linkages in APC catalysis and proteasomal 
degradation at more physiologically relevant ubiquitin concentrations.   
Our analysis revealed that the availability of free ubiquitin in Xenopus extract has a 
strong effect on the kinetics of cyclin degradation. One future direction would be to extend our 
analysis and examine the possibility that control of ubiquitin availability may be a mechanism by 
which the rate of APC-substrate degradation can be controlled. Utilizing this system, we can 
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quantitatively evaluate how proteasomal targeting of different APC substrates may be 
differentially sensitive to levels of free ubiquitin. Less processive substrates of the APC such as 
cyclin A and UBCH10, which require multiple binding cycles to obtain their proteolytic tags 
(Rape et al., 2006), may exhibit higher sensitivity to ubiquitin levels. Such sensitivity would be 
potentially amplified if proteasomal targeting of a substrate is actively opposed by the activity of 
deubiquitinating enzymes. An exciting finding from our work suggests that proteolysis of 
endogenous UBCH10 in Xenopus extracts may be actively antagonized through the disassembly 
or editing of its ubiquitin signal. Levels of UBCH10 are reduced upon supplementing UbVS-
treated mitotic extract with wild-type ubiquitin. In this context, an interesting question to address 
will be how the balance of ubiquitination and deubiquitination of UBCH10 modulates the levels 
of active E2, thereby providing a mechanism for regulating APC activity. Tools including 
immunodepletion and the APC-specific inhibitor TAME (Zeng and King, 2012; Zeng et al., 
2010) would allow us to test whether the reduction in UBCH10 levels in this context is APC-
dependent and how levels of APC activity influence stability of the E2. Furthermore, the 
deubiqutinating activity that potentially antagonizes UBCH10 degradation can be identified and 
characterized. 
In contrast to our findings about UBCH10, UbVS-sensitive isopeptidases are unlikely to 
present a major kinetic barrier to cyclin B1 proteolysis in mitotic extract. Importantly, this may 
not hold true for interphase extracts. We found that inhibiting the catalytic activity of 
deubiquitinases with UbVS in the presence of wild-type ubiquitin stimulated cyclin proteolysis 
(data presented in appendix). These findings suggest that the activity of interphase APC can 
support cyclin degradation, but is effectively overwhelmed by deubiquitination which prevents 
dysregulated substrate proteolysis. We are currently pursuing identification of such 
deubiquitinating activity which may specifically oppose the activity of interphase APC, thereby 
preventing untimely substrate degradation. 
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Role of ubiquitin linkage and E2 enzymes in APC/C-mediated degradation       
  
There have been significant efforts dedicated to understanding the mechanistic and 
architectural complexities underlying APC activity. Structural studies comprise one aspect of 
these efforts and recent work has shed important insight into how subunit organization of the 
APC and conformational rearrangements may be coupled with proper substrate recognition and 
efficient ubiquitin transfer to substrate residues (Buschhorn et al., 2011; da Fonseca et al., 2011). 
These studies have advanced our understanding of this complex ubiquitin ligase and complement 
work examining the mechanism of ubiquitin-chain formation by the APC. In this context, recent 
findings have suggested that Lys11-linked ubiquitin polymers, assembled by the chain-elongating 
E2 UBE2S, may be important in APC-dependent proteolysis. While important for normal mitotic 
progression in Drosophila S2 cells (Williamson et al., 2009), UBE2S was found to be dispensable 
for this process in human cells (Garnett et al., 2009). The lack of a uniform requirement for 
UBE2S, together with the capacity of the proteasome to rapidly degrade cyclin bearing multiple 
short chains (Kirkpatrick et al., 2006), motivated us to examine whether APC-mediated 
proteolysis is strictly dependent upon polyubiquitination and whether the proteasome exerts a 
requirement for specific ubiquitin-ubiquitin linkages to efficiently degrade cyclin B1. To address 
this question, we utilized the UbVS system. Neither Lys48, nor Lys11, ubiquitin-ubiquitin 
linkages were essential for robust rates of cyclin proteolysis. Furthermore, our analysis revealed 
that ubiquitin-chain formation is dispensable for cyclin proteolysis in Xenopus extracts, unless the 
number of available lysine residues is limited. In agreement with the effects of chain-terminating 
ubiquitin in Xenopus extract, purified proteasomes degraded multiply monoubiquitinated cyclin 
B1 with fast kinetics, comparable to those for substrate bearing ubiquitin chains. Based on our 
findings, we propose that the presence of multiple lysines in cyclin B1 that are in close proximity 
to one another has the potential for generating a high local density of monoubiquitin that 
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promotes receptor binding and proteasomal degradation. Perhaps similar to how linkage of 
ubiquitin units into a polymer structure may determine its potential as a degradative element, 
particular spacing of monoubiquitins along the substrate may be differentially conducive to 
productive engagement with the proteolytic machinery. Previously, Hershko and Heller found 
that while in the presence of methylated ubiquitin lysozyme is conjugated with up to 7 
monoubiquitins, it is degraded with slow kinetics (Hershko and Heller, 1985). An interesting 
possibility is that, unlike in the context of cyclin B1, the distribution of modified lysines in 
lysozyme cannot generate sufficient local density of ubiquitin to facilitate ubiquitin receptor and 
proteasome binding. It may be of interest in the future to examine how the distribution of 
available ubiquitin-acceptor sites in cyclin B1 influences the capacity of multiple 
monoubiquitination to serve as a robust proteolytic signal. These efforts would be particularly 
important as we develop strategies to understanding steps subsequent to dissociation of 
ubiquitinated cyclin B1 from the ligase, including how conjugates are delivered to the 
proteasome, and how those events may be coupled to different aspects of cyclin ubiquitination. 
 An important aspect of our work has been understanding how the architecture of a 
ubiquitin tag is decoded by the proteolytic machinery. Our analysis indicates that multiple 
monoubiquitination can promote rapid and complete degradation of a physiological proteasome 
substrate. Importantly, we define a novel proteolytic signal that confers flexibility in the 
requirement for particular E2 enzymes in modulating the rate of ubiquitin-dependent proteolysis. 
In Xenopus cell-cycle extracts, we found that the chain-elongating E2 UBE2S is dispensable for 
APC/C-mediated degradation of cyclin. Our findings are consistent with a model where 
UBCH10, or possibly UBC4/5 enzymes, catalyzes the conjugation of monoubiquitin to multiple 
lysine residues and possibly the elaboration of some short chains, generating degradation-
competent cyclin. These E2 enzymes are recruited to the ligase through the RING domain of 
APC11 (Peters, 2006; Tang et al., 2001; Yu et al., 1998) without impeding the recruitment of 
UBE2S, which interacts at least in part through the substrate-adaptor proteins Cdc20 and Cdh1 
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(Behrends and Harper, 2011; Wickliffe et al., 2011; Williamson et al., 2009). Such a mode of 
recruitment of multiple ubiquitin-conjugating enzymes would potentially overcome the separation 
of ubiquitin-chain initiation and elongation steps, favoring the processive assembly of long 
polymers. Although UBE2S appears to be present in Xenopus extract at sufficient levels to 
support cyclin proteolysis, it does not appear to be an active component of the conjugation 
machinery and becomes essential only when the number of ubiquitinatable lysine residues in 
cyclin B1 is restricted. This raises questions as to whether UBE2S is tightly associated with the 
APC/C and how its activity is regulated. An intriguing possibility is that levels of free ubiquitin 
regulate activity of UBE2S. Perhaps under conditions of ubiquitin limitation as may be the case in 
Xenopus extract, there are mechanisms in place to conserve ubiquitin, restricting extent of 
ubiquitination to what is sufficient for timely destruction and preventing the formation of multiple 
long chains. Future work will be needed to address these questions. 
 While our work provides strong evidence that multiple monoubiquitination can serve as 
an efficient proteolytic signal in the context of cyclin B1, further studies are required to determine 
if such mode of ubiquitination targets additional APC substrates to the proteasome or if it is a 
degradative pathway uniquely pertaining to cyclin B1. The UbVS system, described earlier, 
provides an exciting opportunity to extend our analysis to other APC substrates and better 
understand how the lysine profile of a substrate may influence the balance between multiple 
monoubiquitination and ubiquitin-chain extension. Perhaps robust APC-mediated proteolysis of 
securin, which like cyclin B1 has 18 lysines, may show little or no dependence on ubiquitin-chain 
formation and catalysis by the E2 UBE2S. For other substrates such as cyclin A2 and UBCH10, 
each of which has 12 lysines, degradation may be more dependent on the chain-elongating 
enzyme UBE2S. Currently, we are investigating whether the blockage of lysines by other post-
translational modifications or a crosstalk between neighboring post-translational modifications 
may limit the availability of ubiquitin-acceptor sites in cyclin B1, enforcing a requirement for 
synthesis of long ubiquitin chains for efficient turnover. Work carried out in collaboration with 
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the Gygi lab has uncovered residues within the N-terminal domain of cyclin B1 that are modified 
with acetyl groups. Current and future efforts may be dedicated to identifying a physiological 
setting most conducive to studying effects of acetylation on APC-mediated catalysis and 
ubiquitin-dependent proteolysis. 
 It was surprising to find that in Xenopus cell-cycle extracts multiple monoubiquitination 
can signal robust proteasomal turnover. Our findings in a purified system and in Xenopus extract 
suggest that the proteasome does not impose a requirement for ubiquitin-chain formation for 
cyclin B1 destruction.  One could envision that degradation of a substrate conjugated with 5 or 6 
monoubiquitins, as appears to be the case for cyclin B1, may be more sensitive to 
deubiquitinases, as compared to a heavily ubiquitinated protein. We found that one such DUB 
able to remove monoubiquitins attached to cyclin is the proteasome-associated enzyme USP14. 
Unlike in an in vitro system, USP14 did not appear to antagonize cyclin B1 degradation in 
Xenopus extracts (data also shown in appendix). APC-dependent proteolysis of cyclin B1, at least 
in mitotic Xenopus extracts, was not appreciably impeded by UbVS-sensitive DUBs. These 
findings do not rule out the possibility that multiply monoubiquitinated species of cyclin B1 are 
effectively “shielded” by the activity of deubiquitinating enzymes through binding to proteins 
such as ubiquitin receptors. There is minimal knowledge of what factors may recognize and 
decode a signal specifically comprised of multiple monoubiquitins or Lys11-linked ubiquitin 
polymers. With reports demonstrating that several DUBs, including the OTU-domain containing 
Cezanne protein, have a preference for Lys11-linked chains (Bremm et al., 2010), we are only 
beginning to understand how the ubiquitin code is read.  Development of tools to identify factors 
interacting with ubiquitin conjugates downstream of different E2-E3 complexes will provide us 
with an opportunity to examine how distinct ubiquitin-ubiquitin linkages are assigned 
independent functions in the pathway leading to the proteasome.  
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Results 
 
Analysis of the role of USP14 in cyclin B1 degradation in Xenopus extracts 
 
 
Our previous findings indicated that as long as ubiquitin (Ub) availability is high enough, 
deubiquitination mediated by UbVS-sensitive DUBs is unlikely to present a major kinetic barrier 
to cyclin B1 degradation in mitotic Xenopus extract (Dimova et al., 2012). While the analysis we 
carried out could not ascertain a role for DUBs, which are not inhibited by UbVS, our findings 
suggested that there are few, if any, UbVS-senstitive deubiquitinases that actively antagonize 
proteasomal targeting of cyclin B1 in mitotic extracts. Alternatively, our findings suggested that 
for such activity to oppose degradation, it may be crucial that the rate of ubiquitination be 
constrained by limiting activity of the ubiquitination machinery or by limiting availability of free 
ubiquitin.  
Activity of the APC in mitotic Xenopus extracts is dependent on the reversible 
association with the activator Cdc20, which helps recruit substrates to the APC and may also 
directly stimulate the catalytic activity of the ligase (Kimata et al., 2008). Surprisingly, work from 
our lab uncovered that in Xenopus extracts Cdc20 also interacted with interphase APC, albeit 
with different dynamics relative to the mitotically phosphorylated ligase (Xing Zeng, unpublished 
observations). We hypothesized that the catalytic capacity of interphase APC
Cdc20
, while 
sufficient to promote ubiquitin-dependent proteolysis, is strongly opposed by the activity of 
deubiquitinases. To test this idea, we took advantage of the UbVS system (described in chapter 
II) (Dimova et al., 2012) and a purified 
35
S-labeled N-terminal fragment (1-88 amino acid 
residues) of human cyclin B1 (referred to as cycB1-NT).  When added to interphase extract, 
cycB1-NT, which is incapable of binding endogenous CDK1 and phosphorylating the APC, 
remained largely stable for the duration of the experiment. Low levels of degradation, observed at 
later times, were presumably resulting from partial activation of the ubiquitination machinery. 
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Addition of 110 μM of wild-type ubiquitin, which accelerates substrate degradation in mitotic 
extracts (Dimova et al., 2012), had no appreciable impact on cyclin stability in interphase extract. 
Upon pre-treatment with 20 μM UbVS, basal proteolysis was slightly inhibited in extracts, likely 
due to ubiquitin deficiency. Surprisingly, wild-type ubiquitin stimulated cyclin B1degradation in 
UbVS-treated extract (Figure S1b). The degree of stimulation depended on the concentration of 
added ubiquitin (data not shown). Under these conditions, no phosphorylation of Cdc27 was 
observed by western blotting (Figure S1a), suggesting that the observed degradation was unlikely 
due to mitotic entry. These findings indicate that UbVS-sensitive deubiquitination may oppose 
proteasomal targeting of cyclin B1 in interphase extract. 
Previous work, carried out in collaboration with the Finley lab, revealed that in a 
reconstituted system, the proteasome-associated DUB USP14 strongly attenuated the capacity of 
proteasomes to rapidly degrade polyubiquitinated cyclin B1 (Hanna et al., 2006; Lee et al., 
2010b), presumably by trimming ubiquitin chains. Unexpectedly, USP14 was comparably 
efficient at removing substrate-linked ubiquitin, suppressing the turnover of multiply 
monoubiquitinated cyclin B1 (Dimova et al., 2012).  These findings motivated us to examine a 
potential role of USP14 in cyclin proteolysis in Xenopus extract. To this end, we first wanted test 
whether USP14 was required for cyclin turnover. USP14 levels in total extracts were hard to 
detect by western analysis (Figure S2a). To confirm its presence in this physiological context, we 
sought to enrich for USP14 by isolating endogenous proteasomes from Xenopus extract using the 
UBl-domain of ubiquitin receptor Rad23 (Figure S2a). Mass spectrometry (Mike Aguiar, Gygi 
lab) and western blot analyses of isolated proteasomes indicated that levels of proteasome-bound 
USP14 in interphase extracts are comparable to those in mitotic extracts. Importantly, species in 
both extracts were similarly UbVS-reactive (Borodovsky et al., 2001), suggesting proper 
proteasomal association and activation of USP14 (Figure S2a).  
We next examined how inhibiting the activity of USP14 will impact cyclin B1 
degradation in Xenopus extract. Pre-treatment of mitotically arrested Xenopus extract with IU1  
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(Lee et al., 2010a) or IU2, two different small-molecule inhibitors of the catalytic activity of 
USP14, had a slightly inhibitory effect on cycB1-NT degradation (Figure S2b). To compensate 
for the ubiquitin deficiency potentially imposed by USP14 inhibition, we supplemented extracts 
with wild-type ubiquitin. In the presence of 44 μM of added ubiquitin, the rate of cyclin 
degradation was no faster in IU1- or IU2-treated extract relative to a non-treated extract. Similar 
trends were observed in interphase Xenopus extracts (data not shown).  The failure of the USP14 
inhibitors to stimulate cyclin turnover could result from inefficiency of USP14 in opposing the 
processive ubiquitination and proteasomal targeting, mediated by the APC. We therefore sought 
to examine whether partial inhibition of APC activity may reveal an effect of USP14 on cyclin 
degradation. To this end, we used TAME which was suggested to stabilize APC substrates by 
terminating ubiquitination prior to assembly of an efficient proteolytic signal, favoring 
deubiquitination rather than degradation (Zeng and King, 2012). We hypothesized that if USP14 
acts on such under-ubiquitinated species, then attenuating its isopeptidase activity with IU1 or 
IU2 may rescue substrate degradation in TAME-treated extracts. As expected, the proteolysis of 
cycB1-NT was highly sensitive to TAME addition (Zeng and King, 2012; Zeng et al., 2010) 
(Figure S2c). Concomitant treatment of extract with USP14 inhibitors, IU1 or IU2, failed to 
rescue the TAME effect on substrate stability. These findings suggest that USP14 may not 
actively oppose APC-mediated proteolysis by deubiquitinating modified intermediates. 
We next sought to determine whether a partial inhibition of the 26S proteasome may 
better reveal an effect of USP14 on cyclin degradation. When the catalytic activity of the 
proteasome is attenuated, ubiquitin conjugates may remain associated with the 19S sub-complex 
longer, allowing potentially for more extensive deubiquitination by USP14. At final 
concentrations higher than 100 μM, the proteasome inhibitor MG262 largely blocked cyclin 
turnover (data not shown). In contrast, pre-treatment of extract with 25 μM MG262 delayed 
degradation, extending substrate half-life from 30 minutes in untreated extract to 55 minutes 
(Figure S2d). Following treatment with the proteasome inhibitor, extract was incubated with IU1 
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for 15 minutes prior to substrate addition. The kinetics of cyclin degradation observed in MG262-
treated extracts were largely unaffected by the addition of the USP14 inhibitor IU1. A possible 
explanation for the lack of effect of IU1 is that the catalytic activity of USP14 does not modulate 
the rate of cyclin degradation in a major way. Alternatively, our data indicate that in spite of the 
sequence conservation between the human and frog USP14, IU1 fails to efficiently inhibit the 
activity of the enzyme in Xenopus extract.  
We next attempted to rule out the possibility that our results thus far were influenced by 
failure of the small-molecule inhibitors to bind Xenopus USP14. To this end, we examined the 
ability of IU1to interact with the enzyme‟s catalytic site, preventing labeling with UbVS. When 
isolated Xenopus proteasomes were briefly incubated with UbVS, a significant fraction of the 
present USP14 was found as a covalent adduct with the ubiquitin derivative (Figure S3a). At 20 
μM final concentration, IU1 was not capable of inhibiting the formation of USP14-UbVS 
adducts, as compared to untreated or negative-control IU1C-treated proteasomes (Figure S3a). 
When the concentration of IU1 was increased 5-fold to 100 μM, labeling with UbVS was 
partially diminished, as suggested by reduced levels of the slower migrating form of USP14. IU1-
47 exhibited higher affinity for the Xenopus USP14 than the parental compound. Even at 20 μM 
final concentration, IU1-47 significantly reduced extent of UbVS labeling, whereas at 100 μM, it 
completely abolished this interaction (Figure S3a). Surprisingly, this more potent inhibitor IU1-
47 had no appreciable effect on the kinetics of cyclin degradation in mitotic Xenopus extracts, 
supplemented with 44 μM of wild-type ubiquitin (Figure S3b). Similar results were obtained in 
interphase extracts (data not shown).  
Degradation of cyclin conjugates generated with wild-type or chain-terminating ubiquitin 
was largely unaffected by pre-treatment of interphase Xenopus extract with the USP14-specific 
inhibitor IU1-47 (Figure S3c). This is very similar to what we observed in analogous experiments 
performed with IU1 (Dimova et al., 2012). The efficiency of cyclin degradation in Xenopus 
extracts suggested, surprisingly, that USP14 activity is unlike to strongly impact the proteasomal  
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targeting of cyclin B1. A possible explanation for these observations is that deubiquitinating 
enzymes such as USP14 are present at much lower levels in Xenopus extracts than in our in vitro 
reconstituted reactions (Dimova et al., 2012).   
The Ub-AMC hydrolyzing activity of USP14 was reported to increase 800-fold upon 
association with the proteasome over that of isolated protein (Lee et al., 2010a). Thus, the 
deubiquitinating activity of USP14 is strongly enhanced by proteasomes (Borodovsky et al., 
2001; Lee et al., 2010a; Leggett et al., 2002). Our findings raised the possibility that levels of 
USP14 associated with proteasomes in extracts may be insufficient to impede cyclin turnover. To 
test this idea, we sought to increase loading of proteasomes with USP14 by adding recombinant 
protein to extracts. Based on previous reports (Borodovsky et al., 2001; Lee et al., 2010a; Leggett 
et al., 2002), we reasoned that exogenous USP14 would be specifically activated in the context of 
the proteasome and perhaps render kinetics of substrate turnover comparable to those in a purified 
system reconstituted with the deubiquitinase (Crosas et al., 2006; Dimova et al., 2012; Hanna et 
al., 2006; Lee et al., 2010a). When added to mitotically arrested extract, GST-tagged human 
USP14, but not GST alone, delayed cyclin proteolysis in a dose-dependent fashion (Figure S4a; 
data not shown). Surprisingly, we found that co-treatment of these extracts with 200 μM IU1-47 
failed to accelerate degradation (Figure S4b).  
Previous work demonstrated that USP14 delays the breakdown of conjugates by the 
proteasome and that a major component of its inhibitory effect is non-catalytic in nature (Hanna 
et al., 2006). These findings prompted us to examine the possibility that in Xenopus extracts 
USP14 utilizes mostly non-catalytic functions to modulate the activity of the proteasome. We 
found that an active-site mutant of USP14, USP14 (C114A), inhibited cyclin degradation, albeit 
to a lesser degree than the wild-type protein (Figure S4b). The kinetics of degradation in extracts 
supplemented with USP14 (C114A) were not altered by the addition of IU1-47, consistent with 
resistance of USP14 non-catalytic functions to IU1 treatment (Lee et al., 2010a). Thus, our 
analysis may indicate a contribution of USP14, independent of its catalytic function, even though  
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further work will be required to address this possibility. Together our findings suggest that the 
abundance of proteasomes containing USP14 in Xenopus extract may be below levels necessary 
to influence cyclin proteolysis. Alternatively, the ubiquitin signal assembled on cyclin B1 may be 
primarily modulated by activities upstream of the proteasome. Even following a recent 
identification of USP37 as a DUB antagonizing ubiquitination of cyclin A2 by APC
Cdh1 
(Huang et 
al., 2011), it remains to be determined if there is a ubiquitin isopeptidase specific for cyclin B1. 
We set out, therefore, to search for such activity that may influence the rate of cyclin B1 
proteolysis and perhaps that of other APC substrates. 
 
 
Deubiquitinating activity antagonizing APC-dependent proteolysis in Xenopus extracts 
 
We sought to broaden our approach and look for APC-associating DUBs which could 
potentially influence APC-mediated proteolysis. Based on our findings in interphase extract, we 
initially examined potential association of the ligase with UbVS-sensitive isopeptidases. We 
immunopurified interphase or mitotic APC from Xenopus egg extract and treated the isolated 
material with hemagglutinin (HA)-tagged UbVS to label any co-purifying deubiquitinases. 
Following incubation with HA-UbVS, covalently labeled species were analyzed by western 
blotting against the HA epitope tag. When material isolated on anti-Cdc27 resin was subjected to 
less stringent washes, multiple HA immunoreactive species were evident (Figure S5a). We 
reasoned that any deubiquitinase that may specifically modulate the ubiquitin signal built on 
substrates by the APC is likely to be recruited to the ligase module in the presence of substrate. 
Thus, extract was supplemented with 10 μM N-terminal fragment of sea urchin cyclin B1 (13-110 
amino acid residues) during immunoprecipitation. Isolated APC was washed with excess low-salt 
buffer and incubated with 10 μM HA-UbVS for 30 minutes. We found that the patterns of HA-
reactive species for the Cdc27- and control IgG-immunopurification were largely identical. 
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Interestingly, one band in the high Mr region of the gel appeared specific for the Cdc27 
immunopurifcation (Figure S5b). The intensity of the band remained largely unaffected by the 
addition of excess substrate (Figure S5b; data not shown).  
To examine the pattern of isopeptidase activities co-purifying with interphase Xenopus 
APC in an independent manner, we carried out labeling with a different active-site probe. To this 
end, we utilized ubiquitin-vinyl methylester (Ub-VME) where vinyl methylester is used as the 
thiol-reactive functional group at the carboxy terminus. As the vinyl sulfone substitution may 
hinder interaction or not be reactive with the active sites of some deubiquitinases, such proteins 
will be refractory to labeling. Thus, a ubiquitin probe in which the vinyl sulfone moiety is 
replaced with a different group such as vinyl methylester can potentially allow for additional 
DUBs to be visualized. Consistent with this idea, we found the overall pattern of labeling with 
Ub-VME to be different from that in assays containing UbVS (data not shown). Intriguingly, far 
fewer species form covalent adducts with Ub-VME, suggesting differential affinity for the 
ubiquitin probe (data not shown).  Interestingly, we found a Ub-VME-reactive species that 
migrated similarly to the APC-IP specific band seen in UbVS experiments. Using this approach, 
we were unable to detect any DUB/DUBs associating with mitotic APC (data not shown). We 
found no evidence of differential labeling with UbVS even when extracts were supplemented 
with cyclin B1 and wild-type ubiquitin (data not shown). 
We next tested whether the UbVS labeling we observed was indeed reflecting specific 
association of particular deubiquitinases with the APC.  To this end, we immunopurified APC 
from interphase extract that had been pre-depleted with either a control IgG or an antibody 
against the APC subunit Cdc27 and incubated the resulting material with HA-UbVS. 
Surprisingly, western analysis revealed that the appearance of labeled species remained 
unchanged in extracts pre-depleted of the APC, as compared to control-depleted extracts (Figure 
S5b). These results suggest that the UbVS-reactive species may not be specifically binding to the  
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ubiquitin ligase. Together our findings may indicate that there are few, if any, UbVS-reactive 
DUBs that form a stable association with the APC in Xenopus extract. 
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Discussion 
 
 Here we have evaluated a potential role of USP14 in proteasomal targeting of cyclin B1 
in Xenopus cell-cycle extracts. Our study was motivated by previous work (Dimova et al., 2012; 
Hanna et al., 2006; Lee et al., 2010a) indicating that that the proteasome-associated 
deubiquitinase USP14 or its yeast orthologue Ubp6 strongly reduces the efficiency of cyclin B1 
degradation by purified proteasomes. Although, USP14 has been found to modulate the stability 
of a number of cellular proteins in vivo (Hanna et al., 2006; Lee et al., 2010a), to date, its activity 
has not been linked to APC-mediated proteolysis. In the context of Xenopus egg extracts, we 
conclude that USP14 is unlikely to regulate the magnitude of proteasome activity against 
ubiquitinated cyclin B1. 
 Our previous work showed that in a reconstituted system USP14 can antagonize the 
degradation of cyclin B1-Ubn species (Dimova et al., 2012; Lee et al., 2010a). At the basis of this 
inhibition was the capacity of USP14 to trim polyubiquitin assemblies (Dimova et al., 2012; Lee 
et al., 2010b), as well as remove substrate-attached monoubiquitins (Dimova et al., 2012). Cyclin 
turnover in vitro was markedly stimulated by USP14-specific inhibitor IU1, whereas degradation 
of pre-ubiquitinated cyclin B1 in Xenopus extract was largely insensitive to IU1 treatment 
(Dimova et al., 2012). We sought to resolve this paradox by examining a potential role of USP14 
in the context of Xenopus proteasomes. Although USP14 is present in the Xenopus system and 
associates with the proteasome in both interphase and mitotic extract, our analysis suggested that 
it may be of low abundance. This raises an interesting possibility that the limited ubiquitin 
availability in extracts may be accounted, at least in part, by lower levels of proteasome-bound 
USP14.  Consistent with this idea, treatment with the USP14-specific inhibitor IU1caused a slight 
delay in cyclin proteolysis, an effect rescued by exogenous ubiquitin.   
 The magnitude of proteasome inhibition by USP14 that has been observed in a 
reconstituted system (Dimova et al., 2012; Hanna et al., 2006; Lee et al., 2010a) and in some 
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physiological contexts (Hanna et al., 2006; Lee et al., 2010a) does not appear to parallel that in 
Xenopus egg extracts. Perhaps this reflects that the deubiquitinating enzyme USP14 is present at 
much lower levels on Xenopus proteasomes than in our in vitro reconstituted reactions. Consistent 
with this idea, upon increasing the levels of USP14 by adding recombinant protein, we observed a 
significant delay in cyclin turnover. Interestingly, in Xenopus extracts a major component of this 
inhibitory effect may be noncatalytic in nature. Similar observations have been reported for the 
yeast orthologue Ubp6 (Hanna et al., 2006). This may provide a possible explanation for the lack 
of effect of USP14-specific inhibitors, IU1 and IU2, on the kinetics of degradation of cyclin-
ubiquitin conjugates introduced in extract. It is unlikely that these findings reflect some artifact of 
in vitro ubiquitination, rendering conjugates insensitive to deubiquitinating activity in extract. 
When allowed to be ubiquitinated by the endogenous machinery, cyclin was efficiently degraded 
in IU1- or IU2-treated extracts, with rates largely identical to those in untreated extract. These 
findings are in agreement with our previous work indicating that few, if any, UbVS-sensitive 
DUBs such as USP14 may be strongly modulating cyclin degradation in mitotic Xenopus 
extracts.  
 Importantly, exogenous ubiquitin was found to stimulate cyclin proteolysis in interphase 
extracts in a manner dependent on DUB inhibition with UbVS. Under these conditions, there is 
no detectable phosphorylation of Cdc27 that would indicate mitotic entry of extracts. Intriguingly, 
both interphase and mitotic APC appear to associate with proteasomes in Xenopus extract. Future 
work will be required to elucidate the functional significance of such interactions. Such an 
association, however, raises an important question as to how ubiquitination and degradation may 
be coupled, and how this may influence sensitivity to deubiquitination. Our analysis thus far has 
not yielded any UbVS-sensitive deubiquitinases that form stable interaction with the APC. These 
findings do not rule out the possibility that there are isopeptidases antagonizing APC activity or 
modulating the ubiquitin signal it assembles on target proteins. Such deubiquitinating enzymes 
would not necessarily associate with the E3 ligase to exert their effect.  
  
181 
Methods 
Antibodies and biochemical reagents 
Protein samples were resolved by SDS-PAGE on NuPAGE 4-12% Bis-Tris or 12% Bis-
Tris gels (Invitrogen), followed by wet transfer to PVDF and immunoblotting against the 
indicated proteins. Sources of commercial antibodies used for western analysis are as follows: 
anti-cyclin B1 (Ab-2; RB-008-P, Neomarkers), anti-Cdc27 (610455, BD Transduction 
Laboratories
TM
), Secondary antibodies used include anti-goat IgG-HRP (sc2020; Santa Cruz 
Biotechnology), anti-rabbit IgG-HRP (NA934; GE Healthcare), and anti-mouse IgG-HRP 
(NA931; GE Healthcare). For APC/C immunopurification from Xenopus extract, anti-Cdc27 
(AF3.1; sc-9972, Santa Cruz Biotechnology) was used. Other reagents utilized include ubiquitin 
vinyl sulfone (UbVS) (U-202, Boston Biochem), TAME (T4626, Sigma), Mg262 (I-120, Boston 
Biochem), methylated ubiquitin (U-502, Boston Biochem), ubiquitin mutants except for Ub
11,48R
, 
Ub
11,63R
, and Ub
triR
 were purchased from Boston Biochem. Wild-type ubiquitin was purchased 
from Sigma-Aldrich (U6253-25MG) and Boston Biochem. 
 
Preparation of recombinant proteins 
        CycB1-NT (1-88 amino acids of human cyclin B1) , containing an HA tag at the N 
terminus and a 6xHis tag at the C terminus was generated using PCR amplification with forward 
primer (5´-CCA GGA CCA TGG GTT ACC CAT ACG ATG TTC CAG ATT ACG CTG GCT 
CGA TGG CGC TCC GAG TCA CG-3´) and reverse primer (5´-GGG AGC CTC GAG CTA 
GGG AGC GTG ATG GTG ATG GTG ATG CAT AGG TAC CTT TTC AAG AGG-3´). The 
resulting PCR product was digested with NcoI and XhoI for subcloning into pET28a. Plasmids 
were verified by restriction enzyme mapping and sequencing. For 
35
S labeling in Escherichia  
coli, cultures (50 ml) were grown at 37 ˚C to D600 nm =  0.8, then collected  by centrifugation 
(3,700g for 15 min, at 4 
o
C) and resuspended in modified M9 medium (50 ml final volume). After 
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resuspension in modified M9 medium, cells were allowed to grow for additional 15 min at 37 °C 
before 5 mCi of Easy Tag
TM
 L-[35S]-Methionine (NEG709A005MC; Perkin Elmer) was added. 
Expression was induced with 0.5 mM IPTG for 2.5 h at 37 
o
C. Cells were ruptured in 5 ml g
-1
 of 
pellet guanidine-HCl lysis buffer (pH 8.0) and lysates rotated at 24 °C until the lysate became 
slightly translucent; approximately 45 min. Lysates were clarified by centrifugation and cycB1-
NT was purified using Ni-NTA affinity chromatography (Qiagen). Eluted protein was desalted 
into XB buffer (100 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, at pH 7.8 with 
KOH), supplemented 2% glycerol, protease inhibitors and phenylmethylsulfonyl fluoride, and 
stored at – 20 °C.  
Maltose-binding protein (MBP)-tagged E1 was expressed in E. coli inducing cultures at 
D600 nm = 0.6 with 300 μM IPTG for 5 h at room temperature. Purification was carried out using a 
standard MBP purification protocol. For expression of His-tagged UBCH10 and His-tagged 
UBC4, bacterial cultures were induced at D600 nm = 0.6 at 37 ˚C with 500 μM IPTG for 4 h. The 
enzymes were purified through Ni-NTA affinity and gel-filtration chromatography. Glutathione 
S-transferase (GST)-tagged USP14, wild-type or catalytically inactive variant C114A, were 
expressed and purified as reported previously (Lee et al., 2010a).  
 
Preparation of Xenopus egg extract  
Interphase Xenopus egg extract was prepared from eggs laid overnight according to the 
protocol of Murray (Murray, 1991) with the exception that eggs were activated with 2 μg ml-1 
calcium ionophore (A23187, free acid form, Calbiochem) for 30 min prior to the crushing spin. 
Extract was frozen in liquid nitrogen and stored at -80 ºC. Interphase extract was induced to enter 
mitosis by addition of non-degradable cyclin B, which activates CDK1 and stimulates mitotic 
phosphorylation, resulting in APC/C activation. A fusion of the maltose-binding protein (MBP) 
to Xenopus cyclin B lacking its N-terminal 90 amino acids (MBP-Δ90) (Salic and King, 2005) 
was expressed in E. coli by inducing cultures at an D600nm=0.6 with 300 μM 
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isopropylthiogalactoside (IPTG) for 5 h at room temperature. Purification was carried out 
following New England BioLabs (NEB) protocol. To make mitotic extract, MBP- Δ90 was added 
to interphase extract generally at ~ 20 μg ml-1 and incubated at 22-24 ºC for 45-60 min. 
 
APC/C purification and reconstituted ubiquitination of cyclin B1 
Reactions were performed essentially as described previously (Kirkpatrick et al., 2006) 
for the indicated times. Briefly, for each 30 µl reaction, APC/C was immunopurified from 600 µl 
of mitotic Xenopus egg extract by incubation for 1 h at 4 °C with 12 µg of anti-Cdc27 antibodies 
(AF3.1, Santa Cruz Biotechnology) immobilized onto 30 µl of Affiprep Protein A beads (156-
0006, Bio-Rad). Following incubation with extract, beads were washed very quickly to minimize 
loss of associated APC/C co-activator Cdc20 three times with XB high salt (10 mM potassium 
HEPES, pH 7.7, 500 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2), two times with XB (the same 
content as XB high salt, except with 100 mM KCl), and then three times with the reaction buffer 
(20 mM Tris, pH 7.5, 100 mM KCl, 2.5 mM MgCl2, 2 mM ATP).  Ubiquitination reactions were 
typically performed at 24 °C with agitation on a shaker at 1500 r.p.m.. Ubiquitination reactions 
contained immunoprecipitated APC/C on 30 µl beads, and 30 µl of a mix containing recombinant 
MBP-human E1 (1.3 µM), His-tagged UBCH10 (100 nM – 4 μM, concentrations as indicated) as 
the E2 enzyme, wild-type or different forms of ubiquitin (118-145 μM, concentrations as 
indicated), and 450-500 nM of HA-cyclin B1 NT(1-88)-His.  
 
Cyclin B1 degradation in Xenopus egg extract 
Degradation assays where nonubiquitinated cyclin B1 was added to extract were 
generally performed in 40 μl total volume per reaction condition with extract constituting 75-80% 
of that volume. For experiments with TAME and Mg262, extracts were pre-treated with relevant 
compound or DMSO control for 15 min at 24 °C, 1250 r.p.m.. Extracts contained 100 μg ml-1 
cycloheximide to prevent re-incorporation of free labeled amino acid. Degradation experiments 
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were performed at 24 °C, 1250 r.p.m., with samples taken at indicated times. In degradation 
assays with 
35
S-labeled cyclin B1 NT, reactions (3 μl per time-point) were terminated by addition 
of 97 μl of 20% TCA (in H2O), vortexed and incubated on ice ≥ 30 min before centrifugation at 
14,000g, 4 °C. A fraction (50%) of sample supernatants was combined with NaOH to neutralize 
the acid and added to Ultima Gold scintillation fluid (6013327, Perkin Elmer). A Packard 
scintillation counter was used to take all measurements. Acid-soluble counts were compared to 
total radioactive counts and results were graphed as percent soluble radioactive counts.  
For degradation of preubiquitinated cycB1-NT in extract, interphase extract was pre-
treated with USP14 inhibitor, as indicated, or DMSO for 15 min at 24 °C, 1250 r.p.m. and 
supplemented with 100 μg ml-1 cycloheximide prior to substrate addition. For degradation of 5S 
cyclin B1 NT-Ub conjugates, extract (14 μl) was added to 4 μl of cyclin B1 NT-Ubn conjugates 
for each time-point. Degradation mixtures were incubated at 24 °C, 1250 r.p.m. for indicated 
times. Reactions were quenched by addition of 107 μl of 20% TCA (in H2O), vortexed and 
incubated on ice ≥ 30 min before centrifugation at 14,000g, at 4 °C for 30 min. A fraction of 
supernatants was combined with NaOH and added to Ultima Gold scintillation fluid (6013327, 
Perkin Elmer). 
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